HEXO (HEXO) 40-F 29 Oct 21 2021 FY Annual report (Canada) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jul. 31, 2021shares
Entity Addresses [Line Items]
Entity Registrant Name	HEXO CORP.
Entity Central Index Key	0001690947
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding	152,645,946
Document Type	40-F
Document Period End Date	Jul. 31, 2021
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Trading Symbol	HEXO
Security Exchange Name	NASDAQ
Title of 12(g) Security	Common Shares, no par value
Entity File Number	001-38781
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	120 Chemin de la Rive
Entity Address, City or Town	Gatineau
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	J8M 1V2
City Area Code	844
Local Phone Number	406-1852
Annual Information Form	true
Audited Annual Financial Statements	true
Document Annual Report	true
Document Registration Statement	false
Business Contact [Member]
Entity Addresses [Line Items]
Contact Personnel Name	CT Corporation System
Entity Address, Address Line One	Street N.W
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Washington
Entity Address, State or Province	DC
Entity Address, Postal Zip Code	20005
City Area Code	202
Local Phone Number	572-3100

Consolidated Statements of Fina

Consolidated Statements of Financial Position $ in Thousands, $ in Thousands	Jul. 31, 2021CAD ($)	Jul. 31, 2020CAD ($)
Current assets
Cash and cash equivalents	$ 67,462	$ 184,173
Restricted funds	132,246	8,261
Cash held in escrow	285,779	0
Trade receivables	37,421	19,426
Commodity taxes recoverable and other receivables	13,549	16,733
Prepaid expenses	7,490	4,606
Inventory	135,327	64,933
Biological assets	14,284	7,571
Total current assets	693,558	305,703
Non-current assets
Property, plant and equipment	393,902	285,366
Intangible assets	50,608	16,008
Investment in associate and joint ventures	74,679	76,306
Lease receivable	4,453	3,865
License and prepaid royalty	0	1,020
Long-term investments	2,492	3,209
Prepaid expenses	3,922	1,392
Goodwill	88,189	0
Total assets	1,311,803	692,869
Current liabilities
Accounts payable and accrued liabilities	63,557	32,451
Excise taxes payable	6,591	7,121
Warrant liabilities	5,733	3,450
Lease liability	1,730	4,772
Loans and borrowings- current	50,159	29,930
Convertible debentures - current	3,406	0
Senior secured convertible note	367,699	0
Onerous contract	4,763	4,763
Total current liabilities	503,638	82,487
Non-current liabilities
Lease liability	42,155	24,344
Convertible debentures	33,089	28,969
Deferred income tax liability	136	0
Other long-term liabilities	520	393
Total liabilities	579,538	136,193
Shareholders' equity
Share capital	1,267,967	1,023,788
Share-based payment reserve	69,750	65,746
Warrant reserve	124,112	95,617
Contributed surplus	41,290	27,377
Accumulated deficit	(773,993)	(659,231)
Accumulated other comprehensive income	1,152	0
Total equity attributable to shareholders of Hexo Corp.	730,278	553,297
Non-controlling interest	1,987	3,379
Total shareholders' equity	732,265	556,676
Total liabilities and shareholders' equity	$ 1,311,803	$ 692,869

Consolidated Statements of Net

Consolidated Statements of Net Loss and Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Profit (loss) [abstract]
Revenue from sale of goods	$ 173,081	$ 110,149
Excise taxes	(49,583)	(29,598)
Net revenue from sale of goods	123,498	80,551
Ancillary revenue	271	233
Net revenue	123,769	80,784
Cost of goods sold	94,703	127,205
Gross profit/(loss) before fair value adjustments	29,066	(46,421)
Fair value component in inventory sold	31,767	40,910
Unrealized gain on changes in fair value of biological assets	(51,499)	(29,356)
Gross profit/(loss)	48,798	(57,975)
Operating expenses
Selling, general and administrative	58,187	52,793
Marketing and promotion	10,348	12,474
Share-based compensation	11,731	25,790
Research and development	3,835	4,639
Depreciation of property, plant and equipment	6,097	6,072
Amortization of intangible assets	2,050	3,939
Restructuring Costs	3,283	4,767
Impairment of property, plant and equipment	20,230	79,418
Impairment of intangible assets	0	108,189
Impairment of goodwill	0	111,877
Recognition of onerous contract	0	4,763
Disposal of long-lived assets	1,294	0
Loss/(gain) on disposal of property, plant and equipment	64	3,855
Acquisition and transaction costs	17,174	0
Total expenses, by nature	134,293	418,576
Loss from operations	(85,495)	(476,551)
Interest income (expense), net	(30,523)	(8,141)
Non-operating income (expense), net	859	(67,820)
Loss and comprehensive loss attributable to shareholders before tax	(115,159)	(552,512)
Current and deferred tax expense recovery	397	6,023
Net loss	(114,762)	(546,489)
Other comprehensive income
Foreign currency translation	(17)	0
Gain on fair value due to changes in credit spread, net of tax	1,169	0
Net loss and comprehensive loss	(113,610)	(546,489)
Comprehensive loss attributable to:
Shareholders of HEXO Corp.	(113,477)	(546,489)
Non-controlling interest	(133)	0
Total comprehensive loss	$ (113,610)	$ (546,489)
Net loss and comprehensive loss per share, basic and diluted (in dollars per share)	$ (0.89)	$ (7.08)
Weighted average number of outstanding shares
Basic and diluted (in shares)	127,300,903	77,376,174

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Share capital	Share-based payment reserve	Warrant reserves	Contributed surplus	Accumulated OCI	Accumulated deficit	Non-controlling Interest	Total
Balance at Jul. 31, 2019	$ 799,706	$ 40,315	$ 60,433			$ (112,742)	$ 1,000	$ 788,712
Balance (shares) at Jul. 31, 2019	64,245,441
June 2020 at the market offering	$ 33,263							33,263
June 2020 at the market offering (Shares)	8,235,620
May 2020 at the market offering	$ 43,495		10,998					54,493
May 2020 at the market offering (shares)	15,985,000
April 2020 underwritten offering	$ 22,928		20,182					43,110
April 2020 underwritten offering (shares)	14,950,000
$70m private placement unsecured convertible debenture				$ 23,902				23,902
USD$25m registered offering	$ 25,229							25,229
USD$25m registered offering (shares)	3,742,516
USD$20m registered offering	$ 21,073							21,073
USD$20m registered offering (shares)	2,994,012
Early conversion of debentures	$ 72,005		13,354	(10,362)				74,997
Early Conversion of Debentures (shares)	9,331,250
Issuance fees				(27)				(27)
Exercise of stock options	$ 223	(89)						134
Exercise of stock options (shares)	29,133
Expiry of stock options		(5,983)		5,983
Exercise of warrants	$ 5,866		(1,469)					4,397
Exercise of warrants (shares)	1,103,469
Expiry of warrants			(7,881)	7,881
Equity-settled share-based payments		31,503						31,503
Non-controlling interest							2,379	2,379
Net loss						(546,489)		(546,489)
Balance at Jul. 31, 2020	$ 1,023,788	65,746	95,617	27,377		(659,231)	3,379	556,676
Balance (shares) at Jul. 31, 2020	120,616,441
June 2020 at the market offering (Shares)	244,875
May 2021 at the market offering, net	$ 45,257							45,257
May 2021 at the market offering, net (shares)	6,373,926
Acquisition of Zenabis Global Inc	$ 151,358	7,282	32,354				(1,340)	189,654
Acquisition of Zenabis Global Inc (shares)	17,579,336
Senior secured convertible note, net	$ 29,540							29,540
Senior secured convertible note, net (shares)	4,602,241
Transaction costs	$ 3,612							3,612
Transaction costs (shares)	448,639
Exercise of stock options	$ 3,213	(1,983)						1,230
Exercise of stock options (shares)	410,051
Exercise of equity settled RSUs	$ 1,267	(1,554)						(287)
Exercise of equity settled RSUs (shares)	223,506
Expiry of stock options		(12,891)		12,891
Exercise of warrants	$ 9,932		(3,126)					6,806
Exercise of warrants (shares)	2,146,931
Expiry of warrants			(733)	733
Equity-settled share-based payments		13,150						13,150
Other comprehensive Income					$ 1,152			1,152
Non-controlling interest				289				289
Net loss						(114,762)	(52)	(114,814)
Balance at Jul. 31, 2021	$ 1,267,967	$ 69,750	$ 124,112	$ 41,290	$ 1,152	$ (773,993)	$ 1,987	$ 732,265
Balance (shares) at Jul. 31, 2021	152,645,946

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Operating activities
Net loss	$ (114,762)	$ (546,489)
Items not affecting cash	71,263	508,484
Changes in non-cash operating working capital items	431	(56,549)
Cash used in operating activities	(43,068)	(94,554)
Financing activities
Proceeds from issuance of senior secured note, net	377,433	0
Proceeds from issuance of common shares, net	46,140	186,673
Shortfall payments and other transaction costs	(4,482)	0
Proceeds from the exercise of stock options	1,230	134
Payments on RSU exercise	(287)	0
Proceeds from the exercise of warrants	6,806	4,291
Repayments of term loan	(38,415)	(3,500)
Interest paid on term loan	(2,035)	(1,849)
Lease payments	(4,835)	(4,341)
Issuance of unsecured convertible debentures	0	70,000
Interest paid on unsecured convertible debentures	(3,583)	(3,205)
Cash provided financing activities	377,972	248,203
Investing activities
Settlement of short-term investments	0	25,420
Proceeds from sale of investments	0	7,871
Cash outflows to restricted cash	(120,985)	13,089
Cash outflows to cash held in escrow	(276,654)	0
Net cash acquired on business combination	2,804	0
Issuance of convertible debenture receivable	(19,500)	0
Proceeds from sale of property, plant and equipment	93	10,966
Acquisition of property, plant and equipment	(30,004)	(109,040)
Purchase of intangible assets	(2,336)	(856)
Investment in associates and joint ventures	(5,033)	(30,494)
Cash used in investing activities	(451,615)	(83,044)
(Decrease)/increase in cash and cash equivalents	(116,711)	70,605
Cash and cash equivalents, beginning of year	184,173	113,568
Cash and cash equivalents, end of year	$ 67,462	$ 184,173

Description of Business

Description of Business	12 Months Ended
	Jul. 31, 2021
Disclosure Description Of Business [Abstract]
Description of Business	1. Description of Business HEXO Corp. ("HEXO" or the "Company"), is a publicly traded corporation, incorporated in Ontario, Canada. HEXO is licensed to produce and sell cannabis and cannabis products under the Cannabis Act. The head office is located at 120 Chemin de la Rive, Gatineau, Canada. The Company's common shares are listed on the Toronto Stock Exchange ("TSX") and the National Association of Securities Dealers Automated Quotations ("Nasdaq"), both under the trading symbol "HEXO". The Company was listed on the New York Stock Exchange up to August 24, 2021, at which time the Company transferred its US listing to the Nasdaq.

Going Concern

Going Concern	12 Months Ended
	Jul. 31, 2021
Disclosure Of Going Concern [Abstract]
Going Concern	2. Going Concern These consolidated financial statements have been prepared using International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board applicable to a going concern, which assumes that the Company will be able to continue its operations and will be able to realize its assets and settle its liabilities in the normal course of business as they come due in the foreseeable future. For the year ended July 31, 2021, the Company reported an operating loss of $85,495; cash outflows from operating activities of $43,068 and an accumulated deficit of $773,993. In addition, the Cash held in escrow were released subsequent to year end to finance the Redecan acquisition (Note 38). Under the terms of the Senior Secured Convertible Note, the holder has the option to require monthly redemptions, which are settled in either cash or equity. In order to retain the right to settle the monthly redemptions in either cash or equity, the Company must maintain, for each of the 20 previous trading days, a daily volume weighted average price per common share on the Nasdaq Capital Market ("VWAP") above US$1.50, as well as meet certain other conditions (Note 19). In the event that these conditions are not met, the Company must seek a waiver from the holder in order to settle each monthly redemption in equity (the "Equity Condition Waiver"). If the holder does not grant the Equity Condition Waiver, the monthly redemption is required to be settled in cash. These monthly redemptions may result in significant cash outflows over the next twelve months (Note 19). On October 22, 2021, the Company negotiated an amendment to the terms of the Senior Secured Convertible Note which resulted in reducing the daily VWAP attached to the Equity Condition Waiver from US$5.00 to US$1.50. In addition, to date, when requested, the holder has granted the Equity Condition Waiver and has permitted settlement of the monthly redemptions in equity. However, there can be no assurances that the Equity Conditions Waiver will continue to be met, or if they are not met, that the holder will continue to grant equity waivers to permit settlement of the monthly redemptions in equity. As such, there exists a risk that significant cash outflows may be required over the next twelve months under the terms of the Senior Secured Convertible Note. Existing funds on hand, when combined with operational cash flow, are not sufficient to fund existing debt repayments, capex budgets, and potential cash requirements under the Senior Secured Convertible Note. Management is exploring several options to secure the necessary financing, which could include the issuance of new public or private equity or debt instruments, supplemented with operating cash inflows from operations. Nevertheless, there is no assurance that certain sources of additional future funding will be available to the Company or will be available on terms which are acceptable to management. These circumstances create material uncertainties that lend substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The Company's ability to continue as a going concern is dependent upon its ability to fund the repayment of existing borrowings, secure additional financing and to generate positive cash flows from operations. These financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and balance sheet classifications that would be necessary If the company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Jul. 31, 2021
Basis Of Presentation [Abstract]
Basis of Preparation	3. Basis of Preparation i. Statement of Compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ('IASB"). These consolidated financial statements were approved and authorized for issue by the Board of Directors on October 29, 2021. ii. Basis of Measurement The consolidated financial statements have been prepared on an historical cost basis except for certain financial instruments which are carried at fair value and biological assets carried at fair value less cost to sell, as detailed in the Company's accounting policies. iii. Functional and Presentation Currency The consolidated financial statements are presented in Canadian dollars, which is the parent's functional currency. Each entity within the Company determines its own functional currency based on the primary economic environment in which it operates. iv. Uncertainty of COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. More recently, outbreaks of COVID-19 variants across the globe continue to prolong the pandemic. In response to the outbreak, governmental authorities in Canada and internationally have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. These measures are continuously monitored and modified by the applicable governmental authorities in Canada and certain of these remained in effect as at July 31, 2021. The production and sale of cannabis in Canada was deemed an essential service throughout the year ended July 31,2021 and 2020. However, the industry was impacted by the COVID-19 restriction of limited in store shopping at retailers. The Company regularly monitors the impact of the ongoing pandemic on all aspects of its business and operations and as of July 31, 2021, we have not observed any material changes to the Company’s operations. v. Share Consolidation The Company finalized a share consolidation on the basis of four pre-consolidation common shares for one post-consolidation common share (4:1) by way of shareholder approval at the annual and special meeting of shareholders held December 11, 2020 (the "Share Consolidation"). The Share Consolidation was effected by the filing of articles of amendment to the Company's articles under the Business Corporations Act (Ontario) on December 18, 2020. All balances of common shares, common share purchase warrants, stock options and restricted share units herein are reflective of the Share Consolidation (unless otherwise noted). Basis of Consolidation SUBSIDIARIES Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and be exposed to, or have rights to, the variable returns from its activities. The financial statements of subsidiaries are consolidated from the date that control commences until the date that control ceases. All intercompany transactions, balances, and unrealized gains and losses are eliminated upon consolidation. Non-controlling interest ("NCI") represents the portion of equity ownership in subsidiaries not attributable to the Company's shareholders. NCI is initially measured as the proportionate share of its interest in the acquiree's identifiable net assets as at the date of acquisition and subsequently adjusted for the proportionate share of net earnings and other comprehensive income (loss) attributable to the NCI, as well as any dividends or distributions paid to the NCI. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statements of loss and comprehensive loss, statements of changes in equity and balance sheets respectively. Principal Operating Subsidiaries Jurisdiction Interest Held Principal Activity HEXO Operations Inc. Quebec, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. HEXO USA Inc. Delaware, USA 100% To facilitate expansion into the US market. Zenabis Global Inc. British Columbia, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. Keystone Isolation Ontario, Canada 60% To provide the Company with extraction technology to supply of CBD and THC to supply the Canadian and global market for cannabis derivatives Keystone Isolation Colorado, 100% To allow for in state, HEXO controlled cannabis extraction activity to support the manufacturing of CBD beverages and future products in the U.S. (where permissible) JOINT ARRANGEMENTS Investments in joint arrangements are classified as either joint operations or joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than the legal structure of the joint arrangement. The Company currently holds interests in joint ventures but has no interest in joint operations. Joint ventures Interests in joint ventures are accounted for using the equity method (see "Equity Method" below), after initially being recognized at cost in the consolidated balance sheet. The following are the Company's joint venture however, none are considered material to the Company: Joint Venture Jurisdiction Interest Held Principal Activity Belleville Complex Inc. Ontario, Canada 25% The venture was established to manage the property of the Belleville facility. Associate Associates are all entities over which the Company has significant influence but not control or joint control. This is generally the case where the Company holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting (see "Equity Method" below), after initially being recognized at cost. The following associates are significant to the Company; however, only Truss Limited Partnership is considered material to the Company: Significant associates Jurisdiction Interest Held Principal Activity Truss Limited Partnership ("Truss LP") Ontario, Canada 42.5% To pursue opportunities to develop non- alcoholic, cannabis infused beverages for the Canadian market. Truss CBD USA LLP ("Truss CBD US") Colorado USA 42.5% To explore opportunities for non-alcoholic hemp derived CBD beverages in the State of Colorado. EQUITY METHOD Under the equity method of accounting, investments in associate and joint ventures are initially recognized at cost and adjusted thereafter to recognize the Company's share of the post-acquisition profits or losses of the investee in profit or loss, and the Company's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from associates and joint ventures are recognized as a reduction in the carrying amount of the investment. Where the Company's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Company does not recognize further losses, unless it has incurred obligations or made payments on behalf of the other entity. Unrealized gains on transactions between the Company and its associates and joint ventures are eliminated to the extent of the Company's interest in these entities. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity-accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Company. The carrying amount of equity-accounted investments is tested for impairment in accordance with the policy described in note 4(m). OPERATING SEGMENTS An operating segment is a component of the Company for which discrete financial information is available and whose operating results are regularly reviewed by the entity's chief operating decision maker, the board of directors, to make decisions about resources to be allocated to the segment and assess its performance, and that engages in business activities from which it may earn revenue and incur expenses. The Company only has one operating segment.

Significant Accounting Policies

Significant Accounting Policies and Pronouncements	12 Months Ended
	Jul. 31, 2021
Significant Accounting Policies [Abstract]
Significant Accounting Policies	4. Significant Accounting Policies and Pronouncements (a) CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertible into known amounts of cash with original maturities of three months or less. (b) RESTRICTED FUNDS Restricted funds represent cash that is pledged as collateral or guarantees for certain of the Company's projects, obligations, and agreements. Funds related to the Company's captive insurance program are included in restricted funds. Captive Insurance is coverage for the Company's directors and officers that has been secured through a Captive Cell program ("the Captive Program"). The Captive Program was effected by entered into a participation agreement with a registered insurer for the purposes of holding and managing the Company's coverage funds through a separate cell account (the "Cell Captive").Captive Program funds are held as cash in the Cell Captive with the possibility of reinvestment into short-term investments and/or marketable securities in the future. As the funds cannot be transferred to other parts of the group without providing 6 month notice, the funds are disclosed as Restricted cash. The Company recognizes gains and losses from, interest, foreign exchange activity and/or fair market value adjustments through the Statement of Loss and Comprehensive Loss. (c) CASH HELD IN ESCROW Cash held in escrow is cash that is held by independent escrow agents to fund future acquisitions but restricted by certain release conditions. (d) SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are measured at amortized cost using the effective interest method, less loss allowance. (e) TRADE RECEIVABLES Trade receivables are recognized initially at the amount of consideration that is unconditional, unless they contain significant financing components when they are recognized at fair value. Trade receivables are subsequently measured at amortized cost using the effective interest method, less loss allowance. (f) COMMODITY TAX RECOVERABLES & OTHER RECEIVABLES Commodity tax recoverable and other receivables are initially measured at fair value fair value and subsequently measured at amortized cost, less any provisions for impairment. (g) BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell at the point of harvest, which becomes the basis for the cost of related inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs (including share based compensation), grow consumables, materials, utilities, facilities costs, depreciation, overhead, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item 'costs of goods sold' on the statement of loss and comprehensive loss in the period that the related product is sold. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period. (h) INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis ("Dried cannabis") are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, depreciation, amortization, and labor related costs (including share-based compensation) involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within 'cost of goods sold' on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross profit. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value. (i) PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Construction in progress is transferred to a depreciable asset class property, plant and equipment when the assets are available for use and depreciation of the assets commences at that point. Depreciation is provided using the following terms and methods: Asset Method Term Land Not depreciated No term Buildings Straight line 5 to 40 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years An asset's residual value and useful life are reviewed at each reporting date and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss. (j) FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Asset Method Term Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3-5 years Patents Straight line 20 years Finite life, brands Straight line 3 years The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. (k) INDEFINITE LIFE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company intends to utilize the brand indefinitely. The capitalized indefinite life brand consists of the Company's premium Up brand, which was recognized upon the acquisition of Newstrike in May 2019. Brand Not amortized Indefinite (l) GOODWILL Goodwill is not amortized but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. Goodwill is allocated to cash-generating units ("CGUs") for the purpose of impairment testing. The allocation is made to those CGUs or groups of CGUs that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the Company's single operating segment. (m) IMPAIRMENT OF NON-FINANCIAL ASSETS Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's or CGU's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal ("FVLCD") and value in use ("VIU"). For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (CGUs) Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. In assessing the VIU, the estimated future cash flows are discounted to their present value using a pre- tax discount rate that reflects current market assessments of the time value of money to the Company and the risks specific to the asset. In determining FVLCD an appropriate valuation model is used. Where the carrying amount of a CGU exceeds its recoverable amount, the CGU is considered impaired and is written down to its recoverable amount. Any impairment loss is recorded in earnings and previously recognized impairment losses (excluding the impairment of Goodwill) are reversed or partially reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized, in which case, the carrying amount of the asset is increased to its recoverable amount. The new carrying amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized. (n) BUSINESS ACQUISITIONS The acquisition method is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. Operating results are included in the consolidated financial statements as of the acquisition date. The consideration transferred for the acquisition comprises the: • fair values of the assets transferred; • liabilities incurred to the former owners of the acquired business; • equity interests issued by the Company; • fair value of any asset or liability resulting from a contingent consideration arrangement; and • fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, with the exceptions of leases under IFRS 16 and deferred taxes. The Company recognizes any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets. The Company has one year from the acquisition date to finalize the estimates and assumptions that support the finalized fair value analysis and purchase price allocation. Until this time, these values reported are subject to change. Changes to fair values and allocations are retrospectively adjusted in subsequent periods. Acquisition-related costs are expensed as incurred and are presented under 'Acquisition and transaction costs' in the consolidated statements of loss and comprehensive loss. The excess of the consideration transferred, amount of any non-controlling interest in the acquired entity, and acquisition-date fair value of any previous equity interest in the acquired entity over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in profit or loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value, with changes in fair value recognized in profit or loss. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in profit or loss. (o) NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs of disposal of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Non-current assets (including those part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized. Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. (p) ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. Accounts payable and accrued liabilities are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method. (q) REVENUE RECOGNITION Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Net revenue is presented net of taxes, estimated returns, allowances and discounts. Canada Revenue Agency ("CRA") levies excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an ad valorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019, excise tax calculated on edible cannabis products, cannabis extracts and cannabis topicals will prospectively be calculated as a flat rate based on the quantity of total tetrahydrocannabinol (THC) contained in the final product. There were no changes in the legislation in calculating excise taxes for fresh cannabis, dried cannabis, seeds and plants. Net revenue from sale of goods, as presented on the consolidated statements of comprehensive (loss) income, represents revenue from the sale of goods less applicable excise taxes. (r) COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labor. (s) INCOME TAXES The income tax expense or recovery for the period is the tax payable on the current period's taxable income, based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax expense or recovery is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment. The Company measures its tax balances either based on the most likely amount or the expected value, depending on which method provides a better prediction of the resolution of the uncertainty. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. (t) SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company's estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received (u) RESTRICTED SHARE UNITS ("RSU's") RSUs are cash or equity settled share-based payments granted to certain employees, directors and executives within the Company. RSUs are measured at their initial fair value on the date of the grant utilizing the Black- Scholes Merton model. The fair value of cash-settled RSUs is revalued at each period end and is recognized as share-based compensation expense over the vesting period with a corresponding adjustment to the liability. Upon the settlement of cash based RSUs, which are valued at the market value at the time of exercise, the related liability is transferred to share capital. The fair value of equity-settled RSUs are recognized in the share- based reserve at the grant date. Upon the settlement of equity-based payments, RSUs are settled in the form of common shares and the related share-based reserve is transferred to share capital. Amounts recorded for forfeited RSUs are transferred to the accumulated deficit in the year of forfeiture or expiry. (v) LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. (w) B ORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred. (x) FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. The Company classifies its financial assets in the following measurement categories: • • those to be measured at amortized cost. The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. The Company has made the following classifications: Financial assets IFRS 9 Classification Cash and cash equivalents Amortized cost Restricted funds Amortized cost Short-term investments Amortized cost Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investments FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liabilities FVTPL Deferred rent liability Amortized cost Convertible debentures Amortized cost Senior secured convertible note FVTPL Lease liabilities Amortized cost Loans and borrowings Amortized cost (i) Fair Value Through Profit or Loss ("FVTPL") Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest ("SPPI") or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. (ii) Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. An amortized cost financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost using the effective interest rate. (iii) Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. (iv) Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities mandatory classified at FVTPL, such derivates, are stated at fair value, with changes being recognized through the consolidated statements of loss. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Senior secured convertible note issued in currency other than the functional currency of the Company are classified entirely as liabilities. As the Note contains equity and non-equity embedded derivatives, they are designated at fair value through profit or loss on initial recognition when embedded features are not separated. The component of fair value changes relating to the Company’s own credit risk is recognized in other comprehensive loss. Amounts recorded in other comprehensive loss related to credit risk are not subject to recycling in profit or loss but are transferred to retained earnings when realized. Financial liabilities are classified as current when the Company does not retain an unconditional right to defer settlement, due to a conversion feature or otherwise, beyond 12 months from the reporting date. (v) Derivatives Derivatives are initially measured at fair value and are subsequently measured at FVTPL. If the transaction price does not equal to fair value at the point of initial recognition, management measures the fair value of each component of the investment and any unrealized gains or losses at inception are either recognized in profit or loss or initially unrecognized and recognized over the term of the investment, depending on whether the valuation inputs are based on observable market data. The resulting unrealized gain or loss at inception and subsequent changes in fair value are recognized in profit or loss for the period. Transaction costs, which are directly attributable to the acquisition of the investment, are expensed as incurred. (vi) Convertible Debentures The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument's maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. (vii) Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. Fair Value on initital recognition Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal (or most advantageous) market at the measurement date under current market conditions (i.e. an exit price) regardless of whether that price is directly observable or estimated using another valuation technique. If, after considering the terms of the transaction, the Company determines that the fair value of a financial instrument at initial recognition differs from the transaction price, the difference is recognized as a gain or loss in the statement of loss only if fair value is evidenced by quoted prices or based on a valuation technique that uses only data from observable markets. In all other cases, the difference is deferred and recognized systematically to the extent that it arises from a change in a factor (including time) that market participants would consider in setting a price. Any subsequent measurement of the instrument excludes the balance of the deferred day one gain or loss. (y) FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign Operations The assets and liabilities of foreign operations are translated to the presentation currency at exchange rates at the reporting date. The income and expenses of foreign operations are translated to the presentation currency using average exchange rates for the month during which the transactions occurred. Foreign currency differences are recognized in Other Comprehensive Loss in the Accumulated Other Comprehensive Loss account. (z) SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Significant Accounting Judgements Impairment of non-financial assets Non-financial asset impairment tests require the allocation of assets to CGUs or CGU groups, which req

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Jul. 31, 2021
Categories of current financial assets [abstract]
Cash and Cash Equivalents	5. Cash and Cash Equivalents Interest rate July 31, 2021 July 31, 2020 $ $ Operating cash - 31,702 70,318 High interest savings accounts 0.60% 35,760 113,855 Cash and cash equivalents 67,462 184,173

Restricted Funds

Restricted Funds	12 Months Ended
	Jul. 31, 2021
Disclosure Of Restricted Cash [Abstract]
Restricted Funds	6. Restricted Funds July 31, 2021 July 31, 2020 $ $ Debt service reserve account - Term loan (Note 21a) - 8,191 Letters of credit, collateral and guarantees for purchases 2,552 70 Restricted cash under terms of the Senior Secured Convertible Note (Note 19) 99,696 - Cash restricted in captive insurance subsidiary 29,998 - Total 132,246 8,261

Cash Held in Escrow

Cash Held in Escrow	12 Months Ended
	Jul. 31, 2021
Disclosure For Cash Held In Escrow [Abstract]
Cash Held in Escrow	7. Cash Held in Escrow On May 27, 2021, the Company issued US$360 million in a senior secured convertible note at a purchase price of US$327.6 million (Note 19). Under the senior secured convertible note agreement, US$229.32 million of the proceeds were immediately placed into an escrow account. The Cash held in escrow was used subsequent to year-end to partially fund the acquisition of all of the outstanding shares of the entities that carry on the business of Redecan (the “Redecan Acquisition”)(Note 38).

Commodity Taxes Recoverable and

Commodity Taxes Recoverable and Other Receivables	12 Months Ended
	Jul. 31, 2021
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity Taxes Recoverable and Other Receivables	8. Commodity Taxes Recoverable and Other Receivables July 31, 2021 July 31, 2020 Commodity taxes recoverable $ 56 $ 12,821 Lease receivable - current 1 107 630 Receivable on conversion of Inner Spirit Holdings Shares (Note 12) 2,698 - Loan receivable 2 5,000 - Other receivables 5,688 3,282 Total $ 13,549 $ 16,733 1 2

Inventory

Inventory	12 Months Ended
	Jul. 31, 2021
Classes of current inventories [abstract]
Inventory	9. Inventory As at July 31, 2021 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 81,784 $ 24,257 $ 106,041 Purchased dried cannabis 1,754 - 1,754 Extracts 11,945 4,411 16,356 Purchased extracts 2,247 - 2,247 Packaging and supplies 8,929 - 8,929 $ 106,659 $ 28,668 $ 135,327 As at July 31, 2020 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 29,702 $ 16,981 $ 46,683 Purchased dried cannabis 1,956 - 1,956 Extracts 4,828 385 5,213 Purchased extracts 5,977 - 5,977 Hemp derived distillate 566 - 566 Packaging and supplies 4,538 - 4,538 $ 47,567 $ 17,366 $ 64,933 The Company recognizes the costs (capitalized cost and biological asset fair value adjustment) of harvested cannabis inventory expensed in two separate lines on the consolidated statement of net loss: (i) Capitalized costs relating to inventory expensed and included in Cost of goods sold amounted to $94,703 for the year ended July 31, 2021 (July 31, 2020 – $127,205) (ii) The fair value component (biological asset fair value adjustments) of inventory sold on the consolidated statement of net loss was $31,767 for the year ended July 31, 2021, (July 31, 2020 – $40,910). During the year ended July 31, 2021, the Company reversed previous inventory write downs of $2,927, (July 31, 2020 – $nil) recorded in costs of good sold $688 (July 31, 2020 – $nil) recorded in fair value component on inventory sold on the statement of loss. Total share-based compensation capitalized in inventory in the year ended July 31, 2021 was $1,505 (July 31, 2020 – $6,105).

Biological Assets

Biological Assets	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about biological assets [abstract]
Biological Assets	10. Biological Assets The Company's biological assets consist of cannabis plants throughout the growth cycle, from mother plants to plants in propagation, vegetative and flowering stages. The changes in the carrying value of biological assets are as follows: For the years ended July 31, 2021 July 31, 2020 $ $ Balance, beginning of year 7,571 7,371 Acquired on business combination 8,892 - Production costs capitalized 36,156 38,638 Net increase in fair value due to biological transformation and estimates 51,499 29,356 Harvested cannabis transferred to inventory (89,834 ) (67,131 ) Disposal of biological assets - (663 ) Balance, end of year 14,284 7,571 The valuation of biological assets is based on an income approach (Level 3) in which the fair value at the point of harvesting is estimated based on selling prices less the costs to sell. For in process biological assets (growing plants), the fair value at the point of harvest is adjusted based on the stage of growth at period-end. Harvested cannabis is transferred from biological assets at their fair value at harvest. The inputs and assumptions used in determining the fair value of cannabis plants are as follows: yield per plant; stage of growth percentage, estimated as age of plant from date of harvest as a percentage of total days in an average growing cycle, as applied to the estimated total fair value per gram (less fulfilment costs) to arrive at an in-process fair value for estimated biological assets to be harvested; selling price per gram; post-harvest cost (cost to complete and cost to sell) per gram; and destruction/wastage of plants during the harvesting and processing process. The table below summarized the significant inputs and assumptions used in the fair value model, their weighted average range of value and sensitivity analysis: Significant inputs and assumptions Input values An increase or decrease of 5% applied to the July 31, 2021 July 31, 2020 July 31, 2021 July 31, 2020 Weighted average selling price Derived from actual retail prices on a per product basis using the expected Flower and Trim yields per plant. Which is expected to approximate future selling prices and where applicable, considering strains $3.05 per dried gram $3.23 per dried gram $746 $550 Yield per plant Derived from historical harvest cycle results on a per strain basis, which is expected to be harvested from plants 24-116 grams per plant 46 - 135 grams per plant $460 $376 Post-harvest cost Derived from historical costs of production activities on a per product basis. 0.67%-0.84 % dependent upon the stage within the harvest cycle 0.26%-0.81 % dependent upon the stage within the harvest cycle $636 $219

Investments in Associates & Joi

Investments in Associates & Joint Ventures	12 Months Ended
	Jul. 31, 2021
Disclosure Of Associate And Joint Ventures [Abstract]
Investments in Associates & Joint Ventures	11. Investments in Associates & Joint Ventures July 31, 2021 July 31, 2020 Truss LP Other Total Truss LP Other Total $ $ $ $ $ $ Opening Balance 74,966 1,340 76,306 51,786 1,063 52,849 Cash contributed to investment 4,250 783 5,033 29,155 1,231 30,386 Capitalized transaction costs - - - - 109 109 Share of net (loss) (6,343 ) (162 ) (6,505 ) (5,975 ) (356 ) (6,331 ) Impairment - - - - (707 ) (707 ) Foreign exchange loss through OCI - (155 ) (155 ) - - - Ending Balance 72,873 1,806 74,679 74,966 1,340 76,306 Truss LP The Truss LP was formed between the Company and Molson Coors Canada (the "Partner") and is a standalone entity, incorporated in Canada, with its own board of directors and an independent management team. The Partner holds 57,500 common shares representing 57.5% controlling interest in Truss LP with the Company holding 42,500 common shares and representing the remaining 42.5%. Truss LP is a private limited partnership and its principal operating activities consist of pursuing opportunities to develop non-alcoholic, cannabis-infused beverages. Truss LP As at July 31, 2021 July 31, 2020 Statement of Financial Position $ $ Cash and cash equivalents 6,757 19,561 Other current assets 14,182 7,867 Non- current assets 67,766 66,863 Current liabilities 11,184 11,112 Non-current liabilities 8,667 8,903 Year ended July 31, 2021 July 31, 2020 Statement of Comprehensive Loss Revenue 6,498 (1) 705 (1) Operating expenses excluding depreciation and amortization (14,261 ) (12,647 ) Depreciation and amortization (4,884 ) (617 ) Other expenses - (7 ) Loss from operations (14,643 ) (13,827 ) Other income 130 1 Interest expenses (412 ) (233 ) Income tax expenses - - Total comprehensive loss (14,925 ) (14,059 ) 1 The following table is a reconciliation of summarized financial information of the Company's' significant investment in Truss LP to the carrying amount of the investment for the year ended July 31, 2021 and 2020. For the year ended July 31, 2021 July 31, 2020 $ $ Opening net assets 74,964 20,423 Acquisition of associate/capital calls 10,000 68,600 Total comprehensive loss (14,925 ) (14,059 ) Closing net assets 70,039 74,964 Interest in associate 42.5% 42.5% Interest in associate value 29,767 31,860 Fair value of warrant consideration 42,386 42,386 Capitalized transaction costs 720 720 Total interest in associate value 72,873 74,966

Long-term Investments

Long-term Investments	12 Months Ended
	Jul. 31, 2021
Disclosure Of Long Term Investment Abstract
Long-term Investments	12. Long-term Investments Fair value Transfer Divestiture Change in Fair value $ $ $ $ Level 1 Investments Fire and Flower common shares 1,292 - - (65 ) 1,227 Sundial Growers Inc. common shares - 720 - (99 ) 621 Inner Spirit Holdings Ltd common shares 1,260 (720 ) (2,698 ) 2,158 - Other long-term investments 517 - (13 ) - 504 Level 3 Investments Segra International Corp. 140 - - - 140 Total 3,209 - (2,711 ) 1,994 2,492 Fair value Investment Divestiture Change in Fair value $ $ $ $ $ Level 1 Investments Fire and Flower common shares - 1,232 - 60 1,292 Inner Spirit common shares 3,000 - (643 ) (1,097 ) 1,260 Other long-term investments - 517 - - 517 Level 2 Investments Inner Spirit common share purchase warrants 403 - - (403 ) - Level 3 Investments Greentank Technologies 6,574 - - (6,574 ) - Neal Brothers Inc. 4,000 - - (4,000 ) - Segra International Corp. 300 - - (160 ) 140 Total 14,277 1,749 (643 ) (12,174 ) 3,209 The Company's Level 1 publicly traded investments were initially acquired as strategic investments in Canadian cannabis private retailers and are held for the long term. The investments have been classified as non-current. Fire & Flower Holdings Corp. On November 30, 2019, the Company obtained 1,000,000 common shares in Fire & Flower Holdings Corp., a publicly traded company, through the conversion of its $800 zero interest bearing convertible debentures, at a conversion rate of $0.80 per common share. The fair value of the shares upon conversion was $920. On February 11, 2020, the Company received an additional 319,377 common shares of Fire & Flower as settlement for accrued and unpaid interest on the Fire and Flower convertible debentures. The fair value of the shares on settlement was $1,232. The Company holds 1,319,377 common shares in Fire & Flower at July 31, 2021 (July 31, 2020 - 1,319,377). The common shares were revalued to $1,227 using the quoted share price at July 31, 2021 of $0.93 (July 31, 2020 - $0.98). Sundial Growers Inc. / Inner Spirit Holdings Ltd. On May 24, 2019, on acquisition of Newstrike, the Company acquired 15,000,000 common shares in Inner Spirit Holdings Ltd., which were valued at $2,850 on initial recognition. During the year ended July 31, 2020, the Company disposed of 6,005,500 common shares, at prices ranging from $0.09-$0.15 per share, resulting in a gain of $24. The remaining 8,994,500 shares held at July 31, 2020 were valued based upon the market price of $0.14 per share resulting in a fair value of $1,260 at July 31, 2020. On July 21, 2021, Sundial Growers Inc. ("Sundial") acquired all of the issued and outstanding common shares of Inner Spirit Holdings Ltd. The consideration per Inner Spirit common share consisted of (i) $0.30 in cash and (ii) 0.0835 of a common share of Sundial. The Company received 751,041 common shares of Sundial and a cash component of $2,698, which is presented in Other receivables. The Sundial shares were fair valued on July 21, 2021 (initial recognition) and July 31, 2021 at quoted share prices of $0.87 and $0.82, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jul. 31, 2021
Property, plant and equipment [abstract]
Property, Plant and Equipment	13. Property, Plant and Equipment Cost Land Buildings Leasehold Cultivation Furniture, Construction Right-of-Use Total $ $ $ $ $ $ $ $ At July 31, 2019 5,339 150,834 627 42,029 10,368 57,550 - 266,747 Additions - 24,432 1,395 14,969 9,404 66,246 24,405 140,851 Disposals (3,683 ) (18,260 ) - (13,402 ) (909 ) (5,428 ) - (41,682 ) Transfers - 7,943 22,417 (10,135 ) 8 (20,233 ) - - At July 31, 2020 1,656 164,949 24,439 33,461 18,871 98,135 24,405 365,916 Business acquisition 1,100 95,788 - 6,154 8,578 395 17,059 129,074 Additions - 1,213 63 2,284 294 16,960 20,814 Disposals - 1 - (67 ) - - (1,055 ) (1,121 ) Transfers - 3,951 17,649 884 1,388 (23,544 ) - 328 At July 31, 2021 2,756 265,902 42,151 42,716 29,131 91,946 40,409 515,011 Accumulated depreciation and impairments At July 31, 2019 - 4,392 130 2,216 1,216 - - 7,954 Depreciation - 7,395 879 3,702 3,562 - 2,522 18,060 Transfers - - - 271 (271 ) - - - Disposals - (17,081 ) - (7,435 ) (366 ) - - (24,882 ) Impairments 307 19,006 - 9,937 - 48,990 1,178 79,418 At July 31, 2020 307 13,712 1,009 8,691 4,141 48,990 3,700 80,550 Depreciation - 7,981 2,173 5,145 4,229 - 2,246 21,774 Transfers - (110 ) (16 ) (78 ) (277 ) - - (481 ) Disposals - - - - - - (964 ) (964 ) Impairments - 160 85 2,104 61 - 17,820 20,230 At July 31, 2021 307 21,743 3,251 15,862 8,154 48,990 22,802 121,109 Net book value At July 31, 2019 5,339 146,442 497 39,813 9,152 57,550 - 258,793 At July 31, 2020 1,349 151,237 23,430 24,770 14,730 49,145 20,705 285,366 At July 31, 2021 2,449 244,159 38,900 26,854 20,977 42,956 17,607 393,902 During the year ended July 31,2021, the Company capitalized $15,677 (July 31, 2020 - $11,988) of depreciation to inventory. During the year ended July 31, 2021, depreciation expensed to the consolidated statement of loss and comprehensive loss was $6,097 (July 31,2020 - $6,072). Capitalized borrowing costs to buildings in the year ended July 31, 2021 was $1,269 (July 31, 2020 - $2,385) at an average interest rate of 5.6% (July 31, 2020 - 7.22%). Transfers from construction in progress during the year reflect the activation of an asset's useful life, transitioning from construction in progress to the appropriate property, plant and equipment classification. Impairment of right of use assets During the year ended July 31, 2021, the Company impaired $17,820 (July 31, 2020 - $1,178 ) of right of use assets related to the Company's Langley and Montreal facilities. Subsequent to the acquisition of Zenabis (Note 15), the Company in order to recognize the synergies, assessed the output capacity of its production and cultivation facilities and made the decision to exit the Langley lease. As a result, the carrying amount of the associated right of use asset of $17,059 was impaired as the Company has assessed the recoverable amount at $nil. During the year ended July 31, 2021 the Company identified it’s Montreal research lab lease, which resulted in impairment losses $761. The recoverable amount of the assets was determined to be nil, as the assets have no continuing use to the Company. The associated lease liabilities remain as at July 31, 2021 (Note 20). Impairment of cultivation and production equipment During the year ended July 31, 2021, the Company identified impairments of certain packaging equipment that is no longer expected to be used. As a result of this, impairment losses of $2,104 (July 31, 2020 - $9,937) were recorded. Impairment and Sale of Niagara Facility On March 2, 2020, the Company completed a strategic review of its cultivation capacity and made the decision to market the Niagara facility for sale. As a result, the carrying amount of the Niagara facility was expected to be recovered principally through its sale. The Niagara facility was acquired from Newstrike in May 2019 and consists primarily of equipment, cultivation and processing facilities and land assets that are included within property, plant and equipment, as well as related cultivation and processing licenses that are recorded as intangible assets. These assets were previously included in the HEXO CGU. The recoverable amount was determined by reference to fair value less costs of disposal using a market approach. The market approach was based on comparable transactions for similar assets, which is categorized within Level 2 of the fair value hierarchy. As a result, an impairment loss of $31,606 was recorded in property, plant and equipment. Additional impairment losses were recorded for cultivation and processing licenses (Note 14). On June 17, 2020, the Company closed the sale of the Niagara Facility for proceeds of $12,250 and a loss on disposal of $2,219 for the year ended July 31, 2020. Impairment of Certain Optimization Projects During the year ended July 31, 2020, the Company identified an impairment indicator for certain capital assets and expenditures made as a result of suspending certain optimization projects that were under construction. As a result, the Company recorded an impairment loss of $43,585 relating to redundant and idle capital assets, as well as excess leasehold improvement expenditure that is not expected to contribute to future cash flows of the Company. The recoverable amount of the assets was determined to be zero, as the assets have no continuing use to the Company and negligible value would be derived from sale as the assets were highly customised for a specific purpose and location. Impairment of HEXO CGU At July 31, 2021, no indicators of impairment were identified for the HEXO CGU. During the year ended July 31, 2020, an indicator of impairment was identified for the HEXO CGU as the carrying amount of the Company's total net assets significantly exceeded the Company's market capitalization. The HEXO CGU consists of the Company's Canadian cultivation and production facilities. The recoverable amount of the CGU was determined based on fair value less cost of disposal using a market-based approach (Level 3) based on an income based discounted cash flow analysis (DCF). The Company uses its market capitalization and comparative market multiples to aid in validating the discounted cash flow results. The significant assumptions in the DCF analysis were as follows: i. Cash flows: Estimated cash flows were projected based on actual operating results from internal sources as well as industry and market trends. A discrete four year period was forecasted with an extended 5 year period calculated using the H-Model which is an alternative dividend discount model that assumes the growth rate will fall linearly to the terminal value with a short-term growth rate of 10% in the first year, declining each year over the 5 years to a terminal growth rate of 3%. If all other assumption were held constant and the short-term growth rate in the first year was decreased by 1%, the recoverable amount would decrease by approximately $24,000; ii. Revenue and gross margin: Forecast revenues and resulting gross margin are based on internal projections, developed with reference to historical experience and external market information. If all other assumptions were held constant and forecasted revenues and resulting gross margin declined by 3%, the recoverable amount would decrease by approximately $34,000; iii. Terminal value growth rate: Management used a 3% terminal growth rate which is based on historical and projected consumer inflation, historical and projected economic indicators, and projected industry growth. If all other assumption were held constant and the terminal growth rate was decreased by 1%, the recoverable amount would decrease by approximately $38,000; iv. Discount rate: Management used a 14.1% post-tax discount rate which is reflective of an industry Weighted Average Cost of Capital ("WACC"). The WACC was estimated based on the risk-free rate, equity risk premium based on a direct comparison approach, a size premium and company specific risk, and after-tax cost of debt based on corporate bond yields. If all other assumption were held constant and the discount rate was in increased by 1%, the recoverable amount would decrease by approximately $59,000; and v. Tax rate: The tax rates used in determining the future cash flows were those substantively enacted at the respective valuation date.

Intangible Assets

Intangible Assets	12 Months Ended
	Jul. 31, 2021
Changes in intangible assets other than goodwill [abstract]
Intangible Assets	14. Intangible Assets Cost Cultivating and Brands Software Domain Patents Total $ $ $ $ $ $ At July 31, 2019 116,433 8,440 3,558 585 1,231 130,247 Additions - - 702 - 875 1,577 Disposals - - (550 ) - (173 ) (723 ) At July 31, 2020 116,433 8,440 3,710 585 1,933 131,101 Additions - - 1,546 - 790 2,336 Business acquisition 28,914 5,400 - - - 34,314 Disposals - - (872 ) - - (872 ) At July 31, 2021 145,347 13,840 4,384 585 2,723 166,879 Accumulated amortization and impairments At July 31, 2019 1,601 - 1,269 66 29 2,965 Amortization 3,167 - 697 59 16 3,939 Impairment 106,189 2,000 - - - 108,189 At July 31, 2020 110,957 2,000 1,966 125 45 115,093 Amortization 765 170 922 59 134 2,050 Disposals - - (872 ) - - (872 ) At July 31, 2021 111,722 2,170 2,016 184 179 116,271 Net book value At July 31, 2019 114,832 8,440 2,289 519 1,202 127,282 At July 31, 2020 5,476 6,440 1,744 460 1,888 16,008 At July 31, 2021 33,625 11,670 2,368 401 2,544 50,608 Research and development expenses in the year ended July 31, 2021 were $3,835, (July 31, 2020 - $4,639). Impairment The Company recognized no intangible asset impairment losses during the year ended July 31, 2021. In connection with the impairment loss recorded in the second quarter of fiscal 2020, for the Niagara facility, the Company recorded an impairment loss of $106,189 relating to cultivation and processing licenses associated with the Niagara facility. The acquired brand from the 2019 acquisition of Newstrike Brands Limited was also impaired by $2,000 as result of an impairment test as at July 31, 2020.

Business Acquisition

Business Acquisition	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about business combination [abstract]
Business Acquisition	15. Business Acquisition Acquisition of Zenabis Global Inc On June 1, 2021, pre-market open, the Company acquired 100% of the issued and outstanding common shares of Zenabis Global Inc. ("Zenabis") pursuant to an arrangement agreement entered into on February 15, 2021. Zenabis is a Canadian-licensed cultivator and seller of medical and adult-use cannabis. Zenabis was acquired for its key brands, indoor growing capability and its established additional market share. Under the arrangement, each former Zenabis common share was exchanged for 0.01772 of a HEXO common share. In addition, all issued and outstanding stock options and compensation units of Zenabis were replaced with HEXO backed units, having the same terms but adjusted for the exchange ratio, and all issued and outstanding common share purchase warrants of Zenabis became exercisable for HEXO common shares adjusted for the exchange ratio. The following table summarizes the purchase consideration and preliminary values of the net assets acquired from Zenabis on the acquisition date: Units Unit Price Fair Value ($) ($) Consideration Shares issued (i) 17,579,336 8.61 151,358 Replacement warrants outstanding (ii) 5,196,164 32,354 Replacement stock options issued (iii) 905,902 5,727 Replacement RSU's and DSU's issued 223,497 1,554 Settlement of pre-existing debt (iv) n/a 20,760 Total fair value of consideration 211,753 Net assets acquired Current assets Cash and cash equivalents 2,804 Accounts receivable 3,822 Other receivables 198 Excise taxes receivable 86 Inventory 40,636 Biological assets 8,892 Non-current assets Property, plant and equipment 129,074 Prepaid expenses 5,670 Cultivation and processing license 28,914 Brands 5,400 Goodwill Note 16 88,189 Total assets 313,685 Current liabilities Accounts payable and accrued liabilities (22,161 ) Loans Note 21 (52,194 ) Convertible debentures (11,724 ) Non-current liabilities Lease Liability (17,059 ) Deferred tax liabilities (134 ) Total liabilities (103,272 ) Non-controlling interest 1,340 Total net assets acquired 211,753 (i) As the acquisition closed pre-markets on June 1, 2021, the share price is based upon the closing HEXO Corp. TSX market price of common shares on May 31, 2021. (ii) Warrants were valued using the Black-Scholes option pricing model as at the acquisition date June 1, 2021, using the following assumptions: Risk free rate of 0.31%-0.74% Expected life of 0.32 - 4.35 years Volatility rate of 96%; determined using historical volatility data Exercise prices of $3.96-$151.24 Share price of $8.61 (iii) All vested and replaced stock options were valued using the Black-Scholes option pricing model as at the acquisition date of June 1, 2021, using the following assumptions and inputs; Risk free rate of 0.31%-0.74% Expected life of 0.25 - 4.49 years Volatility rate of 96%; determined using historical volatility data Exercise prices of $2.54 - $234.7 Share price of $8.61 (iv) Prior to the transaction closing date, the Company entered into a convertible debt agreement with Zenabis in which the Company advanced $19,500 in convertible debentures which bear interest of 8% annually and mature February 15, 2023. Both the issuer and lender accounted for the debentures as FVTPL. For purpose of the acquisition accounting the debentures, which had a fair value of $20,760, were effectively settled at the acquisition date. The fair value of the vested share based compensation as at the acquisition date was deemed consideration paid in the transaction. The fair value of those options not yet vested at the acquisition date was added to the Company’s share-based payment reserve to be expensed over the remaining vesting period of the options as permitted under IFRS 3 – Business Combinations. The identifiable cultivation and processing license (“the license”) enables the Company to cultivate and produce cannabis products for sale, and was valued at $28,914 using a with-or-without approach in an income based discounted cash flow (“DCF”) valuation model (Level 3). The model estimates the value of the license as the difference between the present value of the future cash flows of the facility with-or-without a license in place, as at the acquisition date. Significant estimates in the model include the forecast gross margin and the estimated time to obtain a licence and complete cultivation and production ramp up. The significant estimates in the DCF analysis were the forecasted gross margin and the estimated time to obtain a licence and complete cultivation and production ramp up. If all other assumptions were held constant, and the forecasted gross margin rate was decreased by 10%, the valuation of the cultivation and processing license would decrease by $6,336. In the with-or-without approach, reducing the estimated time to obtain a licence and complete cultivation and production ramp up by six months would reduce the valuation of the license to $18,665. During the year ended July 31, 2021, Zenabis contributed net revenue of $6,800 and a comprehensive net loss attributed to shareholders of $1,513 to the Company’s consolidated results since the date of acquisition. If the acquisition had occurred on August 1, 2020 management estimates that the Company’s consolidated net revenue would have increased by $54,746 and the comprehensive net loss would have increased by $9,078 for the year ended July 31, 2021. Goodwill arising from the acquisition represents the expected synergies, future income and growth, and other intangibles that do not qualify for separate recognition. None of the goodwill arising from the acquisition is expected to be deductible for tax purposes. The Company recognized transaction costs of $9,634 related to the acquisition (inclusive of $3,614 in share-based compensation for issuance of 448,639 common shares).

Goodwill

Goodwill	12 Months Ended
	Jul. 31, 2021
Goodwill [Abstract]
Goodwill	16. Goodwill Newstrike Brands Zenabis Global Ltd Total $ $ $ At July 31 ,2019 111,877 - 111,877 Impairment (111,877 ) - (111,877 ) At July 31, 2020 - - - Acquisition (Note 15) - 88,189 88,189 Balance as at July 31, 2021 - 88,189 88,189 Zenabis Goodwill was recognized on acquisition of Zenabis on June 1, 2021 and was allocated to the company-wide level aggregated CGU level ("HEXO Corporate CGU"). Goodwill arising from the acquisition represents the expected synergies, future income and growth potential, and all other intangibles that do not qualify for separate recognition. Management performed the annual impairment test of goodwill as at July 31, 2021 and no impairment loss was required to be recorded. The recoverable amount was determined based on fair value less cost of disposal using a market-based approach (Level 2) with reference to an adjusted current market capitalization of the Company. The calculation of the adjusted market capitalization was based on a 20-day volume weighted average share price of the Company on July 31, 2021, adjusted for a control premium of 5%, which was estimated by reference to premiums in recent acquisitions involving control, and from data on empirical control premium studies that considered industry, pricing, background, deal size, and timing of the observed premiums. If all other assumptions were held constant, and the share price declined by 5%, the recoverable amount would have decreased by $45,087. If all other assumptions were held constant and the control premium was increased by 5%, the recoverable amount would have increased by $42,941. Newstrike Brands Ltd. Goodwill was initially recognized on acquisition of Newstrike Brands Limited ("Newstrike") on May 24, 2019 and was monitored at the operating segment level, which is a company-wide level ("HEXO Corporate CGU"). On January 31, 2020, the carrying amount of the Company's total net assets significantly exceeded the Company's market capitalization. In addition, slower than expected retail store roll outs in Canada and delays in government approval for cannabis derivative products resulted in a constrained distribution channel, which have adversely affected overall market sales and profitability. As a result of these factors, management performed an indicator-based impairment test of goodwill as at January 31, 2020. The recoverable amount was determined based on fair value less cost of disposal using a market-based approach (Level 2) which considered both the adjusted current market capitalization of the Company and an income based discounted cash flow analysis (DCF). The calculation of the adjusted market capitalization was based on the share price of the Company on January 31, 2020, adjusted for a control premium of 10%, which was estimated by reference to premiums in recent acquisitions involving control, and from data on empirical control premium studies that considered industry, pricing, background, deal size, and timing of the observed premiums. If all other assumptions were held constant, and the share price declined by 5%, the impairment loss would increase by $26,647. If all other assumption were held constant and the control premium was decreased by 5%, the impairment loss would increase by $24,283. An income based Discounted cash flow ("DCF") analysis (Level 3) was also used to corroborate the results of the adjusted market capitalisation-based valuation. The significant assumptions in the DCF analysis were as follows: i. Cash flows: Estimated cash flows were projected based on actual operating results from internal sources as well as industry and market trends. A discrete four-and-a-half-year period was forecasted with an extended 5 year period calculated using the H-Model which is an alternative dividend discount model that assumes the growth rate will fall linearly to the terminal value with a short-term growth rate of 10% in the first year, declining each year over the 5 years to a terminal growth rate of 3%. If all other assumption were held constant and the short-term growth rate in the first year was decreased by 1%, the impairment loss would increase by $12,598; ii. Terminal value growth rate: Management used a 3% terminal growth rate which is based on historical and projected consumer inflation, historical and projected economic indicators, and projected industry growth. If all other assumption were held constant and the terminal growth rate was decreased by 1%, the impairment loss would increase by $27,000; iii. Post-tax discount rate: Management used a 15.9% post-tax discount rate which is reflective of an industry Weighted Average Cost of Capital ("WACC"). The WACC was estimated based on the risk-free rate, equity risk premium based on a direct comparison approach, a size premium and company specific risk, and after-tax cost of debt based on corporate bond yields. If all other assumption were held constant and the discount rate was in increased by 1%, the impairment loss would increase by $53,933; and iv. Tax rate: The tax rates used in determining the future cash flows were those substantively enacted at the respective valuation date. As a result, during the year ended July 31, 2020 management concluded that the carrying value of the HEXO Corporate CGU was higher than the recoverable amount and recorded a goodwill impairment loss of $111,877.

Warrant Liabilities

Warrant Liabilities	12 Months Ended
	Jul. 31, 2021
Warrant Liabilities [Abstract]
Warrant Liabilities	17. Warrant Liabilities 2017 Unsecured Convertible US$25,000 US$20,000 Registered Direct Offering Total $ $ $ $ Opening balance as at August 1, 2019 493 - - 493 Issued - 5,629 3,967 9,596 Exercised (106 ) - - (106 ) (Gain) on revaluation of financial instruments (387 ) (3,712 ) (2,434 ) (6,533 ) Balance as at July 31, 2020 - 1,917 1,533 3,450 Loss on revaluation of financial instruments - 1,269 1,014 2,283 Balance as at July 31, 2021 - 3,186 2,547 5,733 The warrants are classified as a liability because the exercise price is denominated in US dollars, which is different to the functional currency of the Company. Losses (gains) on revaluation of the warrant liabilities are presented in Non-operating income (expenses) on the consolidated statements of loss and comprehensive loss. USD$20,000 Registered Direct Offering - Warrants On January 21, 2020, the Company closed a registered direct offering with institutional investors for gross proceeds of US$20,000. Under this offering, the Company originally issued 5,988,024 common share purchase warrants with an exercise price of US$2.45 per share with a five year-term. As a result of the share consolidation completed on December 18, 2020 (Note 22), the number of warrants outstanding was reduced to 1,497,007 and the exercise price was increased to US$9.80 per share. The warrant liability was measured at fair value using the Black-Scholes-Merton option pricing model (Level 2), using the following assumptions: As at As at Initial recognition Number of warrants 1,497,007 1,497,007 1,497,007 Share price US$3.97 US$2.72 US$5.80 Expected life 2.5 years 2.5 years 2.5 years Dividend US $nil US $nil US $nil Volatility 95% 97% 80% Risk free rate 0.38% 0.22% 1.57% Exchange rate (USD/CAD) 1.2462 1.3404 1.3116 US$25,000 Registered Direct Offering - Warrants On December 31, 2019, the Company closed a registered direct offering with institutional investors for gross proceeds of US$25,000. Under this offering, the Company originally issued 7,485,032 common share purchase warrants with an exercise price of US$2.45 per share with a five year-term. As a result of the share consolidation completed on December 18, 2020 (Note 22), the number of warrants outstanding was reduced to 1,871,259 and the exercise price was increased to US$9.80 per share. The warrant liability was measured at fair value using the Black-Scholes-Merton option pricing model (Level 2), using the following assumptions: As at As at Initial recognition Number of warrants 1,871,259 1,871,259 1,871,259 Share price US$3.97 US$2.72 US$6.36 Expected life 2.5 years 2.5 years 2.5 years Dividend US $nil US $nil US $nil Volatility 95% 97% 79% Risk free rate 0.38% 0.22% 1.71% Exchange rate (USD/CAD) 1.2462 1.3404 1.2988 2017 Unsecured Convertible Debenture - Warrants During the year ended July 31, 2020, 17,856 warrants were exercised prior to the expiry date of November 14, 2019, for cash proceeds of $72 (US$54), based on an exercise price of US$3.04.

Convertible Debentures

Convertible Debentures	12 Months Ended
	Jul. 31, 2021
Debt instruments held [abstract]
Convertible Debt	18. Convertible Debentures Note July 31,2021 July 31,2020 $ $ Unsecured convertible debenture- March 2019 (a) 3,406 - Unsecured convertible debenture- December 2019 (b) 33,089 28,969 Unsecured convertible notes (c) - - Total convertible d ebentures 36,495 28,969 Current 3,406 - Non-Current 33,089 28,969 (a) Unsecured Convertible Debenture March 2019 Balance as at July 31, 2020 $ - Acquired on business combination 3,722 Interest payments (372 ) Interest expense 56 Balance as at July 31, 2021 $ 3,406 On June 1, 2021, the company completed its business acquisition of Zenabis (Note 15) which included the assumption of Zenabis' unsecured convertible debentures issued in March 2019. The debentures bear interest, payable in cash only, from the date of issue at 6.0% per annum, payable semi-annually on June 30 and December 31 of each year and are convertible at a price of $147.29 The convertible debenture is convertible, at the option of the holder, into common shares of the Company at any time prior to the close of business on the last business day immediately preceding the maturity date. During the two months ended July 31, 2021, the accretion expense recognized in interest expense was $56, and no unsecured convertible debentures were converted into common shares. Subsequent to year end, the debentures were repaid in full in cash of $3,461. (b) Unsecured Convertible Debenture December 2019 Balance as at July 31, 2019 $ - Issued at amortized cost, net issuance costs 45,922 Conversion (20,602 ) Interest expense 6,854 Interest paid (3,205 ) Balance as at July 31, 2020 $ 28,969 Interest expense 7,331 Interest paid (3,211 ) Balance as at July 31,2021 $ 33,089 On December 5, 2019, the Company closed a $70,000 private placement of convertible debentures. The Company issued a total of $70,000 principal amount of 8.0% unsecured convertible debentures maturing on December 5, 2022 (the "Debentures"). The Debentures are convertible at the option of the holder at any time after December 7, 2020 and prior to maturity at a conversion price of $12.64 per share (the "Conversion Price"), subject to adjustment in certain events. The Company may force the conversion of all of the then outstanding Debentures at the Conversion Price at any time after December 7, 2020 and prior to maturity on 30 days' notice if the daily volume weighted average trading price of the common shares of the Company is greater than $30.00 for any 15 consecutive trading days. The Company had the option to at any time on or before December 4, 2020, to repay all, but not less than all, of the principal amount of the ‎Debentures, ‎plus accrued and unpaid interest. Upon maturity, the holders of the Debentures ‎have the right to require the Company to repay any principal amount of their ‎Debentures through the issuance of common shares of the Company in satisfaction of such ‎amounts at a price equal to the volume weighted average trading price of the ‎common shares on the TSX for the five trading days immediately preceding the ‎payment date. Early Conversion Inducement (common shares presented in pre 4:1 share consolidation figures) In May 2020, the Company provided notice to all holders of the Debentures of an option to voluntarily convert their Debentures into units of the Company (the "Conversion Units") at a discounted early conversion price of $0.80 (the "Early Conversion Price") calculated based on the 5-day volume weighted average HEXO Corp. share price (the "VWAP") preceding the announcement. The VWAP utilised data from both the TSX and NYSE. Each Conversion Unit provided the holder one common share and one half common share purchase warrant (with an exercise price of $1.00 and term of three years). The early conversion occurred in two phases, the first being on June 10, 2020 followed by the second and final phase June 30, 2020. During phases one and two, $23,595 principal amount and $6,265 principal amount of the Debentures were converted under the Early Conversion Price into 29,493,750 and 7,831,250 common shares and 14,746,875 and 3,915,625 common share purchase warrants of HEXO Corp., respectively. The reduction of the conversion price to induce early conversion resulted in a loss of $54,283 during the year ended July 31, 2020, which is presented in Non-operating income (expense) in the statement of net loss. The loss is calculated as the difference between the fair value of the consideration the holders received on conversion under the revised terms and the fair value of the consideration the holders would have received under the original terms of the agreement. On July 31, 2021, there remains $40,140 in principal debentures (July 31, 2020 - $40,140) outstanding. The accrued and unpaid interest as at July 31, 2021 was $483 (July 31, 2020 - $202). (c) Unsecured Convertible Notes Balance as at July 31, 2020 $ - Acquired on business combination 7,790 Debt repayment (7,790 ) Balance as at July 31, 2021 $ - On June 1, 2021, the Company completed its business acquisition of Zenabis (Note 15) and acquired unsecured convertible notes. The unsecured convertible notes were originally issued by the acquiree in October 2018 and matured on June 30, 2021. The notes bore interest of 6% and a conversion rate of $147.86. The notes were repaid subsequent to the close of the acquisition.

Senior Secured Convertible Note

Senior Secured Convertible Note	12 Months Ended
	Jul. 31, 2021
Senior Secured Convertible Note [Abstract]
Senior Secured Convertible Note	19. Senior Secured Convertible Note July 31, 2021 July 31, 2021 Senior Secured Convertible Note US$ $ Opening balance, beginning of the year - - Issued at fair value 407,284 491,714 Early conversions (413 ) (497 ) Redemptions (27,500 ) (33,525 ) Gain on fair value adjustment (14,524 ) (18,100 ) Foreign exchange loss - 15,081 Ending balance, end of the year 364,847 454,673 Unrecognized Day 1 Loss Opening balance, beginning of the year - - Unrecognized loss at issuance (79,684 ) (96,203 ) Recognized loss 7,470 9,229 Ending balance, end of the year (72,214 ) (86,974 ) Total balance, end of year, net 292,633 367,699 Current portion 292,633 367,699 Non-current - - On May 27, 2021 (the "issuance date"), the Company issued a Senior Secured Convertible Note (the "Note") directly to an institutional purchaser and certain of its affiliates or related funds (collectively, the "Holder") at a principal amount of $434,628 (US$360,000). The Note was sold at a purchase price of $395,511 (US $327,600), or approximately 91% of the principal amount ("transaction price"). The Note bears no periodic cash interest payments and is repayable on May 1, 2023 (the "maturity date") at 110% of the principal amount, (the “Redemption Amount”), if not converted or redeemed earlier. The Redemption Amount on issuance date was $478,091 (US$396,000). The Company used a portion of the net proceeds of the Note to fund the Redecan Acquisition (Note 39).38). The Note is secured against the assets of HEXO Operations Inc. and, it’s subsidiaries, as well as the assets of HEXO USA Inc and it’s subsidiaries. The Note can be converted in full or in part by the Holder into freely tradeable common shares of the Company at any time before the second last trading day before the maturity date at a conversion rate of 142.6533 common shares per US$1 ("conversion rate"). The Note includes different conversion and redemption options (summarized below) available to the Holder and the Company, subject to certain terms and limitations. At any given point, the beneficial ownership of the Holder in the Company is restricted to 9.99% (the "maximum ownership threshold"). Any conversion or redemption option exercised in common shares which would result in the Holder exceeding the maximum ownership threshold is null and void. Any outstanding payments due on maturity date will be settled in cash. Other than the above-mentioned conversion feature, the Holder has the following conversion and redemption options available: • Early Conversion Option • Optional Redemption Option • Fundamental Change Repurchase option The Company has the following conversion option: • Forced Conversion The conversion rate applied to equity settlements is calculated in reference to 88.0% of the lesser of (i) the average of the daily VWAPs during the five VWAP trading day period ending on the VWAP trading day immediately prior to the settlement date, and (ii) the fifteen VWAP trading day period ending on the VWAP trading day immediately prior to the settlement date. Additionally, up until the date of shareholder approval of the Note, shortfall cash payments were required to be made by the Company on any redemptions made under the terms of the Note. Shareholder approval was obtained on August 28, 2021, and as such, no further cash shortfall payments will be required from that date. Shortfall cash payments settled in the period are disclosed below. The Note includes a number of financial and non-financial covenants, including: • a requirement to maintain US$95,000 on deposit with a collateral agent, a portion of which is set aside to fund the repayment of the Senior notes payable (Note 21(b)). On July 23, 2021, the Note was amended to reduce the collateral amount on deposit to US$80,000. • Beginning for the quarter ending January 31, 2022, the Company will be subject to a minimum adjusted EBITDA covenant, as defined in the agreement. The Note represents a hybrid instrument with multiple embedded derivatives requiring separation. The Note, as a whole, has been designated as FVTPL, as at least one of the derivatives does significantly modify the cash flows of the Note and it is clear with limited analysis that separation is not prohibited. The changes in fair value of the instrument are recorded in the Statement of loss with changes in credit spread being recognized through Other comprehensive income. The transaction costs of $18,078 (US$14,975) have been recognized in the statement of loss during the period. The fair value of the Note at inception was $491,714 determined using the partial differential equation method with the following inputs; Share Price $6.53; Volatility 85%, Risk-free rate 0.227%; Credit spread 16.06%; Dividend yield $nil and Dilution 284.6 million common shares. The partial differential equation determines the fair value of the note by using an iterative approach to solve the differential equation that the instrument satisfies. The Note is classified as Level 2 in the fair value hierarchy. The fair value of the Note at initial recognition was determined using a valuation technique that includes unobservable inputs. The Company identified a difference between the transaction price and the fair value of $96.2 million (US$79.7 million) (the "Day 1 loss"). The Company believes that time is the factor that market participants would take into account when pricing the note. Therefore, the unrecognized Day 1 loss is recognized on a straight line basis in the statement of net loss over the contractual life of the Note. The following table represents the movement of redemption amounts in the year ended July 31, 2021. As disclosed above, redemptions are made at 110% of the principal amount owed. Shares Issued Redemption Amount $ Balance, beginning of year - - Issuances: Initial issuance 478,091 Settlements: Early conversion option 53,495 (497 ) Optional redemption options 4,548,746 (33,525 ) Foreign exchange loss - 14,641 Balance, end of year - 458,710 Shortfall cash payments of $3,893 are presented as share issuance costs in shareholders’ equity. At July 31, 2021 the fair value of the Note was determined to be $454,673 and was fair valued using the following inputs; Share Price $3.98; Volatility 85%, Risk-free rate 0.327%; Credit spread 15.44%; and a Dividend $nil. The gain on fair value adjustments related to changes in credit spread amounted to $1,590 (July 31, 2020 - $nil). An increase/decrease in the US$/CA$foreign exchange rate of 1% would result in a foreign exchange loss/gain adjustment of $4,547. Further, an increase/decrease of credit spread by 1% and share price of the Company by 10% would change the fair value of the instrument by $2,614 and $7,443 respectively. The following table depicts amounts that can be demanded by the Holder in accordance with the monthly redemption option up to the instrument's maturity date, reflective of 110% of the principal amount of Note. Fiscal Year Redemption amount Redemption amount US$ $ 2022 253,000 315,289 2023 115,087 143,421 Total 368,087 458,710

Lease Liabilities

Lease Liabilities	12 Months Ended
	Jul. 31, 2021
Disclosure of quantitative information about leases for lessee [abstract]
Lease Liabilities	20. Lease Liabilities The following is a continuity schedule of lease liabilities for the years ended July 31, 2021 and 2020: $ Balance at July 31, 2019 - Adjustment on adoption of IFRS 16 21,360 Balance at August 1, 2019 21,360 Lease additions 9,030 Lease payments (4,341 ) Interest expense on lease liabilities 3,067 Balance at July 31, 2020 29,116 Assumed on business combination (Note 15) 17,059 Lease disposals (789 ) Lease payments (4,835 ) Interest expense on lease liabilities 3,334 Balance at July 31, 2021 43,885 Current 1,730 Non-current 42,155 The Company's leases consist of administrative real estate leases and a production real estate property. Effective August 1, 2020, the Company exited two real estate leases and the related lease liability was reduced, resulting in a gain of $181 recognized in Other income and losses on the consolidated statements of loss. During the year ended July 31, 2021 the associated right of use assets were impaired for a loss of 17,820 (Note 13). The Company expensed variable lease payments of $3,885 for the year ended July 31, 2021 (July 31, 2020 - $3,769). The following table is the Company's lease obligations over the next five fiscal years and thereafter as at July 31, 2021: Fiscal year 2022 2023 - 2024 2025 - 2026 Thereafter Total $ $ $ $ $ Lease obligations 6,155 11,858 10,835 49,522 78,370

Loans and Borrowings

Loans and Borrowings	12 Months Ended
	Jul. 31, 2021
Borrowings [abstract]
Loans and Borrowings	21. Loans and Borrowings The following table is the Company's loans and borrowings as at July 31, 2021 July 31, 2021 July 31, 2020 $ $ Term Loan (A) - 29,930 Senior notes payable (B) 50,159 - RDC Loan (C) - - Total Loans and Borrowings 50,159 29,930 Current 50,159 29,930 Non-current - - A. Term Loan On February 14, 2019, the Company entered into a syndicated credit facility with Canadian Imperial Bank of Commerce ("CIBC") as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together "the Lenders"). The Lenders provided the Company with up to $65,000 in secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range. The credit facility consisted of an up to $50,000 term loan ("Term Loan") and up to a $15,000 in a revolving credit facility which is limited to the Company's working capital assets available to support funded balances. The credit facility had a maturity date of February 14, 2022 and was secured against the Company's property, plant and equipment. The Company was to repay at minimum 2.5% of the initial amount drawn each quarter per the terms of the credit facility agreement. On February 14, 2019, the Company received $35,000 on the Term Loan and incurred financing costs of $1,347. On July 31, 2020 the Company was not in compliance with an administrative banking covenant which mandated that the Company does not utilize a Canadian dollar operating bank account with any institution other than the Lenders. The Company was subject to the covenant 90 days after entering the syndicated credit facility on February 14, 2019. The Company received an amendment on October 29, 2020 allowing it to rectify this administrative breach by April 27, 2021. Due to the amendment being received after July 31, 2020 and within the three months ended October 31, 2020 the Company classified its Term Loan as a current liability on July 31, 2020. On April 30, 2021, the Company repaid the credit facility in full and therefore is no longer subject to the credit facility's financial or administrative covenants. In the year ended July 31, 2021, total interest expenses were $990 (July 31, 2020 - $723) and total interest capitalized was $419 (July 31, 2020 - $896). The following table illustrates the continuity schedule of the term loan as at July 31, 2021 and July 31, 2020: July 31, 2021 July 31, 2020 Term loan $ $ Opening balance 30,625 34,125 Repayments (30,625 ) (3,500 ) Ending balance - 30,625 Deferred financing costs $ $ Opening balance (695 ) (751 ) Additions (98 ) (445 ) Amortization of deferred finance costs 793 501 Ending balance - (695 ) Total term loan - 29,930 Current portion - 29,930 Long-term portion - - B. Senior Notes Payable On June 1, 2021 as part of the Zenabis acquisition, the Company assumed senior notes which have a principal amount owing of $51,875 and a maturity date of March 31, 2025. The senior notes bear interest at 14% per annum calculated and compounded monthly in arrears and payable to the lender on the first day of each month. The debt is secured against the assets of Zenabis Global Inc and it’s subsidiaries. Prior to the business acquisition of Zenabis, certain covenants were claimed by the lender to be in breach, and a demand for repayment was received by the borrower. Zenabis filed a petition on February 19, 2021 for a determination of the amount required to repay and terminate the senior notes and to obtain discharges of the debenture and related security (Note 31). Further, the senior notes contain a covenant that requires lender permission for a change in control event. This was not obtained prior to the close of the acquisition of Zenabis and as such, the debt remains in default. Accordingly, the senior notes have been classified as current debt and recorded initially at fair value at the business acquisition date and amortized cost thereafter. The following table illustrates the continuity schedule of the senior notes payable as at July 31, 2021 and July 31, 2020: July 31,2021 July 31, 2020 $ $ Opening Balance Assumed on business combination 50,138 - Interest paid (1,210 ) - Interest expense 1,231 - Closing Balance 50,159 - Current portion 50,159 - Long-term portion - - The following table represents the loans and borrowings repayment schedule as at July 31, 2021: July 31, 2022 $ 51,875 Thereafter - $ 51,875 C. RDC Loan Balance as at July 31, 2020 $ – Acquired on business acquisition 2,056 Debt repayment (2,056 ) Balance as at July 31, 2021 $ – On June 1,2021 the Company completed its business acquisition of Zenabis (Note 15) and assumed a loan payable. The loan payable was originally issued by the acquiree in August 2017 and matures on August 30, 2027. The loan bore interest of 6%. The loan was repaid subsequent to the close of the acquisition.

Share Capital

Share Capital	12 Months Ended
	Jul. 31, 2021
Share Capital [Abstract]
Share Capital	22. Share Capital (a) Authorized An unlimited number of common shares and an unlimited number of special shares, issuable in series. (b) Share Consolidation The Company finalized the share consolidation on the basis of four pre-consolidation common shares for one post-consolidation common share (4:1) by way of shareholder approval at the annual and special meeting of shareholders held December 11, 2020 (the "Consolidation"). The Consolidation was effected by the filing of articles of amendment to the Company's articles under the Business Corporations Act All balances of common shares, common share purchase warrants, stock options and restricted share units herein are reflective of the Consolidation (unless otherwise noted). (c) Issued and Outstanding As at July 31, 2021, a total of 152,645,946 (July 31, 2020 - 120,616,441) common shares were issued and outstanding. No special shares have been issued or are outstanding. Number of shares Share Capital Balance at July 31, 2019 64,245,441 $ 799,706 June 2020 at the market offering (ii) 8,235,620 33,263 May 2020 underwritten public offering (iii) 15,985,000 43,495 April 2020 underwritten public offering (iv) 14,950,000 22,928 January 2020 registered offering (v) 2,994,012 21,073 December 2019 registered offering (vi) 3,742,516 25,229 December 2019 private placement Note 18 9,331,250 72,005 Exercise of options Note 24 29,133 223 Exercise of warrants Note 23 1,103,469 5,866 Balance at July 31, 2020 120,616,441 $ 1,023,788 May 2021 at the market offering, net (i) 6,373,926 45,257 June 2020 at the market offering (ii) 244,875 - Senior secured convertible note 3 Note 19 4,602,241 29,540 Acquisition shares - Zenabis Note 15 17,579,336 151,358 Transaction costs 2 Note 15 448,639 3,612 Exercise of warrants Note 23 2,146,931 9,932 Exercise of stock options Note 24 410,051 3,213 Exercise of equity settled RSUs Note 24 223,506 1,267 Balance at July 31, 2021 152,645,946 $ 1,267,967 1 2 3 (i) May 2021 At-the-market ("ATM") Offering On May 11, 2021, the Company established an ATM equity program allowing the Company to issue up to $150,000 (or its US equivalent) of common shares to the public. The program ceased activity on May 25, 2021 and a total of approximately $46,987, (after foreign exchange gains) was generated through the issuance of 6,373,926 common shares in the year ended July 31, 2021. Issuance costs in the year ended July 31, 2021 were $1,730. (ii) June 2020 At-the-market ("ATM") Offering On June 16, 2020, the Company established an ATM equity program allowing the Company to issue up to $34,500 (or its US equivalent) of common shares to the public. The program closed on July 31, 2020 and a total of approximately $34,551 (after foreign exchange gains) was generated through the issuance of 8,235,620 common shares in the year ended July 31, 2020. On July 31, 2020 a receivable of $883 remained for irrevocable sales which occurred prior to year end and subsequently settled on August 5, 2020, at which time the remaining 244,875 shares were issued. (iii) May 2020 Underwritten Public Offering On May 21, 2020 the Company closed an underwritten public offering for total gross proceeds or $57,545 through the issuance of 15,985,000 units at a price of $3.60 per unit. Each unit contained one common share and one half common share purchase warrant at an exercise price of $4.20. The net contribution to share capital, after warrant reserve adjustment, was $46,547 and total issuance costs amounted to $3,052. (iv) April 2020 Underwritten Public Offering On April 13, 2020, the Company closed an underwritten public offering in which 14,950,000 units were issued at $3.08 a unit for total gross proceeds of $46,046. Each unit consisted of one common share and one common share purchase warrant at an exercise price of $3.84. The net contribution to share capital after warrant reserve was $25,863 and total issuance costs amounted to $2,936. (v) January 2020 Registered Direct Offering On January 22, 2020, the Company closed a registered direct offering in which 2,994,012 common shares were issued at US$6.68 each for total gross proceeds of $26,290 (US$20,000). Investors also received one half common share purchase warrant for each common share purchased at an exercise price of US$9.80. The net contribution to share capital, after warrant reserve adjustment, was $22,323 and total issuance costs amounted to $1,250. (vi) December 2019 Registered Direct Offering On December 31, 2020, the Company closed a registered direct offering in which 3,742,516 common shares were issued at US$6.68 each for total gross proceeds of $32,411 (US$25,000). Investors also received one half common share purchase warrant for each common share purchased at an exercise price of US$9.80.

Common Share Purchase Warrants

Common Share Purchase Warrants	12 Months Ended
	Jul. 31, 2021
Disclosure Of Common Share Purchase Warrants [Abstract]
Common Share Purchase Warrants	23. Common Share Purchase Warrants The following table summarizes warrant activity during the year ended July 31, 2021 and year ended July 31, 2020. July 31, 2021 July 31, 2020 Number of Weighted average Number of Weighted average warrants exercise price 1 warrants exercise price 1 Outstanding, beginning of year 33,379,408 $ 7.60 7,396,354 $ 39.80 Expired and cancelled (535,889 ) 4.09 (3,889,871 ) 49.00 Issued on acquisition 5,970,370 14.59 - - Issued - - 30,976,394 4.96 Exercised (2,146,931 ) 4.10 (1,103,469 ) 3.88 Outstanding, end of year 36,666,958 $ 8.85 33,379,408 $ 7.60 1 purposes. Of the Company's expired and cancelled warrants in the year ended July 31, 2021, 509,089 cancellations were due to cashless exercises of the Company's April 2020 and May 2020 warrants. In lieu of cash equal to the number of warrants exercised multiplied by the exercise price, the warrant holder forgoes the corresponding number of warrants which are effectively cancelled. The following table summarizes the warrants issues during the years ended July 31, 2021 and July 31, 2020. Issuance date Exercise price Warrants Expiry period December 31, 2019 US$9.80 1,871,259 5 years January 22, 2020 US$9.80 1,497,007 5 years April 13, 2020 $3.84 14,950,000 5 years May 21, 2020 $4.20 7,992,500 5 years June 10, 2020 $4.00 3,686,721 3 years June 30, 2020 $4.00 978,907 3 years Total issued during the year ended July 31, 2020 30,976,394 June 01, 2021 $3.96-$155.19 5,970,370 0.17-4 years Total issued during the year ended July 31, 2021 5,970,370 All warrants issued during the year ended July 31, 2021 are related to replacement warrants issued upon the acquisition of Zenabis (Note 15). The following is a consolidated summary of warrants outstanding as at July 31, 2021 and July 31, 2020. July 31, 2021 July 31, 2020 Number Book value Number Book value Classified as Equity $ $ June 2019 financing warrants Exercise price of $63.16 expiring June 19, 2023 546,135 10,022 546,135 10,022 April 2020 underwritten public offering warrants Exercise price of $3.84 expiring April 13, 2025 11,830,075 15,971 14,004,375 18,906 May 2020 underwritten public offering warrants Exercise price of $4.20 expiring May 21, 2025 7,591,876 10,446 7,852,513 10,805 Conversion Unit warrants Exercise price of $4.00 expiring June 10, 2023 3,686,721 11,427 3,686,721 11,426 Exercise price of $4.00 expiring June 30, 2023 978,907 1,928 978,907 1,928 Broker / Consultant warrants Exercise price of $3.00 expiring November 3, 2021 18,905 34 43,905 78 Exercise price of $3.00 expiring March 14, 2022 23,571 66 23,571 66 Exercise price of $63.16 expiring June 19, 2023 15 - 15 - Molson warrants Exercise price of $24.00 expiring October 4, 2021 2,875,000 42,386 2,875,000 42,386 Issued in connection with business acquisition Exercise price of $3.96 expiring April 23, 2025 631,322 4,232 - - Exercise price of $5.64 expiring September 23, 2025 1,228,873 7,902 - - Exercise price of $8.47 expiring October 30, 2025 43,856 261 - - Exercise price of $9.03 expiring June 25, 2025 3,205,378 18,236 - - Exercise price of $11.29 expiring January 27, 2023 356,689 1,195 - - Exercise price of $78.16 expiring August 21, 2022 15,992 3 - - Exercise price of $102.71 expiring August 21, 2022 24,338 2 - - Exercise price of $151.24 expiring September 27, 2021 14,617 - - - Exercise price of $155.19 expiring April 17, 2022 226,422 1 - - 33,298,692 124,112 30,011,142 95,617 Classified as Liability US$25m Registered Direct Offering Warrants Exercise price of US$9.80 expiring December 31, 2024 1,871,259 3,185 1,871,259 1,917 US$20m Registered Direct Offering Warrants Exercise price of US$9.80 expiring January 22, 2025 1,497,007 2,548 1,497,007 1,533 3,368,266 5,733 3,368,266 3,450 36,666,958 129,845 33,379,408 99,067

Share-based Compensation

Share-based Compensation	12 Months Ended
	Jul. 31, 2021
Stock Options And Restricted Share Units [Abstract]
Share-based Compensation	24. Share-based Compensation Omnibus Plan The Company has a share option plan (the "Former Plan"), adopted in July 2017, that was administered by the Board of Directors who established exercise prices and expiry dates. Expiry dates are up to 10 years from issuance, as determined by the Board of Directors at the time of issuance. On June 28, 2018, the Board of Directors put forth a new share option plan (the "Omnibus Plan") which was approved by shareholders on August 28, 2019. Unless otherwise determined by the Board of Directors, options issued under both the Former Plan and Omnibus Plan vest over a three-year period. The maximum number of common shares reserved for issuance for options that may be granted under the Omnibus Plan is 10% of the issued and outstanding common shares or 15,264,595 common shares as at July 31, 2021 (July 31, 2020 - 12,061,644). The Omnibus plan is subject to cash and equity settlement, the Former Plan , Newstrike plan and Zenabis plan are subject to equity settlements. Options issued prior to July 2018 under the outgoing plan and the options assumed through the acquisition of Newstrike and Zenabis do not contribute to the available option pool reserved for issuance. As of July 31, 2021, the Company had 10,624,759 issued and outstanding under the Omnibus Plan, 780,429 issued and outstanding under the Former Plan and 612,955 issued and outstanding under the assumed plan from business combinations. Stock Options The following table summarizes stock option activity during the year ended July 31, 2021 and the year ended July 31, 2020. July 31, 2021 July 31, 2020 Number of Weighted average Number of Weighted average options exercise price options exercise price Opening balance 7,503,691 $ 16.30 6,072,245 $ 23.48 Granted 5,273,906 5.21 2,986,507 6.48 Replacement options issued 905,902 3.81 - - Forfeited (630,473 ) 12.80 (1,145,610 ) 22.20 Expired (624,832 ) 25.95 (380,318 ) 36.64 Exercised (410,051 ) 3.00 (29,133 ) 4.60 Closing balance 12,018,143 $ 10.63 7,503,691 $ 16.30 The following table summarizes the stock option grants during the year ended July 31, 2021 and July 31, 2020: Options granted Grant date Exercise price ($) Executives and Non-executive Total Vesting terms Expiry period October 29, 2019 13.20 207,259 683,068 890,327 Terms A 10 years January 29, 2020 7.20 - 73,255 73,255 Terms A 10 years April 28, 2020 2.76 225,000 641,331 866,331 Terms A 10 years June 26, 2020 4.08 763,756 183,103 946,859 Terms A 10 years July 28, 2020 3.84 - 209,735 209,735 Terms A 10 years Total 1,196,015 1,790,492 2,986,507 October 30, 2020 3.88 349,652 315,358 665,010 Terms A 10 years December 22, 2020 5.44 380,673 960,100 1,340,773 Terms A 10 years April 28, 2021 7.54 - 85,389 85,389 Terms A 10 years June 17, 2021 7.43 75,000 45,613 120,613 Terms A 10 years July 29, 2021 5.24 580,164 2,481,957 3,062,121 Terms A 10 years Total 1,385,489 3,888,417 5,273,906 Vesting terms A - One-third of the options will vest on each of the one-year anniversaries of the date of grant over a three-year period. The following table summarizes information concerning stock options outstanding as at July 31, 2021. Exercise price Number outstanding Weighted average Number exercisable Weighted average $2.32-$10.76 8,292,550 8.82 1,853,536 6.30 $15.56-$26.16 1,576,409 7.79 1,779,478 7.33 $28.52-$34.00 2,141,186 7.40 474,040 7.50 $47.36-$234.76 7,998 0.35 7,333 0.32 12,018,143 4,114,387 Restricted Share Units ("RSUs") Under the Omnibus Plan, the Board of Directors is authorized to issue RSUs up to 10% of the issued and outstanding common shares, inclusive of the outstanding stock options. At the time of issuance, the Board of Directors establishes conversion values and expiry dates, which are up to 10 years from the date of issuance. The restriction criteria of the units are at the discretion of the Board of Directors and from time to time may be inclusive of Company based performance restrictions, employee-based performance restrictions or no restrictions to the units. The following table summarizes RSU activity during the year ended July 31, 2021 and the year ended July 31, 2020. July 31, 2021 July 31, 2020 Value of units on Value of units on Units grant date Units grant date Opening balance 587,108 $ 8.41 - $ - Granted 24,008 3.17-7.17 609,636 8.52 Replacement units issued 223,506 8.61 - - Exercised - equity settled (223,506 ) 8.61 - - Exercised - cash settled (25,483 ) 5.62-8.60 - - Forfeited (34,801 ) 11.76 (22,528 ) 11.76 Closing balance 550,832 $ 7.91 587,108 $ 8.41 The following table summarizes the RSUs granted during the year ended July 31, 2021 and the year ended July 31, 2020. RSUs granted Grant date Unit value Executive and Non-executive Vesting terms Expiry period October 29,2019 11.76 357,111 - Terms A 10 years June 26, 2020 3.96 252,525 - Terms A 10 years Total 609,636 October 30, 2020 $ 3.16 7,161 - Terms A 10 years June 17, 2021 7.17 9,413 - Terms A 10 years July 29, 2021 5.38 7,434 - Terms A 10 years Total 24,008 Vesting terms A - One-third of the units vest on each of the one-year anniversaries for the first three years after the grant date. Share-based Compensation Share-based compensation is measured at fair value at the date of grant and are expensed over the vesting period. In determining the amount of share-based compensation, the Company used the Black-Scholes-Merton option pricing model to establish the fair value of stock options and RSUs granted at the grant date by applying the following assumptions: July 31, 2021 July 31, 2020 Exercise price (weighted average) $ 17.03 $ 26.04 Share price (weighted average) $ 17.19 $ 26.44 Risk-free interest rate (weighted average) 1.24% 1.79% Expected life (years) of options (weighted average) 5 5 Expected annualized volatility (weighted average) 85% 75% Volatility was estimated using the average historical volatility of the Company and comparable companies in the industry that have trading history and volatility history. For the year ended July 31, 2021, the Company allocated to inventory $1,506, (July 31, 2020 - $6,105) of share-based compensation applicable to direct and indirect labour in the cultivation and production process. The cash-settled share-based compensation liability is presented in Other liabilities. The following table summarizes the Company's equity-settled and cash-settled share- based payments for the year ended July 30, 2021 and 2020. July 31, 2021 July 31, 2020 $ $ Stock option share-based compensation 12,863 31,503 RSU share-based compensation 287 - Total equity-settled share-based compensation 13,150 31,503 RSU share-based compensation 127 393 Total cash-settled share-based compensation 127 393

Net Loss per Share

Net Loss per Share	12 Months Ended
	Jul. 31, 2021
Earnings per share [abstract]
Net Loss per Share	25. Net Loss per Share The following securities could potentially dilute basic net loss per share in the future but have not been included in diluted loss per share because their effect was anti-dilutive: Instrument July 31, 2021 July 31, 2020 Stock options 12,018,143 7,503,690 RSUs 550,832 587,108 Acquired and reissued warrants 5,747,487 - 2019 June financing warrants 546,135 546,135 US$25m registered direct offering warrants 1,871,259 1,871,259 US$20m registered direct offering warrants 1,497,007 1,497,007 2020 April underwritten public offering warrants 11,830,075 14,004,375 2020 May underwritten public offering warrants 7,591,876 7,852,513 Warrants issued under conversion of debentures 4,665,628 4,665,628 Joint venture issued warrants 2,875,000 2,875,000 Convertible debenture broker/finder warrants 42,491 67,491 49,235,933 41,470,206

Financial Instruments

Financial Instruments	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	26. Financial Instruments Market Risk Interest Risk The Company has minimal exposure to interest rate risk related to any investments of cash and cash equivalents. The Company may invest cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at July 31, 2021, the Company has $50,159 in notes payable (July 31, 2020 - $29,930) (Note 21) that bear interest at a fixed rate and therefore are not subject to interest risk (July 31, 2020 - not material). The Company hold senior secured convertible debt (Note 19) that bears no cash interest and is repayable at a fixed rate of 110% of the face value. Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. Financial assets The Company's level 1 and 2 investments are susceptible to price risk arising from uncertainties about their future outlook, future values and the impact of market conditions. The fair value of marketable securities and derivatives held in publicly traded entities is based on quoted market prices, which the shares of the investments can be exchanged for. Financial liabilities The Company elected an early conversion option in the year ended July 31, 2020 in which $29,860 of the aggregate principal amount of its 8% unsecured convertible debentures (Note 18) were converted, which partially mitigates the Company's Price Risk. The Company obtained an amendment to the Senior secured convertible notes equity condition (subsequent to July 31, 2021) effectively reducing the equity conditions market price threshold allowing the Company increased discretion over redemption payments to be repaid in cash or equity (Note 19). The sensitivity of the Senior secured convertible note due to price risk is disclosed in Note 19. If the July 31, 2021 fair value of these financial assets and liabilities were to increase or decrease by 10% the Company would incur a related increase or decrease to Comprehensive loss of an estimated $37,100 (July 31, 2020 - no material impact). The price risk exposure as at July 31, 2021 and July 31, 2020 is presented in the table below. July 31, 2021 July 31, 2020 $ $ Financial assets 2,492 2,692 Financial liabilities (373,432 ) (3,450 ) Total exposure (370,940 ) (758 ) Credit Risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash held in escrow, restricted cash and trade receivables. As at July 31, 2021, the Company was exposed to credit related losses in the event of non-performance by the counterparties. The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Since the majority of the medical sales are transacted with clients that are covered under various insurance programs, and adult use sales are transacted with crown corporations, the Company has limited credit risk. Cash and cash equivalents, restricted funds and cash held in escrow are held with three Canadian commercial banks that hold Dun & Bradstreet credit ratings of AA (July 31, 2020 - AA), an American commercial bank with a credit rating of A- and $111 is held with a credit union that does not have a publicly available credit rating. Certain restricted funds in the amount of $29,999 are managed by an insurer and are held as a cell captive within a Bermuda based private institution which does not have a publicly available credit rating, however the utilized custodian is Citibank which holds a credit rating of A+. The majority of the trade receivables balance is held with crown corporations of Quebec, Ontario and Alberta. Creditworthiness of a counterparty is evaluated prior to the granting of credit. The Company has estimated the expected credit loss using a lifetime credit loss approach. The current expected credit loss for the year ended July 31, 2021 is $66 (July 31, 2020 - $35). In measuring the expected credit losses, the adult-use cannabis trade receivables have been assessed on a per customer basis as they consist of a low number of material contracts. Medical trade receivables have been assessed collectively as they have similar credit risk characteristics. They have been grouped based on the days past due. The carrying amount of cash and cash equivalents, cash held in escrow, restricted cash and trade receivables represents the maximum exposure to credit risk and as at July 31, 2021; this amounted to $522,908 (July 31, 2020 - $211,860). Subsequent to July 31, 2021 the cash held in escrow has been utilized to fund the Redecan acquisition (Note 38). The following table summarizes the Company's aging of trade receivables as at July 31, 2021 and July 31, 2020: July 31, July 31, 2021 2020 $ $ 0-30 days 22,971 15,253 31-60 days 12,390 2,972 61-90 days 1,435 412 Over 90 days 625 789 Total 37,421 19,426 Economic Dependence Risk Economic dependence risk is the risk of reliance upon a select number of customers, which significantly impacts the financial performance of the Company. For the year ended July 31, 2021, the Company's recorded sales to the crown corporations; Société québécoise du cannabis ("SQDC") the Ontario Cannabis Store ("OCS") and the Alberta Gaming, Liquor and Cannabis agency ("ALGC") representing 42%, 20% and 14%, respectively (July 31, 2020 - one crown corporation representing 70%) of total applicable periods net cannabis sales. The Company holds trade receivables from the crown corporations SQDC, OCS and the AGLC representing 13%, 29% and 13%, respectively, of total trade receivable, respectively as at July 31, 2021 (July 31, 2020 - the two crown corporations SQDC and OCS representing 47% and 25% of total trade receivables, respectively). Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due (See note 2 - Going Concern Current financial liabilities include the Company's obligation on the senior secured convertible note (Note 19). The Company plans to settle this liability in equity. However, if the Company is unable to meet the requirements Equity Condition Waiver (Note 19) the Holder may demand settlement in cash. The analysis of potential cash outflow to redeem the Note up to the earliest maturity date is given below. Subsequent to the year-end, the Company settled the optional redemption payments for August 2021, September 2021 and October 2021 in equity. The Company has also received a cash settlement waiver for the May 2023 and November 2021 optional redemptions. The following table provides an analysis of contractual maturities for financial liabilities. Fiscal year 2022 2023 2024 2025 Thereafter Total $ $ $ $ $ $ Accounts payable and accrued liabilities 63,557 - - - - 63,557 Excise taxes payable 6,591 - - - - 6,591 Loans and borrowings 60,297 - - - - 60,297 Convertible debentures 6,716 41,273 - - - 47,989 Undiscounted future lease payments 6,155 5,785 6,073 5,561 54,796 78,370 143,316 47,058 6,073 5,561 54,796 256,804 Senior secured convertible note 1 315,289 143,421 - - - 458,710 Total 458,605 190,479 6,073 5,561 54,796 715,514 1 Foreign Currency Risk On July 31, 2021, the Company holds certain financial assets and liabilities denominated in United States Dollars ("US$") which consist of cash and cash equivalents, cash in escrow, restricted funds, the senior secured convertible note and warrant liabilities. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant. The Company closely monitors relevant economic information to minimize its net exposure to foreign currency risk. The Company is exposed to unrealized foreign exchange risk through its cash and cash equivalents. As at July 31, 2021, approximately $434,838 (US$348,931) (July 31, 2020 - $42,981 (US$57,652)) of the Company's cash and cash equivalents was in US. A 1% change in the foreign exchange rate would result in a change of $4,348 to the unrealized gain or loss on foreign exchange or on the gain or loss on financial instrument revaluation of US denominated warrants. Subsequent to year end, cash held in escrow has been utilized to fund the acquisition of Redecan (Note 38). The Company's Senior secured convertible note is denominated in US$. The Company plans to settle this debt in equity. However, if the Company is unable to meet the equity settlement condition or secure cash settlement waivers, the settlement may entail cash outflow. The sensitivity of the Senior secured convertible note due to foreign currency risk is disclosed in Note 19.

Operating Expenses by Nature

Operating Expenses by Nature	12 Months Ended
	Jul. 31, 2021
Expenses by nature [abstract]
Operating Expenses by Nature	27. Operating Expenses by Nature The following table disaggregates the selling, general and administrative expenses as presented on the Statement of Loss and Comprehensive Loss into specified classifications based upon their nature: For the year ended July 31, 2021 July 31, 2020 $ $ Salaries and benefits 21,116 12,202 Professional fees 11,962 9,811 Facilities 6,550 6,895 Selling, general and administrative 13,915 14,409 Consulting 4,379 7,425 Travel 265 2,051 Total 58,187 52,793 The following table summarizes the nature of share-based compensation in the period: For the year ended July 31, 2021 July 31, 2020 $ $ General and administrative related share-based compensation 10,945 24,650 Marketing and promotion related share-based compensation 786 1,140 Total operating expense related share-based compensation 11,731 25,790 Share based compensation capitalized to inventory 1,505 6,105 Total share-based compensation 13,236 31,895 The following table summarizes the total payroll related wages and benefits by nature in the period: For the year ended July 31, 2021 July 31, 2020 $ $ General and administrative related wages and benefits 21,116 12,202 Marketing and promotion related wages and benefits 5,543 5,625 Research and development related wages and benefits 2,706 2,717 Total operating expense related wages and benefits 29,365 20,544 Wages and benefits capitalized to inventory 14,993 21,128 Total wages and benefits 44,358 41,672

Other Income and Losses

Other Income and Losses	12 Months Ended
	Jul. 31, 2021
Other Income And Losses [Abstract]
Other Income and Losses	28. Other Income and Losses For the year ended July 31, 2021 July 31, 2020 $ $ Interest and financing expenses (32,124 ) (10,043 ) Interest income 1,601 1,902 Interest income (expense), net (30,523 ) (8,141 ) Revaluation of warrant liabilities (2,283 ) 6,533 Share of loss from investment in associates and joint ventures (6,505 ) (6,331 ) Loss on Unsecured Convertible Debentures - December 2019 - (54,283 ) Fair value gain/(loss) on convertible debenture 1,260 (4,806 ) Fair value loss on senior secured convertible note (7,478 ) - Unrealized gain/(loss) on investments 1,994 (12,880 ) Realized gain on investments - 24 Foreign exchange gain/(loss) 9,108 1,392 Other income 4,763 2,531 Non-operating income (expense), net 859 (67,820 )

Related Party Disclosure

Related Party Disclosure	12 Months Ended
	Jul. 31, 2021
Disclosure of transactions between related parties [abstract]
Related Party Disclosure	29. Related Party Disclosure Compensation of Key Management Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the Company's operations, directly or indirectly. The key management personnel of the Company are the members of the executive management team and Board of Directors. Compensation provided to key management during the year was as follows: For the year ended July 31, 2021 July 31, 2020 $ $ Salary and/or consulting fees 2,321 3,069 Termination benefits 1,008 1,043 Bonus compensation 800 42 Stock-based compensation 6,800 15,702 Total 10,929 19,856 These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed by the related parties. Related Parties and Transactions Belleville Complex Inc. The Company holds a 25% interest in Belleville Complex Inc. ("BCI") with the related party Olegna Holdings Inc., a company owned and controlled by a director of the Company, holding the remaining 75% in BCI. BCI purchased a configured 2,004,000 sq. ft. facility through a $20,279 loan issued and repaid during the year ended July 31, 2019. The Company will be the anchor tenant for a 15-year lease, with an option to renew for 15 years and additional space to rent. The Company has also subleased a portion of the space to Truss Limited Partnership (Note 11). Consideration for the 25% interest on the joint venture is deemed $ nil The Company leases a space in Belleville from a related party BCI, that supports its manufacturing activities and is based in Belleville, Ontario. Under this lease arrangement, the Company incurred $5,369 in lease and operating expenses during the year ended July 31, 2021 (July 31, 2020 - $7,511). This lease liability is recognized on the Company's balance sheet under IFRS 16 (Note 20). Truss LP The Company owns a 42.5% interest in Truss LP and accounts for the interest as an investment in an associate (Note 11). The Company subleases section of its Belleville lease to Truss LP this sublease is recognized as a finance lease receivable on the Company's balance sheet (Note 8). The Company recognizes a recovery on its partnership with Truss LP in Other receivables and Other income. Under a Temporary Supply and Services Agreement ("TSSA") with Truss LP, the Company produces and packages cannabis infused beverages in the CIB Facility (located at the Belleville Facility) and in the Gatineau Facility, an markets and sells beverages for the legal adult-use markets in Canada, in each case subject to the terms of its regulatory approvals and applicable laws, all for its own account and as a stand-alone division of HEXO. Truss LP applied to be a licensed producer of Cannabis during the period, but until the time where Truss LP obtains all regulatory approval required under the Cannabis Act (Canada), the TSSA will remain in place. Under the TSSA, Truss LP will be an exclusive supplier to the Company of all property and all services required to carry on the business, other than specific services which are required to be provided by HEXO. As a result of this arrangement, there is a net payable to Truss of $6,928 at July 31, 2021 (July 31, 2020 - $1,247). During the year ended July 31, 2021, the Company purchased $7,624 (July 31, 2020 - $2,159) of raw materials from Truss LP under the arrangement and received $1,844 (July 31, 2020 - $2,531) of Income.

Capital Management

Capital Management	12 Months Ended
	Jul. 31, 2021
Disclosure Of Capital Management [Abstract]
Capital Management	30. Capital Management The Company's objectives when managing capital are to (1) safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and (2) maintain an optimal capital structure to reduce the cost of capital. Management defines capital as the Company's shareholders' equity and interest-bearing debt. The Board of Directors does not establish quantitative return on capital criteria for management. The Company has not paid any dividends to its shareholders. The Company is not subject to any externally imposed capital requirements other than the covenants related to the Company's debt instruments as set out in Notes 18 and 19. As at July 31, 2021, total managed capital was $732,265 (July 31, 2020 - $556,676).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2021
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies	31. Commitments and Contingencies COMMITMENTS The Company has certain contractual financial obligations related to service agreements, purchase agreements, rental agreements and construction contracts. Some of these contracts have optional renewal terms that the Company may exercise at its option. The annual minimum payments payable under these obligations over the next five fiscal years and thereafter are as follows: $ July 31, 2022 18,244 July 31, 2023 3,846 July 31, 2024 3,474 July 31, 2025 2,429 July 31, 2026 5,802 Thereafter 13,472 47,267 See Note 20 for recognized contractual commitments regarding the Company's lease obligations under IFRS 16. LETTERS OF CREDIT The Company holds a five-year letter of credit with a Canadian financial institution to provide a maximum of $250 that amortizes $50 annually until its expiry on July 14, 2024. As at July 31, 2021, the remaining balance of the letter of credit is $200, was not drawn upon and is secured by cash held in collateral (Note 6). On August 1, 2020, the Company reissued a pre-existing letter of credit with a Canadian financial institution under an agreement with a public utility provider entitling the utility provider to a maximum of $2,581, subject to certain operational requirements. The letter of credit has a one-year expiry from the date of issuance with an auto renewal feature. On January 1, 2021, the letter of credit was reduced to $2,352 by way of amendment. The letter of credit has not been drawn upon as at July 31, 2021. The letter of credit is secured by cash held in collateral (Note 6). CONTINGENCIES The Company may be, from time to time, subject to various administrative and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated. While the following matters are ongoing, the Company disputes the allegations and intends to continue to vigorously defend against the claims. As of July 31, 2021, the Company and its Chief Executive Officer are defendants in a putative class-action lawsuit pending in the Québec Superior Court brought on behalf of certain purchasers of shares of the Company and filed on November 19, 2019. The lawsuit asserts causes of action for misrepresentations under the Québec Securities Act and the Civil Code of Québec in connection with certain statements contained in HEXO's prospectus, public documents and public oral statements between April 11, 2018 and November 15, 2019. The allegations relate to: (1) statements made by the Company regarding its agreement with the Province of Québec to supply cannabis; (2) statements made by the Company regarding its acquisition of Newstrike, particularly the licensing of the Newstrike facilities and the forecasted synergies and/savings from the Newstrike acquisition; (3) statements made by the Company about the net revenues in Q4 2019 and fiscal year 2020; and (4) the certifications by Sebastian St-Louis and the underwriters of the Company. The plaintiffs seek to represent a class comprised of Québec residents who acquired the Company's securities either in an Offering (primary market) or on the secondary market during such period and seek compensatory damages for all monetary losses and costs. The amount claimed for damages has not been quantified and no accrual has been made as at July 31, 2021 (July 31, 2020 - $nil). As of July 31, 2021, the Company is named as a defendant in a proposed consumer protection class action filed on June 16, 2020, in the Court of Queens' Bench in Alberta on behalf of residents of Canada who purchased cannabis products over specified periods of time. Several other licensed producers are also named as co-defendants in the action. The lawsuit asserts causes of action, including for breach of contract and breach of consumer protection legislation, arising out of allegations that the Tetrahydrocannabinol (THC) or Cannabidiol (CBD) content of medicinal and recreational cannabis products sold by the Company and the other defendants to consumers was different from what was advertised on the products' labels. Many of the cannabis products sold by the Company and other defendants were allegedly sold to consumers in containers using plastic bottles or caps that may have rapidly absorbed or degraded the THC or CBD content within them. By allegedly over-representing the true amount of THC or CBD in the products, the plaintiff claims that consumers would be required to consume substantially more product than they otherwise would have in order to obtain the desired effects or, in the alternative, would have consumed the product without obtaining the desired effects. The action has not yet been certified as a class action. On June 1, 2021, by way of the business acquisition of Zenabis, the Company assumed senior notes payable and the following litigation with the associated lender of the notes (Note 21b). Upon closing the acquisition of Zenabis, the Company was in default under the debenture due to the failure to obtain the lenders consent for a change of control. On February 19, 2021, Zenabis filed a petition in the Supreme Court of British Columbia for a determination of the amount required to repay and terminate the debenture and to obtain discharges of the debenture and related security. The lender took the position that the amount to discharge the debenture and related securities was approximately $72,000. The Company believes the amount is approximately $53,000, which has been provided for in the consolidated financial statements. Under the senior secured convertible note agreement (Note 19), the Company has restricted funds to satisfy this liability (Note 6). The difference largely relates to whether a prepayment fee and default fees are payable under the debenture and to the amount to buyout and discharge of a revenue based royalty liability. The petition was heard on March 29, March 30, March 31, April 1, April 15 and May 14, 2021. The Judge's decision remains on reserve and no indication as to the likely timing of its release has been provided. ONEROUS CONTRACT During the year ended July 31, 2020, the Company recognized a $4,763 onerous contract provision related to a fixed price supply agreement for the supply of certain cannabis products. The supply agreement is currently the subject of legal proceedings as disclosed above. The costs and purchase obligations under the contract exceed the economic benefits expected to be received. The related loss has been included in operating expenses in the year ended July 31, 2020. The onerous contract liability remains as at July 31, 2021.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jul. 31, 2021
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Fair Value of Financial Instruments	32. Fair Value of Financial Instruments The fair values of the financial instruments as at July 31, 2021 are summarized in the following table: Amortized cost FVTPL Total Assets $ $ $ Cash and cash equivalents 67,462 - 67,462 Restricted funds 132,246 - 132,246 Trade receivables 37,421 - 37,421 Commodity taxes recoverable and other receivables 13,549 - 13,549 Lease receivable - long term 4,453 - 4,453 Long - term investments - 2,492 2,492 Liabilities $ $ $ Accounts payable and accrued liabilities 63,557 - 63,557 Warrant liability - 5,733 5,733 Convertible debt- current 3,406 - 3,406 Convertible debt 33,089 33,089 Senior secured convertible note - current - 367,699 367,699 Loans and borrowings - current 50,159 50,159 Other long-term liabilities (1) - 520 520 1 The fair values of the financial instruments as at July 31, 2020 are summarized in the following table: Amortized cost FVTPL Total Assets $ $ $ Cash and cash equivalents 184,173 - 184,173 Restricted funds 8,261 - 8,261 Trade receivables 19,426 - 19,426 Commodity taxes recoverable and other receivables 16,773 - 16,773 Lease receivable - long term 3,865 - 3,865 Long - term investments - 3,209 3,209 Liabilities $ $ $ Accounts payable and accrued liabilities 32,451 - 32,451 Warrant liability - 3,450 3,450 Convertible debentures 28,969 - 28,969 Term loan - current 29,930 - 29,930 Other long-term liabilities (1) - 393 393 1 The carrying values of cash and cash equivalents, restricted funds, cash held in escrow, short term investments, trade and other receivables, lease receivables, accounts payable and accrued liabilities, lease liabilities and term loan approximate their fair values due to their relatively short periods to maturity.

Non-Controlling Interest

Non-Controlling Interest	12 Months Ended
	Jul. 31, 2021
Non Controlling Interest [Abstract]
Non-Controlling Interest	33. Non-Controlling Interest The change in non-controlling interests is as follows. July 31, 2021 July 31, 2020 Balance, Beginning of year $ 3,379 $ - Non-controlling interest acquired on business combination (1,340 ) - Partnership contributions 81 3,379 Share of comprehensive loss for the period (133 ) - Balance, End of year $ 1,987 $ 3,379 Keystone Isolation Technology Inc The Company holds a 60% interest in Keystone Isolation Technology Inc. ("KIT") which is intended to principally operate out of Belleville Facility, and the remaining 40% represents the non-controlling interest held by Chroma Global Technologies Ltd (the "Partner"). Under the terms of the shareholder agreement, the Company has contributed cash of $4,699 (USD$3,100). During the year ended July 31, 2021, the Partner contributed capital equipment in-kind of $371 as required under the terms of the shareholders agreement. There remains approximately $325 of an in-kind commissioning contribution to satisfy the acquisition terms of the shareholders agreement. KIT had no revenues or expenses during the year ended July 31, 2021 and the year ended July 31, 2020.The following table summarizes the information relating to the Company's non-controlling interest in KIT. July 31, 2021 July 31, 2020 Current assets $ - $ - Non-current assets 8,651 7,455 Current liabilities - - Non-current liabilities - - Non-controlling interest (%) 40% 40% Non-controlling interest $ 3,460 $ 3,379 ZenPharm Limited The Company holds a 60% interest in ZenPharm Limited ("ZenPharm") obtained through the acquisition of Zenabis on June 1, 2021. ZenPharm was formed to service the European medical cannabis market. The following table is the summarized financial information of ZenPharm July 31, 2021 Current assets $ 313 Non-current assets 141 Current liabilities (3,233 ) Non-current liabilities - Accumulated deficit (133 ) Non-controlling interest (%) 40% Non-controlling interest $ (1,475

Revenue from Sale of Goods

Revenue from Sale of Goods	12 Months Ended
	Jul. 31, 2021
Revenue [abstract]
Revenue from Sale of Goods	34. Revenue from Sale of Goods The Company disaggregated its revenues from the sale of goods between sales of cannabis beverages ("Cannabis beverage sales") and dried flower, vapes, and other cannabis products ("Cannabis sales excluding beverages"). The Company's cannabis beverage sales are derived from the Cannabis Infused Beverage ("CIB") line, which was established in order to manufacture, produce and sell cannabis beverage products. CIB operates under the Company's cannabis licensing and in compliance with Health Canada and the Cannabis Act's regulations. The Company has assessed the beverage revenue stream to be realized by the Company and presented on a gross basis as defined under IFRS 15. The Company will continue to operate CIB until Truss has obtained its independent licensing to cultivate and manufacture cannabis, at which point the operations will shift to Truss. For the year ended July 31, 2021 July 31, 2020 Revenue stream Cannabis sales Cannabis 1 Total Cannabis sales Cannabis Total $ $ $ $ $ $ Retail 143,098 15,821 158,919 101,713 2,851 104,564 Medical 1,769 - 1,769 3,299 - 3,299 Wholesale 2,458 - 2,458 995 - 995 International 9,935 - 9,935 1,291 - 1,291 Total revenue from sale of goods 157,260 15,821 173,081 107,298 2,851 110,149 1 During the year ended July 31, 2021 the Company incurred $3,736 (July 31, 2020 - $6,942) of net sales provisions and price concessions.

Segmented Information

Segmented Information	12 Months Ended
	Jul. 31, 2021
Disclosure of operating segments [abstract]
Segmented Information	35. Segmented Information The Company operates under one material operating segment. Substantially all property, plant and equipment and intangible assets are located in Canada.

Operating Cash Flow

Operating Cash Flow	12 Months Ended
	Jul. 31, 2021
Operating Cash Flow [Abstract]
Operating Cash Flow	36. Operating Cash Flow The following items comprise the Company's operating cash flow activity for the periods herein. For the year ended July 31, 2021 July 31,2020 $ $ Items not affecting cash Income tax recovery (397 ) (6,023 ) Depreciation of property, plant and equipment 6,097 6,072 Depreciation of property, plant and equipment in cost of sales 8,601 3,567 Amortization of intangible assets 2,050 3,939 Loss on convertible debentures 6,218 4,806 Unrealized gain on changes in fair value of biological assets (51,499 ) (29,356 ) Unrealized fair value adjustment on investments (1,994 ) 12,880 Amortization of deferred financing costs 793 56 Interest and other income 5,837 9,921 Loss on induced conversion of debenture - 54,283 Accretion of convertible debenture 4,075 - Non-cash finance and transaction fees 21,690 - Loss on investment - (24 ) License depreciation and prepaid royalty expenses 118 389 Write-off of inventory and biological assets 2,182 5,055 Write down of inventory to net realizable value 2,927 68,319 Realized fair value amounts on inventory sold 31,767 40,910 Loss from investment in associate and joint ventures 6,505 6,331 Share-based compensation 14,859 25,790 Revaluation of financial instruments (gain)/loss 2,283 (6,533 ) Impairment losses 20,230 299,484 Loss on onerous contract - 4,763 Loss on long lived assets and disposal of property, plant and equipment 1,358 3,855 Gain on exit of lease (789 ) - Foreign exchange gain (11,648 ) - Total items not affecting cash 71,263 508,484 Changes in non-cash operating working capital items Trade receivables (14,203 ) 267 Commodity taxes recoverable and other receivables 5,197 (784 ) Prepaid expenses (106 ) 5,717 Inventory (52,539 ) (100,492 ) Biological assets 53,678 28,493 Accounts payable and accrued liabilities 8,848 6,623 Excise taxes payable (444 ) 3,627 Total non-cash operating working capital 431 (56,549 ) Additional supplementary cash flow information is as follows: For the year ended July 31, 2021 July 31, 2020 $ $ Property, plant and equipment in accounts payable 1,152 19,751 Right-of-use asset additions 17,059 24,405 Capitalized borrowing costs 1,269 2,385 Interest paid 5,618 2,527

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2021
Income taxes paid (refund) [abstract]
Income Taxes	37. Income Taxes Income tax expense recognized in comprehensive loss consists of the following components: July 31, 2021 July 31, 2020 Current tax for the year $ 22 $ - Adjustments of previous years - - Total $ 22 $ - Components of deferred income tax expense (recovery): July 31, 2021 July 31, 2020 Origination and reversal of temporary differences $ (14,659 ) $ (98,141 ) Difference between statutory tax rate and deferred tax rate (249 ) 2,555 Change in temporary difference for which no deferred tax assets are recorded 14,489 89,563 Deferred income tax (recovery) $ (419 ) $ (6,023 ) The Company's expected tax rate is different from the combined federal and provincial income tax rate in Canada. These differences result from the following elements: July 31, 2021 July 31, 2020 Expected tax rate 26.50% 26.54% Earnings before income taxes $ (115,159 ) $ (552,512 ) Expected tax benefit resulting from loss (30,517 ) (146,637 ) Adjustments for the following items: Tax rate differences (652 ) 2,555 Permanent differences 8,696 48,965 Change in temporary differences for which no tax assets are recorded 22,148 89,094 True up and other (72 ) - $ (397 ) $ (6,023 ) The following is a reconciliation of the deferred tax assets and liabilities recognized by the Company: Opening Recognize Business Recognized in Ending August 1, 2020 in income Combination equity July 31, 2021 $ $ $ $ $ Taxable temporary differences 10,415 (14,701 ) (310 ) (421 ) (5,017 ) Biological assets (1,330 ) 724 - - (606 ) Inventory (5,088 ) 1,514 (7,276 ) - (10,850 ) Loss carryforward - 14,028 14,665 - 28,693 Financing costs - (2,738 ) 2,738 - - Intangible assets (3,997 ) 1,592 (9,951 ) - (12,356 ) Net deferred tax asset (liability) - 419 (134 ) (421 ) (136 ) Opening Recognized in Recognized in Ending August 1, 2019 income equity July 31, 2020 $ $ $ $ Taxable temporary differences 6,858 3,557 - 10,415 Biological assets (1,514 ) 184 - (1,330 ) Inventory (2,920 ) (2,168 ) - (5,088 ) Loss carryforward 23,369 (23,369 ) - - Financing costs 721 (721 ) - - Intangible assets (32,537 ) 28,540 - (3,997 ) Net deferred tax asset (liability) (6,023 ) 6,023 - - Deferred income taxes reflect the impact of loss carryforwards and of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws. At July 31, 2021 deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized are attributable to the following: July 31, 2021 July 31, 2020 $ Deductible temporary differences 11,556 8,328 Taxable temporary differences 26,444 8,412 Investments 17,030 14,890 Losses carried forward 278,115 255,635 Research and development expenditures 1,817 669 Fixed Assets, intangibles and other assets 114,384 52,852 Financing costs 40,401 22,599 489,747 363,385 The Company has approximated non-capital losses available to reduce future years' federal and provincial taxable income which expires as follows: $ 2022 219 2023 281 2024 164 2025 748 2026 632 2027 104 2028 2,092 2029 1,350 2030 75 2031 2,867 2032 3,018 2033 4,030 2034 1,772 2035 2,413 2036 12,889 2037 37,244 2038 64,821 2039 57,938 2040 157,595 2041 24,764 Indefinite 1,179 376,195

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2021
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	38. Subsequent Events Transfer of US Stock exchange Listing from NYSE to the Nasdaq On August 13, 2021, the Company applied to transfer its U.S. stock exchange listing from the New York Stock Exchange to the Nasdaq. The transfer was completed on August 24, 2021, at which point the common shares of HEXO began trading as a Nasdaq-listed security with the shares continuing to trade under the symbol "HEXO". Closing of Underwritten Public Offering for US$144.8M On August 24, 2021, the Company closed an underwritten public offering for total gross proceeds of US$144,786. The Company sold 49,080,024 units of the Company at a price of US$2.95 per unit under this offering. Each unit is comprised of one common share of the Company and one half of one common share purchase warrant of the Company. Each full warrant is exercisable to acquire one common share of the Company for a period of five years following the closing date of the Offering at an exercise price of US$3.45. Acquisition of Redecan On August 30, 2021 the Company completed its acquisition of all of the outstanding shares of the entities that carry on the business of Redecan, a privately-owned licensed producer which serves the Canadian adult-use and medical markets. At closing, HEXO paid the selling shareholders of Redecan $400,000 in cash and delivered 69,721,116 newly issued common shares of HEXO with an approximate value of $214,043. Upon closing the acquisition of Redecan, Peter James Montour joined the Company board of directors. Will Montour will act as non-voting observer on the board of directors, until his election to the board in accordance with the investor rights agreement undertaken at acquisition. The transaction is expected to be treated as business acquisition under IFRS 3, accounted for using the acquisition method. Acquisition of 48North Cannabis Corp. On September 1, 2021, HEXO completed the acquisition of 48North Cannabis Corp. ("48North"), a licensed cannabis producer that serves the Canadian medical and adult-use markets with a brand portfolio that includes: 48North, Trail Mix and Latitude. The Company acquired all issued and outstanding common shares of 48North at a conversion rate of one common share of 48North to 0.02366 of a HEXO common share. The total number of shares acquired and reissued were 5,352,005 with an approximate value of $16,951. Shares of 48North were de-listed from the TSX Venture Exchange on September 2, 2021. The transaction is expected to be treated as business acquisition under IFRS 3, accounted for using the acquisition method. Truss Beverage Co. Receives Manufacturing Cannabis Licensing On October 1, 2021, Truss LP received their cannabis manufacturing licenses from Health Canada. As of the date of these financial statements, the Company continues to assess the financial and accounting impact of Truss Beverage Co. receiving their cannabis manufacturing license. The Company is in the process of establishing a new agreement between the Company and Truss LP which may result in the Company acting as an agent, facilitating sales between Truss LP and our customers, and therefore the Company would likely cease recording such sales on a gross basis.

Significant Accounting Polici_2

Significant Accounting Policies and Pronouncements (Policies)	12 Months Ended
	Jul. 31, 2021
Significant Accounting Policies [Abstract]
CASH AND CASH EQUIVALENTS	(a) CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertible into known amounts of cash with original maturities of three months or less.
RESTRICTED FUNDS	(b) RESTRICTED FUNDS Restricted funds represent cash that is pledged as collateral or guarantees for certain of the Company's projects, obligations, and agreements. Funds related to the Company's captive insurance program are included in restricted funds. Captive Insurance is coverage for the Company's directors and officers that has been secured through a Captive Cell program ("the Captive Program"). The Captive Program was effected by entered into a participation agreement with a registered insurer for the purposes of holding and managing the Company's coverage funds through a separate cell account (the "Cell Captive").Captive Program funds are held as cash in the Cell Captive with the possibility of reinvestment into short-term investments and/or marketable securities in the future. As the funds cannot be transferred to other parts of the group without providing 6 month notice, the funds are disclosed as Restricted cash. The Company recognizes gains and losses from, interest, foreign exchange activity and/or fair market value adjustments through the Statement of Loss and Comprehensive Loss.
CASH HELD IN ESCROW	(c) CASH HELD IN ESCROW Cash held in escrow is cash that is held by independent escrow agents to fund future acquisitions but restricted by certain release conditions.
SHORT TERM INVESTMENTS	(d) SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are measured at amortized cost using the effective interest method, less loss allowance.
TRADE RECEIVABLES	(e) TRADE RECEIVABLES Trade receivables are recognized initially at the amount of consideration that is unconditional, unless they contain significant financing components when they are recognized at fair value. Trade receivables are subsequently measured at amortized cost using the effective interest method, less loss allowance.
COMMODITY TAX RECOVERABLES & OTHER RECEIVABLES	(f) COMMODITY TAX RECOVERABLES & OTHER RECEIVABLES Commodity tax recoverable and other receivables are initially measured at fair value fair value and subsequently measured at amortized cost, less any provisions for impairment.
BIOLOGICAL ASSETS	(g) BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell at the point of harvest, which becomes the basis for the cost of related inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs (including share based compensation), grow consumables, materials, utilities, facilities costs, depreciation, overhead, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item 'costs of goods sold' on the statement of loss and comprehensive loss in the period that the related product is sold. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period.
INVENTORY	(h) INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis ("Dried cannabis") are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, depreciation, amortization, and labor related costs (including share-based compensation) involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within 'cost of goods sold' on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross profit. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value.
PROPERTY, PLANT AND EQUIPMENT	(i) PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Construction in progress is transferred to a depreciable asset class property, plant and equipment when the assets are available for use and depreciation of the assets commences at that point. Depreciation is provided using the following terms and methods: Asset Method Term Land Not depreciated No term Buildings Straight line 5 to 40 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years An asset's residual value and useful life are reviewed at each reporting date and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss.
FINITE LIFE INTANGIBLE ASSETS	(j) FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Asset Method Term Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3-5 years Patents Straight line 20 years Finite life, brands Straight line 3 years The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period.
INDEFINITE LIFE INTANGIBLE ASSETS	(k) INDEFINITE LIFE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company intends to utilize the brand indefinitely. The capitalized indefinite life brand consists of the Company's premium Up brand, which was recognized upon the acquisition of Newstrike in May 2019. Brand Not amortized Indefinite
GOODWILL	(l) GOODWILL Goodwill is not amortized but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. Goodwill is allocated to cash-generating units ("CGUs") for the purpose of impairment testing. The allocation is made to those CGUs or groups of CGUs that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the Company's single operating segment.
IMPAIRMENT OF NON-FINANCIAL ASSETS	(m) IMPAIRMENT OF NON-FINANCIAL ASSETS Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's or CGU's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal ("FVLCD") and value in use ("VIU"). For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (CGUs) Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. In assessing the VIU, the estimated future cash flows are discounted to their present value using a pre- tax discount rate that reflects current market assessments of the time value of money to the Company and the risks specific to the asset. In determining FVLCD an appropriate valuation model is used. Where the carrying amount of a CGU exceeds its recoverable amount, the CGU is considered impaired and is written down to its recoverable amount. Any impairment loss is recorded in earnings and previously recognized impairment losses (excluding the impairment of Goodwill) are reversed or partially reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized, in which case, the carrying amount of the asset is increased to its recoverable amount. The new carrying amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized.
BUSINESS ACQUISITIONS	(n) BUSINESS ACQUISITIONS The acquisition method is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. Operating results are included in the consolidated financial statements as of the acquisition date. The consideration transferred for the acquisition comprises the: • fair values of the assets transferred; • liabilities incurred to the former owners of the acquired business; • equity interests issued by the Company; • fair value of any asset or liability resulting from a contingent consideration arrangement; and • fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, with the exceptions of leases under IFRS 16 and deferred taxes. The Company recognizes any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets. The Company has one year from the acquisition date to finalize the estimates and assumptions that support the finalized fair value analysis and purchase price allocation. Until this time, these values reported are subject to change. Changes to fair values and allocations are retrospectively adjusted in subsequent periods. Acquisition-related costs are expensed as incurred and are presented under 'Acquisition and transaction costs' in the consolidated statements of loss and comprehensive loss. The excess of the consideration transferred, amount of any non-controlling interest in the acquired entity, and acquisition-date fair value of any previous equity interest in the acquired entity over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in profit or loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value, with changes in fair value recognized in profit or loss. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in profit or loss.
NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE	(o) NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs of disposal of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Non-current assets (including those part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized. Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	(p) ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. Accounts payable and accrued liabilities are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.
REVENUE RECOGNITION	(q) REVENUE RECOGNITION Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Net revenue is presented net of taxes, estimated returns, allowances and discounts. Canada Revenue Agency ("CRA") levies excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an ad valorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019, excise tax calculated on edible cannabis products, cannabis extracts and cannabis topicals will prospectively be calculated as a flat rate based on the quantity of total tetrahydrocannabinol (THC) contained in the final product. There were no changes in the legislation in calculating excise taxes for fresh cannabis, dried cannabis, seeds and plants. Net revenue from sale of goods, as presented on the consolidated statements of comprehensive (loss) income, represents revenue from the sale of goods less applicable excise taxes.
COST OF GOODS SOLD	(r) COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labor.
INCOME TAXES	(s) INCOME TAXES The income tax expense or recovery for the period is the tax payable on the current period's taxable income, based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax expense or recovery is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment. The Company measures its tax balances either based on the most likely amount or the expected value, depending on which method provides a better prediction of the resolution of the uncertainty. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.
SHARE-BASED COMPENSATION	(t) SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company's estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received
RESTRICTED SHARE UNITS ("RSU's")	(u) RESTRICTED SHARE UNITS ("RSU's") RSUs are cash or equity settled share-based payments granted to certain employees, directors and executives within the Company. RSUs are measured at their initial fair value on the date of the grant utilizing the Black- Scholes Merton model. The fair value of cash-settled RSUs is revalued at each period end and is recognized as share-based compensation expense over the vesting period with a corresponding adjustment to the liability. Upon the settlement of cash based RSUs, which are valued at the market value at the time of exercise, the related liability is transferred to share capital. The fair value of equity-settled RSUs are recognized in the share- based reserve at the grant date. Upon the settlement of equity-based payments, RSUs are settled in the form of common shares and the related share-based reserve is transferred to share capital. Amounts recorded for forfeited RSUs are transferred to the accumulated deficit in the year of forfeiture or expiry.
LOSS PER SHARE	(v) LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.
BORROWING COSTS	(w) B ORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred.
FINANCIAL INSTRUMENTS	(x) FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. The Company classifies its financial assets in the following measurement categories: • • those to be measured at amortized cost. The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. The Company has made the following classifications: Financial assets IFRS 9 Classification Cash and cash equivalents Amortized cost Restricted funds Amortized cost Short-term investments Amortized cost Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investments FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liabilities FVTPL Deferred rent liability Amortized cost Convertible debentures Amortized cost Senior secured convertible note FVTPL Lease liabilities Amortized cost Loans and borrowings Amortized cost (i) Fair Value Through Profit or Loss ("FVTPL") Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest ("SPPI") or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. (ii) Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. An amortized cost financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost using the effective interest rate. (iii) Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. (iv) Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities mandatory classified at FVTPL, such derivates, are stated at fair value, with changes being recognized through the consolidated statements of loss. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Senior secured convertible note issued in currency other than the functional currency of the Company are classified entirely as liabilities. As the Note contains equity and non-equity embedded derivatives, they are designated at fair value through profit or loss on initial recognition when embedded features are not separated. The component of fair value changes relating to the Company’s own credit risk is recognized in other comprehensive loss. Amounts recorded in other comprehensive loss related to credit risk are not subject to recycling in profit or loss but are transferred to retained earnings when realized. Financial liabilities are classified as current when the Company does not retain an unconditional right to defer settlement, due to a conversion feature or otherwise, beyond 12 months from the reporting date. (v) Derivatives Derivatives are initially measured at fair value and are subsequently measured at FVTPL. If the transaction price does not equal to fair value at the point of initial recognition, management measures the fair value of each component of the investment and any unrealized gains or losses at inception are either recognized in profit or loss or initially unrecognized and recognized over the term of the investment, depending on whether the valuation inputs are based on observable market data. The resulting unrealized gain or loss at inception and subsequent changes in fair value are recognized in profit or loss for the period. Transaction costs, which are directly attributable to the acquisition of the investment, are expensed as incurred. (vi) Convertible Debentures The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument's maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. (vii) Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. Fair Value on initital recognition Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal (or most advantageous) market at the measurement date under current market conditions (i.e. an exit price) regardless of whether that price is directly observable or estimated using another valuation technique. If, after considering the terms of the transaction, the Company determines that the fair value of a financial instrument at initial recognition differs from the transaction price, the difference is recognized as a gain or loss in the statement of loss only if fair value is evidenced by quoted prices or based on a valuation technique that uses only data from observable markets. In all other cases, the difference is deferred and recognized systematically to the extent that it arises from a change in a factor (including time) that market participants would consider in setting a price. Any subsequent measurement of the instrument excludes the balance of the deferred day one gain or loss.
FOREIGN CURRENCY TRANSLATION	(y) FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign Operations The assets and liabilities of foreign operations are translated to the presentation currency at exchange rates at the reporting date. The income and expenses of foreign operations are translated to the presentation currency using average exchange rates for the month during which the transactions occurred. Foreign currency differences are recognized in Other Comprehensive Loss in the Accumulated Other Comprehensive Loss account.
SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS	(z) SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Significant Accounting Judgements Impairment of non-financial assets Non-financial asset impairment tests require the allocation of assets to CGUs or CGU groups, which requires significant judgement and interpretation with respect to the integration between assets, the existence of active markets, similar exposure to market risks, shared resources and assets, and the way in which management monitors the operations. Non-financial asset impairment tests require the determination of whether there is an indication of impairment. The assessment of whether there is any indication of impairment is performed at the end of each reporting period, and requires the application of judgement historical experience, and use of external and internal sources of information Revenue - Principal versus Agent The Company evaluates whether it is the principal (reports on gross basis) or agent (reports on a net basis) for revenues generated by the direct sale of cannabis infused beverages ("CIB's). The Company control's the CIB's prior to the sale to its customers as regulated and mandated under the Cannabis Act and Health Canada legislation. The Company's control is evidenced by our sole ability to possess the CIB's once the cannabis distillate has been added and thus establishing the inventory as a cannabis product requiring it to be held by a licensed producer. It is further evidenced by the Company possessing the sole ability to monetize the sale of CIB's through the held sales agreements and purchase orders with customers. The Company presents the revenues from the sale of CIBs on a gross basis. Senior Secured Convertible Note Management used significant judgement to determine that the fair value of the Note on issuance does not equal the transaction price, which was attributed, among other things, to a premium paid as a result of the limited time available to close the financing required to secure the Redecan acquisition. The resulting difference between the transaction price and the fair value on initial recognition (the “Day 1 loss”) is deferred as the fair value of the Note is based on a valuation technique where not all the inputs are observable. The unrecognized Day 1 loss will be recorded in the statement of net loss only to the extent that it arises from a change in factor that market participants would take into account when pricing the Note. The Company believes that time is such a factor specific to the Note and the Day 1 loss is recognized on a straight line basis in the statement of net loss over the contractual life of the note. Going Concern and Liquidity In assessing the Company’s ability to continue as a going concern, management utilizes significant estimates in the forecasting of future cash flows. Critical input estimates such as economic conditions, market demands, production quality, integrated operating activities, capital project expenditures and convertible debt repayments are used. Significant Accounting Estimates Valuation of Biological Assets In determining the fair value less costs to sell of biological assets, management is required to make a number of significant estimates, judgement and assumptions, including estimating the expected yields for the cannabis plants, sales price and expected post-harvesting costs. A weighted average of current observable market sales prices for cannabis derived products, less costs to sell, is used to estimate the sales price input in the fair value less costs to sell model. Valuation of Inventory In calculating the net realizable value (NRV) of inventory, management determines the selling prices based on current observable market sales prices, selling costs, and includes an estimate of spoiled or expired inventory based on the most reliable evidence available at the time, to record inventory at the lower of cost or net realizable value. Impairment of non-financial assets Non-financial asset impairment tests require the estimation of the recoverable amount of the asset or CGU, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions conducted at arm's length for similar assets, valuation appraisals, or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a discounted cash flow model. The cash flows are derived from the Company's approved budget for the first year and the Company's forecast for the next four years and do not include restructuring activities that the Company is not yet committed to, or significant future investments that will enhance the performance of the asset or CGU being tested. The recoverable amount is sensitive to the discount rate used for the discounted cash flow model as well as the expected future cash flows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill, property, plant and equipment and intangible assets. Provisions Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Business Combination Management performs a valuation analysis to allocate the purchase price based on the acquisition date fair values of the identifiable assets acquired and liabilities assumed. Determining the fair value of identifiable assets acquired and liabilities assumed on the acquisition date, require the use of judgement and estimates. The significant estimates related to estimating the fair value of the acquired cultivation and processing license intangible asset, involved significant assumptions such as forecasted gross margin , and the delay in cultivation and production ramp-up . Management also exercises judgement in estimating the probability and timing of future cash flows and uses a discounted cash flow methodology as the basis for estimating fair value. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Determining the fair value of the assumed debenture required the use of significant judgement given the default claims of the Debenture at acquisition and the legal proceedings underway with the lender (see Note 31). As the lender claimed the debenture is in default, management also exercised judgement in estimating the amount required to repay and terminate the Debenture and contingencies attached to the claim. Convertible Debentures Convertible debentures are financial instruments which are accounted for separately dependent on the nature of their components: a financial liability and an equity instrument. The identification of such components embedded within a convertible debenture requires significant estimates including discount rates and future cash flows. The conversion option has a fixed conversion rate thus the financial liability, which represents the obligation to pay coupon interest on the convertible debentures in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual balance, or conversion feature is accounted for as equity at issuance. Transaction costs are apportioned to the debt liability and equity component in proportion to the allocation of proceeds. New and Amended Standards Effective August 1, 2020, the Company adopted the following accounting pronouncements: Amendments to IFRS 3: Definition of a Business In October 2018, the IASB issued “Definition of a Business (Amendments to IFRS 3)”. The amendments clarify the definition of a business, with the objective of assisting entities to determine whether a transaction should be accounted for as a business combination or as an asset acquisition. The amendment provides an assessment framework to determine when a series of integrated activities is not a business. The amendments are effective for business combinations occurring on or after the beginning of the first annual reporting period beginning on or after January 1, 2020. The Company adopted the Amendments to IFRS 3 effective August 1, 2020 with no impact to the Company’s consolidated financial statements. Amendments to IFRS 9, IASB 39 and IFRS 7: Interest Rate Benchmark Reform The amendments revise the existing requirements for hedge accounting and are designed to support the provision of useful financial information by companies during the period of uncertainty arising from the phasing out of interest-rate benchmarks such as Interbank Offered Rates (“IBOR”). The amendments modify some specific hedge accounting requirements to provide relief from potential effects of the uncertainty caused by the IBOR reform. In addition, the amendments require companies to provide additional information to investors about their hedging relationships which are directly affected by these uncertainties. The amendments are effective for annual periods beginning on or after January 1, 2020, with earlier application permitted. The Company adopted the Amendments to IFRS 9, IAS 39 and IFRS 7 effective August 1, 2020 with no impact on the Company’s consolidated financial statements. New Accounting Policies Not Yet Effective The following IFRS standards have been recently issued by the IASB. Pronouncements that are irrelevant or not expected to have a significant impact have been excluded. Amendments to IAS 1: Classification of Liabilities as Current or Non-current The amendment clarifies the requirements relating to determining if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment applies retrospectively for annual reporting periods beginning on or after January 1, 2022. The Company is currently evaluating the potential impact of these amendments on the Company’s consolidated financial statements Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction The amendment narrowed the scope of certain recognition exemptions so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. An entity applies the amendments to transactions that occur on or after the beginning of the earliest comparative period presented. It also, at the beginning of the earliest comparative period presented, recognizes deferred tax for all temporary differences related to leases and decommissioning obligations and recognizes the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at that date. The amendment is effective for annual periods beginning on or after January 1, 2023 with early application permitted. The Company is currently evaluating the potential impact of these amendments on the Company’s consolidated financial statements. Amendments to IAS 37: Onerous Contracts and the Cost of Fulfilling a Contract The amendment specifies that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. The amendment is effective for annual periods beginning on or after January 1, 2022 with early application permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements. Amendments to IAS 16: Property Plant and Equipment: Proceeds before intended use The amendment clarifies the accounting for the net proceeds from selling any items produced while bringing an item of property plant and equipment into use. The amendment prohibits a company from deducting from the cost of property plant and equipment proceeds from selling items produced while the company is preparing that assets for its intended use. The company will recognize such sales proceeds and related costs in profit and loss. The amendment is effective for annual periods beginning on or after January 1,2022 with early application permitted. The Company is currently evaluating the potential impact of this amendment on the Company’s financial statements. Previously Adopted Accounting Policies Effective August 1, 2019 IFRS 16, LEASES The Company adopted IFRS 16 Leases on August 1, 2019, which introduces a new approach to lease accounting. The Company adopted the standard using the modified retrospective approach, which recognized the cumulative impact on the opening balance sheet and applies the standard prospectively. This cumulative impact is included in the comparative information in Note 13. At the inception of a contract, the Company assesses whether the contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. This policy is applied to contracts entered, or modified, on or after August 1, 2019. Practical expedients Effective August 1, 2019, the IFRS 16 transition date, the Company elected to use the following practical expedients under the modified retrospective transition approach: Leases with lease terms of less than twelve months (short-term leases) and leases of low-value assets (less than $5,000 U.S. dollars) (low-value leases) that have been identified at transition were not recognized in the consolidated statement of financial position; Right-of-use assets on transition were measured at the amount equal to the lease liabilities at transition, adjusted by the amount of any prepaid or accrued lease payments; For certain leases having associated initial direct costs, the Company, at initial measurement on transition, excluded these directs costs from the measurement of the right-of-use assets; Application of a single discount rate to portfolios of leases with similar characteristics on transition; and Any provision for onerous lease contracts previously recognized at the date of adoption of IFRS 16 has been applied to the associated right-of-use asset recognized upon transition. The Company as a lessee Where the Company is a lessee, a right-of-use asset representing the right to use the underlying asset with a corresponding lease liability is recognized when the leased asset becomes available for use by the Company. The right-of-use asset is recognized at cost and is depreciated on a straight-line basis over the shorter of the estimated useful life of the asset and the lease term. The cost of the right-of-use asset is based on the following: the amount of initial recognition of related lease liability; adjusted by any lease payments made on or before inception of the lease; increased by any initial direct costs incurred; and decreased by lease incentives received and any costs to dismantle the leased asset. The lease term includes consideration of an option to extend or to terminate if the Company is reasonably certain to exercise that option. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. Lease liabilities are initially recognized at the present value of the lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Subsequent to recognition, lease liabilities are measured at amortized cost using the effective interest rate method. Lease liabilities are remeasured when there is a change in future lease payments arising mainly from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option. The payments related to short-term leases and low-value leases are recognized as other expenses over the lease term in the statement of loss and comprehensive loss. The Company as a lessor The Company's consolidated financial statements were not impacted by the adoption of IFRS 16 Leases Leases. Impact of Change in Accounting Policy On August 1, 2019, the Company recognized $21,360 of right-of-use assets and $21,360 of operating lease liabilities. The Company applied its weighted average incremental borrowing rate as at August 1, 2019 to determine the amount of lease liabilities. The effect of the adjustment to the amounts recognized in the Company's consolidated statement of financial position at August 1, 2019.

Basis of Preparation (Tables)

Basis of Preparation (Tables)	12 Months Ended
	Jul. 31, 2021
Basis Of Presentation [Abstract]
Schedule of major subsidiaries	Principal Operating Subsidiaries Jurisdiction Interest Held Principal Activity HEXO Operations Inc. Quebec, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. HEXO USA Inc. Delaware, USA 100% To facilitate expansion into the US market. Zenabis Global Inc. British Columbia, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. Keystone Isolation Ontario, Canada 60% To provide the Company with extraction technology to supply of CBD and THC to supply the Canadian and global market for cannabis derivatives Keystone Isolation Colorado, 100% To allow for in state, HEXO controlled cannabis extraction activity to support the manufacturing of CBD beverages and future products in the U.S. (where permissible)
Schedule of major joint ventures	Joint Venture Jurisdiction Interest Held Principal Activity Belleville Complex Inc. Ontario, Canada 25% The venture was established to manage the property of the Belleville facility.
Schedule of major associates	Significant associates Jurisdiction Interest Held Principal Activity Truss Limited Partnership ("Truss LP") Ontario, Canada 42.5% To pursue opportunities to develop non- alcoholic, cannabis infused beverages for the Canadian market. Truss CBD USA LLP ("Truss CBD US") Colorado USA 42.5% To explore opportunities for non-alcoholic hemp derived CBD beverages in the State of Colorado.

Significant Accounting Polici_3

Significant Accounting Policies and Pronouncements (Tables)	12 Months Ended
	Jul. 31, 2021
Significant Accounting Policies [Abstract]
Schedule of terms and method use to calculate amortization of tangible assets	Asset Method Term Land Not depreciated No term Buildings Straight line 5 to 40 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years
Schedule of terms and method use to calculate amortization of intangible assets	Asset Method Term Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3-5 years Patents Straight line 20 years Finite life, brands Straight line 3 years

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Jul. 31, 2021
Categories of current financial assets [abstract]
Schedule of Cash and Cash Equivalents	Interest rate July 31, 2021 July 31, 2020 $ $ Operating cash - 31,702 70,318 High interest savings accounts 0.60% 35,760 113,855 Cash and cash equivalents 67,462 184,173

Restricted Funds (Table)

Restricted Funds (Table)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Restricted Cash [Abstract]
Schedule of restricted funds	July 31, 2021 July 31, 2020 $ $ Debt service reserve account - Term loan (Note 21a) - 8,191 Letters of credit, collateral and guarantees for purchases 2,552 70 Restricted cash under terms of the Senior Secured Convertible Note (Note 19) 99,696 - Cash restricted in captive insurance subsidiary 29,998 - Total 132,246 8,261

Commodity Taxes Recoverable a_2

Commodity Taxes Recoverable and Other Receivables (Tables)	12 Months Ended
	Jul. 31, 2021
Commodity Taxes Recoverable And Other Receivables [Abstract]
Schedule of commodity taxes recoverable and other receivables	July 31, 2021 July 31, 2020 Commodity taxes recoverable $ 56 $ 12,821 Lease receivable - current 1 107 630 Receivable on conversion of Inner Spirit Holdings Shares (Note 12) 2,698 - Loan receivable 2 5,000 - Other receivables 5,688 3,282 Total $ 13,549 $ 16,733 1 2

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Jul. 31, 2021
Classes of current inventories [abstract]
Schedule of inventories	As at July 31, 2021 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 81,784 $ 24,257 $ 106,041 Purchased dried cannabis 1,754 - 1,754 Extracts 11,945 4,411 16,356 Purchased extracts 2,247 - 2,247 Packaging and supplies 8,929 - 8,929 $ 106,659 $ 28,668 $ 135,327 As at July 31, 2020 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 29,702 $ 16,981 $ 46,683 Purchased dried cannabis 1,956 - 1,956 Extracts 4,828 385 5,213 Purchased extracts 5,977 - 5,977 Hemp derived distillate 566 - 566 Packaging and supplies 4,538 - 4,538 $ 47,567 $ 17,366 $ 64,933

Biological Assets (Tables)

Biological Assets (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about biological assets [abstract]
Schedule of changes in the carrying value of biological assets	For the years ended July 31, 2021 July 31, 2020 $ $ Balance, beginning of year 7,571 7,371 Acquired on business combination 8,892 - Production costs capitalized 36,156 38,638 Net increase in fair value due to biological transformation and estimates 51,499 29,356 Harvested cannabis transferred to inventory (89,834 ) (67,131 ) Disposal of biological assets - (663 ) Balance, end of year 14,284 7,571
Schedule of significant unobservable inputs, their range of values and sensitivity analysis	Significant inputs and assumptions Input values An increase or decrease of 5% applied to the July 31, 2021 July 31, 2020 July 31, 2021 July 31, 2020 Weighted average selling price Derived from actual retail prices on a per product basis using the expected Flower and Trim yields per plant. Which is expected to approximate future selling prices and where applicable, considering strains $3.05 per dried gram $3.23 per dried gram $746 $550 Yield per plant Derived from historical harvest cycle results on a per strain basis, which is expected to be harvested from plants 24-116 grams per plant 46 - 135 grams per plant $460 $376 Post-harvest cost Derived from historical costs of production activities on a per product basis. 0.67%-0.84 % dependent upon the stage within the harvest cycle 0.26%-0.81 % dependent upon the stage within the harvest cycle $636 $219

Investments in Associates & J_2

Investments in Associates & Joint Ventures (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Associate And Joint Ventures [Abstract]
Schedule of ownership interest in other entities	July 31, 2021 July 31, 2020 Truss LP Other Total Truss LP Other Total $ $ $ $ $ $ Opening Balance 74,966 1,340 76,306 51,786 1,063 52,849 Cash contributed to investment 4,250 783 5,033 29,155 1,231 30,386 Capitalized transaction costs - - - - 109 109 Share of net (loss) (6,343 ) (162 ) (6,505 ) (5,975 ) (356 ) (6,331 ) Impairment - - - - (707 ) (707 ) Foreign exchange loss through OCI - (155 ) (155 ) - - - Ending Balance 72,873 1,806 74,679 74,966 1,340 76,306
Schedule of investment in associate	Truss LP As at July 31, 2021 July 31, 2020 Statement of Financial Position $ $ Cash and cash equivalents 6,757 19,561 Other current assets 14,182 7,867 Non- current assets 67,766 66,863 Current liabilities 11,184 11,112 Non-current liabilities 8,667 8,903
Schedule of investment in joint venture	Year ended July 31, 2021 July 31, 2020 Statement of Comprehensive Loss Revenue 6,498 (1) 705 (1) Operating expenses excluding depreciation and amortization (14,261 ) (12,647 ) Depreciation and amortization (4,884 ) (617 ) Other expenses - (7 ) Loss from operations (14,643 ) (13,827 ) Other income 130 1 Interest expenses (412 ) (233 ) Income tax expenses - - Total comprehensive loss (14,925 ) (14,059 ) 1
Schedule for reconciliation of investment in associate	For the year ended July 31, 2021 July 31, 2020 $ $ Opening net assets 74,964 20,423 Acquisition of associate/capital calls 10,000 68,600 Total comprehensive loss (14,925 ) (14,059 ) Closing net assets 70,039 74,964 Interest in associate 42.5% 42.5% Interest in associate value 29,767 31,860 Fair value of warrant consideration 42,386 42,386 Capitalized transaction costs 720 720 Total interest in associate value 72,873 74,966

Long-term Investments (Tables)

Long-term Investments (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Long Term Investment Abstract
Schedule of long-term investments	Fair value Transfer Divestiture Change in Fair value $ $ $ $ Level 1 Investments Fire and Flower common shares 1,292 - - (65 ) 1,227 Sundial Growers Inc. common shares - 720 - (99 ) 621 Inner Spirit Holdings Ltd common shares 1,260 (720 ) (2,698 ) 2,158 - Other long-term investments 517 - (13 ) - 504 Level 3 Investments Segra International Corp. 140 - - - 140 Total 3,209 - (2,711 ) 1,994 2,492 Fair value Investment Divestiture Change in Fair value $ $ $ $ $ Level 1 Investments Fire and Flower common shares - 1,232 - 60 1,292 Inner Spirit common shares 3,000 - (643 ) (1,097 ) 1,260 Other long-term investments - 517 - - 517 Level 2 Investments Inner Spirit common share purchase warrants 403 - - (403 ) - Level 3 Investments Greentank Technologies 6,574 - - (6,574 ) - Neal Brothers Inc. 4,000 - - (4,000 ) - Segra International Corp. 300 - - (160 ) 140 Total 14,277 1,749 (643 ) (12,174 ) 3,209

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jul. 31, 2021
Property, plant and equipment [abstract]
Schedule of property, plant and equipment	Cost Land Buildings Leasehold Cultivation Furniture, Construction Right-of-Use Total $ $ $ $ $ $ $ $ At July 31, 2019 5,339 150,834 627 42,029 10,368 57,550 - 266,747 Additions - 24,432 1,395 14,969 9,404 66,246 24,405 140,851 Disposals (3,683 ) (18,260 ) - (13,402 ) (909 ) (5,428 ) - (41,682 ) Transfers - 7,943 22,417 (10,135 ) 8 (20,233 ) - - At July 31, 2020 1,656 164,949 24,439 33,461 18,871 98,135 24,405 365,916 Business acquisition 1,100 95,788 - 6,154 8,578 395 17,059 129,074 Additions - 1,213 63 2,284 294 16,960 20,814 Disposals - 1 - (67 ) - - (1,055 ) (1,121 ) Transfers - 3,951 17,649 884 1,388 (23,544 ) - 328 At July 31, 2021 2,756 265,902 42,151 42,716 29,131 91,946 40,409 515,011 Accumulated depreciation and impairments At July 31, 2019 - 4,392 130 2,216 1,216 - - 7,954 Depreciation - 7,395 879 3,702 3,562 - 2,522 18,060 Transfers - - - 271 (271 ) - - - Disposals - (17,081 ) - (7,435 ) (366 ) - - (24,882 ) Impairments 307 19,006 - 9,937 - 48,990 1,178 79,418 At July 31, 2020 307 13,712 1,009 8,691 4,141 48,990 3,700 80,550 Depreciation - 7,981 2,173 5,145 4,229 - 2,246 21,774 Transfers - (110 ) (16 ) (78 ) (277 ) - - (481 ) Disposals - - - - - - (964 ) (964 ) Impairments - 160 85 2,104 61 - 17,820 20,230 At July 31, 2021 307 21,743 3,251 15,862 8,154 48,990 22,802 121,109 Net book value At July 31, 2019 5,339 146,442 497 39,813 9,152 57,550 - 258,793 At July 31, 2020 1,349 151,237 23,430 24,770 14,730 49,145 20,705 285,366 At July 31, 2021 2,449 244,159 38,900 26,854 20,977 42,956 17,607 393,902

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jul. 31, 2021
Changes in intangible assets other than goodwill [abstract]
Schedule of intangible assets	Cost Cultivating and Brands Software Domain Patents Total $ $ $ $ $ $ At July 31, 2019 116,433 8,440 3,558 585 1,231 130,247 Additions - - 702 - 875 1,577 Disposals - - (550 ) - (173 ) (723 ) At July 31, 2020 116,433 8,440 3,710 585 1,933 131,101 Additions - - 1,546 - 790 2,336 Business acquisition 28,914 5,400 - - - 34,314 Disposals - - (872 ) - - (872 ) At July 31, 2021 145,347 13,840 4,384 585 2,723 166,879 Accumulated amortization and impairments At July 31, 2019 1,601 - 1,269 66 29 2,965 Amortization 3,167 - 697 59 16 3,939 Impairment 106,189 2,000 - - - 108,189 At July 31, 2020 110,957 2,000 1,966 125 45 115,093 Amortization 765 170 922 59 134 2,050 Disposals - - (872 ) - - (872 ) At July 31, 2021 111,722 2,170 2,016 184 179 116,271 Net book value At July 31, 2019 114,832 8,440 2,289 519 1,202 127,282 At July 31, 2020 5,476 6,440 1,744 460 1,888 16,008 At July 31, 2021 33,625 11,670 2,368 401 2,544 50,608

Business Acquisition (Tables)

Business Acquisition (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about business combination [abstract]
Schedule of fair value of net assets assumed as at the acquisition date	Units Unit Price Fair Value ($) ($) Consideration Shares issued (i) 17,579,336 8.61 151,358 Replacement warrants outstanding (ii) 5,196,164 32,354 Replacement stock options issued (iii) 905,902 5,727 Replacement RSU's and DSU's issued 223,497 1,554 Settlement of pre-existing debt (iv) n/a 20,760 Total fair value of consideration 211,753 Net assets acquired Current assets Cash and cash equivalents 2,804 Accounts receivable 3,822 Other receivables 198 Excise taxes receivable 86 Inventory 40,636 Biological assets 8,892 Non-current assets Property, plant and equipment 129,074 Prepaid expenses 5,670 Cultivation and processing license 28,914 Brands 5,400 Goodwill Note 16 88,189 Total assets 313,685 Current liabilities Accounts payable and accrued liabilities (22,161 ) Loans Note 21 (52,194 ) Convertible debentures (11,724 ) Non-current liabilities Lease Liability (17,059 ) Deferred tax liabilities (134 ) Total liabilities (103,272 ) Non-controlling interest 1,340 Total net assets acquired 211,753

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jul. 31, 2021
Goodwill [Abstract]
Schedule of reconciliation of changes in goodwill	Newstrike Brands Zenabis Global Ltd Total $ $ $ At July 31 ,2019 111,877 - 111,877 Impairment (111,877 ) - (111,877 ) At July 31, 2020 - - - Acquisition (Note 15) - 88,189 88,189 Balance as at July 31, 2021 - 88,189 88,189

Warrant Liabilities (Tables)

Warrant Liabilities (Tables)	12 Months Ended
	Jul. 31, 2021
Warrant Liabilities [Line Items]
Schedule of warrant liabilities	2017 Unsecured Convertible US$25,000 US$20,000 Registered Direct Offering Total $ $ $ $ Opening balance as at August 1, 2019 493 - - 493 Issued - 5,629 3,967 9,596 Exercised (106 ) - - (106 ) (Gain) on revaluation of financial instruments (387 ) (3,712 ) (2,434 ) (6,533 ) Balance as at July 31, 2020 - 1,917 1,533 3,450 Loss on revaluation of financial instruments - 1,269 1,014 2,283 Balance as at July 31, 2021 - 3,186 2,547 5,733
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Schedule of warrant liability fair value assumptions	As at As at Initial recognition Number of warrants 1,497,007 1,497,007 1,497,007 Share price US$3.97 US$2.72 US$5.80 Expected life 2.5 years 2.5 years 2.5 years Dividend US $nil US $nil US $nil Volatility 95% 97% 80% Risk free rate 0.38% 0.22% 1.57% Exchange rate (USD/CAD) 1.2462 1.3404 1.3116
US$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Schedule of warrant liability fair value assumptions	As at As at Initial recognition Number of warrants 1,871,259 1,871,259 1,871,259 Share price US$3.97 US$2.72 US$6.36 Expected life 2.5 years 2.5 years 2.5 years Dividend US $nil US $nil US $nil Volatility 95% 97% 79% Risk free rate 0.38% 0.22% 1.71% Exchange rate (USD/CAD) 1.2462 1.3404 1.2988

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about borrowings [line items]
Schedule of convertible debentures	Note July 31,2021 July 31,2020 $ $ Unsecured convertible debenture- March 2019 (a) 3,406 - Unsecured convertible debenture- December 2019 (b) 33,089 28,969 Unsecured convertible notes (c) - - Total convertible d ebentures 36,495 28,969 Current 3,406 - Non-Current 33,089 28,969
Unsecured convertible debenture- March 2019
Disclosure of detailed information about borrowings [line items]
Schedule of convertible debentures	Balance as at July 31, 2020 $ - Acquired on business combination 3,722 Interest payments (372 ) Interest expense 56 Balance as at July 31, 2021 $ 3,406
Unsecured convertible debenture- December 2019
Disclosure of detailed information about borrowings [line items]
Schedule of convertible debentures	Balance as at July 31, 2019 $ - Issued at amortized cost, net issuance costs 45,922 Conversion (20,602 ) Interest expense 6,854 Interest paid (3,205 ) Balance as at July 31, 2020 $ 28,969 Interest expense 7,331 Interest paid (3,211 ) Balance as at July 31,2021 $ 33,089
Unsecured convertible notes
Disclosure of detailed information about borrowings [line items]
Schedule of convertible debentures	Balance as at July 31, 2020 $ - Acquired on business combination 7,790 Debt repayment (7,790 ) Balance as at July 31, 2021 $ -

Senior Secured Convertible No_2

Senior Secured Convertible Note (Tables)	12 Months Ended
	Jul. 31, 2021
Senior Secured Convertible Note [Abstract]
Schedule of senior secured convertible note	July 31, 2021 July 31, 2021 Senior Secured Convertible Note US$ $ Opening balance, beginning of the year - - Issued at fair value 407,284 491,714 Early conversions (413 ) (497 ) Redemptions (27,500 ) (33,525 ) Gain on fair value adjustment (14,524 ) (18,100 ) Foreign exchange loss - 15,081 Ending balance, end of the year 364,847 454,673 Unrecognized Day 1 Loss Opening balance, beginning of the year - - Unrecognized loss at issuance (79,684 ) (96,203 ) Recognized loss 7,470 9,229 Ending balance, end of the year (72,214 ) (86,974 ) Total balance, end of year, net 292,633 367,699 Current portion 292,633 367,699 Non-current - -
Schedule of senior secured convertible note conversions	Shares Issued Redemption Amount $ Balance, beginning of year - - Issuances: Initial issuance 478,091 Settlements: Early conversion option 53,495 (497 ) Optional redemption options 4,548,746 (33,525 ) Foreign exchange loss - 14,641 Balance, end of year - 458,710
Schedule of senior secured convertible note monthly redemption option up to the instrument's maturity date	Fiscal Year Redemption amount Redemption amount US$ $ 2022 253,000 315,289 2023 115,087 143,421 Total 368,087 458,710

Lease Liabilities (Tables)

Lease Liabilities (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of quantitative information about leases for lessee [abstract]
Schedule of lease liabilities	$ Balance at July 31, 2019 - Adjustment on adoption of IFRS 16 21,360 Balance at August 1, 2019 21,360 Lease additions 9,030 Lease payments (4,341 ) Interest expense on lease liabilities 3,067 Balance at July 31, 2020 29,116 Assumed on business combination (Note 15) 17,059 Lease disposals (789 ) Lease payments (4,835 ) Interest expense on lease liabilities 3,334 Balance at July 31, 2021 43,885 Current 1,730 Non-current 42,155

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about borrowings [line items]
Schedule of loans and borrowings	July 31, 2021 July 31, 2020 $ $ Term Loan (A) - 29,930 Senior notes payable (B) 50,159 - RDC Loan (C) - - Total Loans and Borrowings 50,159 29,930 Current 50,159 29,930 Non-current - -
Loans and borrowings repayment schedule	July 31, 2022 $ 51,875 Thereafter - $ 51,875
Term loan
Disclosure of detailed information about borrowings [line items]
Continuity schedule of loans and borrowings	July 31, 2021 July 31, 2020 Term loan $ $ Opening balance 30,625 34,125 Repayments (30,625 ) (3,500 ) Ending balance - 30,625 Deferred financing costs $ $ Opening balance (695 ) (751 ) Additions (98 ) (445 ) Amortization of deferred finance costs 793 501 Ending balance - (695 ) Total term loan - 29,930 Current portion - 29,930 Long-term portion - -
Senior Notes Payable
Disclosure of detailed information about borrowings [line items]
Continuity schedule of loans and borrowings	July 31,2021 July 31, 2020 $ $ Opening Balance Assumed on business combination 50,138 - Interest paid (1,210 ) - Interest expense 1,231 - Closing Balance 50,159 - Current portion 50,159 - Long-term portion - -
RDC Loan
Disclosure of detailed information about borrowings [line items]
Continuity schedule of loans and borrowings	Balance as at July 31, 2020 $ – Acquired on business acquisition 2,056 Debt repayment (2,056 ) Balance as at July 31, 2021 $ –

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jul. 31, 2021
Share Capital [Abstract]
Schedule of stock option issued and outstanding	Number of shares Share Capital Balance at July 31, 2019 64,245,441 $ 799,706 June 2020 at the market offering (ii) 8,235,620 33,263 May 2020 underwritten public offering (iii) 15,985,000 43,495 April 2020 underwritten public offering (iv) 14,950,000 22,928 January 2020 registered offering (v) 2,994,012 21,073 December 2019 registered offering (vi) 3,742,516 25,229 December 2019 private placement Note 18 9,331,250 72,005 Exercise of options Note 24 29,133 223 Exercise of warrants Note 23 1,103,469 5,866 Balance at July 31, 2020 120,616,441 $ 1,023,788 May 2021 at the market offering, net (i) 6,373,926 45,257 June 2020 at the market offering (ii) 244,875 - Senior secured convertible note 3 Note 19 4,602,241 29,540 Acquisition shares - Zenabis Note 15 17,579,336 151,358 Transaction costs 2 Note 15 448,639 3,612 Exercise of warrants Note 23 2,146,931 9,932 Exercise of stock options Note 24 410,051 3,213 Exercise of equity settled RSUs Note 24 223,506 1,267 Balance at July 31, 2021 152,645,946 $ 1,267,967 1 2 3

Common Share Purchase Warrants

Common Share Purchase Warrants (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Common Share Purchase Warrants [Abstract]
Schedule of warrant activity	July 31, 2021 July 31, 2020 Number of Weighted average Number of Weighted average warrants exercise price 1 warrants exercise price 1 Outstanding, beginning of year 33,379,408 $ 7.60 7,396,354 $ 39.80 Expired and cancelled (535,889 ) 4.09 (3,889,871 ) 49.00 Issued on acquisition 5,970,370 14.59 - - Issued - - 30,976,394 4.96 Exercised (2,146,931 ) 4.10 (1,103,469 ) 3.88 Outstanding, end of year 36,666,958 $ 8.85 33,379,408 $ 7.60 1 purposes.
Schedule of warrant issued	Issuance date Exercise price Warrants Expiry period December 31, 2019 US$9.80 1,871,259 5 years January 22, 2020 US$9.80 1,497,007 5 years April 13, 2020 $3.84 14,950,000 5 years May 21, 2020 $4.20 7,992,500 5 years June 10, 2020 $4.00 3,686,721 3 years June 30, 2020 $4.00 978,907 3 years Total issued during the year ended July 31, 2020 30,976,394 June 01, 2021 $3.96-$155.19 5,970,370 0.17-4 years Total issued during the year ended July 31, 2021 5,970,370
Schedule of warrants outstanding	July 31, 2021 July 31, 2020 Number Book value Number Book value Classified as Equity $ $ June 2019 financing warrants Exercise price of $63.16 expiring June 19, 2023 546,135 10,022 546,135 10,022 April 2020 underwritten public offering warrants Exercise price of $3.84 expiring April 13, 2025 11,830,075 15,971 14,004,375 18,906 May 2020 underwritten public offering warrants Exercise price of $4.20 expiring May 21, 2025 7,591,876 10,446 7,852,513 10,805 Conversion Unit warrants Exercise price of $4.00 expiring June 10, 2023 3,686,721 11,427 3,686,721 11,426 Exercise price of $4.00 expiring June 30, 2023 978,907 1,928 978,907 1,928 Broker / Consultant warrants Exercise price of $3.00 expiring November 3, 2021 18,905 34 43,905 78 Exercise price of $3.00 expiring March 14, 2022 23,571 66 23,571 66 Exercise price of $63.16 expiring June 19, 2023 15 - 15 - Molson warrants Exercise price of $24.00 expiring October 4, 2021 2,875,000 42,386 2,875,000 42,386 Issued in connection with business acquisition Exercise price of $3.96 expiring April 23, 2025 631,322 4,232 - - Exercise price of $5.64 expiring September 23, 2025 1,228,873 7,902 - - Exercise price of $8.47 expiring October 30, 2025 43,856 261 - - Exercise price of $9.03 expiring June 25, 2025 3,205,378 18,236 - - Exercise price of $11.29 expiring January 27, 2023 356,689 1,195 - - Exercise price of $78.16 expiring August 21, 2022 15,992 3 - - Exercise price of $102.71 expiring August 21, 2022 24,338 2 - - Exercise price of $151.24 expiring September 27, 2021 14,617 - - - Exercise price of $155.19 expiring April 17, 2022 226,422 1 - - 33,298,692 124,112 30,011,142 95,617 Classified as Liability US$25m Registered Direct Offering Warrants Exercise price of US$9.80 expiring December 31, 2024 1,871,259 3,185 1,871,259 1,917 US$20m Registered Direct Offering Warrants Exercise price of US$9.80 expiring January 22, 2025 1,497,007 2,548 1,497,007 1,533 3,368,266 5,733 3,368,266 3,450 36,666,958 129,845 33,379,408 99,067

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Jul. 31, 2021
Stock Options And Restricted Share Units [Abstract]
Schedule of stock option activity	July 31, 2021 July 31, 2020 Number of Weighted average Number of Weighted average options exercise price options exercise price Opening balance 7,503,691 $ 16.30 6,072,245 $ 23.48 Granted 5,273,906 5.21 2,986,507 6.48 Replacement options issued 905,902 3.81 - - Forfeited (630,473 ) 12.80 (1,145,610 ) 22.20 Expired (624,832 ) 25.95 (380,318 ) 36.64 Exercised (410,051 ) 3.00 (29,133 ) 4.60 Closing balance 12,018,143 $ 10.63 7,503,691 $ 16.30
Schedule of stock option granted	Options granted Grant date Exercise price ($) Executives and Non-executive Total Vesting terms Expiry period October 29, 2019 13.20 207,259 683,068 890,327 Terms A 10 years January 29, 2020 7.20 - 73,255 73,255 Terms A 10 years April 28, 2020 2.76 225,000 641,331 866,331 Terms A 10 years June 26, 2020 4.08 763,756 183,103 946,859 Terms A 10 years July 28, 2020 3.84 - 209,735 209,735 Terms A 10 years Total 1,196,015 1,790,492 2,986,507 October 30, 2020 3.88 349,652 315,358 665,010 Terms A 10 years December 22, 2020 5.44 380,673 960,100 1,340,773 Terms A 10 years April 28, 2021 7.54 - 85,389 85,389 Terms A 10 years June 17, 2021 7.43 75,000 45,613 120,613 Terms A 10 years July 29, 2021 5.24 580,164 2,481,957 3,062,121 Terms A 10 years Total 1,385,489 3,888,417 5,273,906
Schedule of stock options outstanding	Exercise price Number outstanding Weighted average Number exercisable Weighted average $2.32-$10.76 8,292,550 8.82 1,853,536 6.30 $15.56-$26.16 1,576,409 7.79 1,779,478 7.33 $28.52-$34.00 2,141,186 7.40 474,040 7.50 $47.36-$234.76 7,998 0.35 7,333 0.32 12,018,143 4,114,387
Schedule of restricted share units activity	July 31, 2021 July 31, 2020 Value of units on Value of units on Units grant date Units grant date Opening balance 587,108 $ 8.41 - $ - Granted 24,008 3.17-7.17 609,636 8.52 Replacement units issued 223,506 8.61 - - Exercised - equity settled (223,506 ) 8.61 - - Exercised - cash settled (25,483 ) 5.62-8.60 - - Forfeited (34,801 ) 11.76 (22,528 ) 11.76 Closing balance 550,832 $ 7.91 587,108 $ 8.41
Schedule of restricted share units granted	RSUs granted Grant date Unit value Executive and Non-executive Vesting terms Expiry period October 29,2019 11.76 357,111 - Terms A 10 years June 26, 2020 3.96 252,525 - Terms A 10 years Total 609,636 October 30, 2020 $ 3.16 7,161 - Terms A 10 years June 17, 2021 7.17 9,413 - Terms A 10 years July 29, 2021 5.38 7,434 - Terms A 10 years Total 24,008
Schedule of fair value of stock options and restricted stock units granted	July 31, 2021 July 31, 2020 Exercise price (weighted average) $ 17.03 $ 26.04 Share price (weighted average) $ 17.19 $ 26.44 Risk-free interest rate (weighted average) 1.24% 1.79% Expected life (years) of options (weighted average) 5 5 Expected annualized volatility (weighted average) 85% 75%
Schedule of equity-settled and cash-settled share-based payments	July 31, 2021 July 31, 2020 $ $ Stock option share-based compensation 12,863 31,503 RSU share-based compensation 287 - Total equity-settled share-based compensation 13,150 31,503 RSU share-based compensation 127 393 Total cash-settled share-based compensation 127 393

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Jul. 31, 2021
Earnings per share [abstract]
Schedule of anti-dilutive securities excluded from computation of diluted earnings per share	Instrument July 31, 2021 July 31, 2020 Stock options 12,018,143 7,503,690 RSUs 550,832 587,108 Acquired and reissued warrants 5,747,487 - 2019 June financing warrants 546,135 546,135 US$25m registered direct offering warrants 1,871,259 1,871,259 US$20m registered direct offering warrants 1,497,007 1,497,007 2020 April underwritten public offering warrants 11,830,075 14,004,375 2020 May underwritten public offering warrants 7,591,876 7,852,513 Warrants issued under conversion of debentures 4,665,628 4,665,628 Joint venture issued warrants 2,875,000 2,875,000 Convertible debenture broker/finder warrants 42,491 67,491 49,235,933 41,470,206

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Schedule of price risk	July 31, 2021 July 31, 2020 $ $ Financial assets 2,492 2,692 Financial liabilities (373,432 ) (3,450 ) Total exposure (370,940 ) (758 )
Schedule of aging of trade receivables	July 31, July 31, 2021 2020 $ $ 0-30 days 22,971 15,253 31-60 days 12,390 2,972 61-90 days 1,435 412 Over 90 days 625 789 Total 37,421 19,426
Schedule of analysis of contractual maturities for financial liabilities	Fiscal year 2022 2023 2024 2025 Thereafter Total $ $ $ $ $ $ Accounts payable and accrued liabilities 63,557 - - - - 63,557 Excise taxes payable 6,591 - - - - 6,591 Loans and borrowings 60,297 - - - - 60,297 Convertible debentures 6,716 41,273 - - - 47,989 Undiscounted future lease payments 6,155 5,785 6,073 5,561 54,796 78,370 143,316 47,058 6,073 5,561 54,796 256,804 Senior secured convertible note 1 315,289 143,421 - - - 458,710 Total 458,605 190,479 6,073 5,561 54,796 715,514 1

Operating Expenses by Nature (T

Operating Expenses by Nature (Tables)	12 Months Ended
	Jul. 31, 2021
Expenses by nature [abstract]
Schedule of expenses by nature	For the year ended July 31, 2021 July 31, 2020 $ $ Salaries and benefits 21,116 12,202 Professional fees 11,962 9,811 Facilities 6,550 6,895 Selling, general and administrative 13,915 14,409 Consulting 4,379 7,425 Travel 265 2,051 Total 58,187 52,793
Schedule of share-based compensation	For the year ended July 31, 2021 July 31, 2020 $ $ General and administrative related share-based compensation 10,945 24,650 Marketing and promotion related share-based compensation 786 1,140 Total operating expense related share-based compensation 11,731 25,790 Share based compensation capitalized to inventory 1,505 6,105 Total share-based compensation 13,236 31,895
Schedule of payroll related wages and benefits	For the year ended July 31, 2021 July 31, 2020 $ $ General and administrative related wages and benefits 21,116 12,202 Marketing and promotion related wages and benefits 5,543 5,625 Research and development related wages and benefits 2,706 2,717 Total operating expense related wages and benefits 29,365 20,544 Wages and benefits capitalized to inventory 14,993 21,128 Total wages and benefits 44,358 41,672

Other Income and Losses (Tables

Other Income and Losses (Tables)	12 Months Ended
	Jul. 31, 2021
Other Income And Losses [Abstract]
Schedule of other income and losses	For the year ended July 31, 2021 July 31, 2020 $ $ Interest and financing expenses (32,124 ) (10,043 ) Interest income 1,601 1,902 Interest income (expense), net (30,523 ) (8,141 ) Revaluation of warrant liabilities (2,283 ) 6,533 Share of loss from investment in associates and joint ventures (6,505 ) (6,331 ) Loss on Unsecured Convertible Debentures - December 2019 - (54,283 ) Fair value gain/(loss) on convertible debenture 1,260 (4,806 ) Fair value loss on senior secured convertible note (7,478 ) - Unrealized gain/(loss) on investments 1,994 (12,880 ) Realized gain on investments - 24 Foreign exchange gain/(loss) 9,108 1,392 Other income 4,763 2,531 Non-operating income (expense), net 859 (67,820 )

Related Party Disclosure (Table

Related Party Disclosure (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of transactions between related parties [abstract]
Schedule of compensation provided to key management	For the year ended July 31, 2021 July 31, 2020 $ $ Salary and/or consulting fees 2,321 3,069 Termination benefits 1,008 1,043 Bonus compensation 800 42 Stock-based compensation 6,800 15,702 Total 10,929 19,856

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Commitments And Contingencies [Abstract]
Schedule of future minimum payments under contractual financial obligations	$ July 31, 2022 18,244 July 31, 2023 3,846 July 31, 2024 3,474 July 31, 2025 2,429 July 31, 2026 5,802 Thereafter 13,472 47,267

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Schedule of carrying values of financial instruments	Amortized cost FVTPL Total Assets $ $ $ Cash and cash equivalents 67,462 - 67,462 Restricted funds 132,246 - 132,246 Trade receivables 37,421 - 37,421 Commodity taxes recoverable and other receivables 13,549 - 13,549 Lease receivable - long term 4,453 - 4,453 Long - term investments - 2,492 2,492 Liabilities $ $ $ Accounts payable and accrued liabilities 63,557 - 63,557 Warrant liability - 5,733 5,733 Convertible debt- current 3,406 - 3,406 Convertible debt 33,089 33,089 Senior secured convertible note - current - 367,699 367,699 Loans and borrowings - current 50,159 50,159 Other long-term liabilities (1) - 520 520 1 Amortized cost FVTPL Total Assets $ $ $ Cash and cash equivalents 184,173 - 184,173 Restricted funds 8,261 - 8,261 Trade receivables 19,426 - 19,426 Commodity taxes recoverable and other receivables 16,773 - 16,773 Lease receivable - long term 3,865 - 3,865 Long - term investments - 3,209 3,209 Liabilities $ $ $ Accounts payable and accrued liabilities 32,451 - 32,451 Warrant liability - 3,450 3,450 Convertible debentures 28,969 - 28,969 Term loan - current 29,930 - 29,930 Other long-term liabilities (1) - 393 393 1 The carrying values of cash and cash equivalents, restricted funds, cash held in escrow, short term investments, trade and other receivables, lease receivables, accounts payable and accrued liabilities, lease liabilities and term loan approximate their fair values due to their relatively short periods to maturity.

Non-Controlling Interest (Table

Non-Controlling Interest (Tables)	12 Months Ended
	Jul. 31, 2021
Disclosure of subsidiaries [line items]
Schedule of change in non-controlling interests	July 31, 2021 July 31, 2020 Balance, Beginning of year $ 3,379 $ - Non-controlling interest acquired on business combination (1,340 ) - Partnership contributions 81 3,379 Share of comprehensive loss for the period (133 ) - Balance, End of year $ 1,987 $ 3,379
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Schedule of information relating to subsidiary	July 31, 2021 July 31, 2020 Current assets $ - $ - Non-current assets 8,651 7,455 Current liabilities - - Non-current liabilities - - Non-controlling interest (%) 40% 40% Non-controlling interest $ 3,460 $ 3,379
ZenPharm Limited
Disclosure of subsidiaries [line items]
Schedule of information relating to subsidiary	July 31, 2021 Current assets $ 313 Non-current assets 141 Current liabilities (3,233 ) Non-current liabilities - Accumulated deficit (133 ) Non-controlling interest (%) 40% Non-controlling interest $ (1,475

Revenue from Sale of Goods (Tab

Revenue from Sale of Goods (Tables)	12 Months Ended
	Jul. 31, 2021
Revenue [abstract]
Schedule of gross revenue	For the year ended July 31, 2021 July 31, 2020 Revenue stream Cannabis sales Cannabis 1 Total Cannabis sales Cannabis Total $ $ $ $ $ $ Retail 143,098 15,821 158,919 101,713 2,851 104,564 Medical 1,769 - 1,769 3,299 - 3,299 Wholesale 2,458 - 2,458 995 - 995 International 9,935 - 9,935 1,291 - 1,291 Total revenue from sale of goods 157,260 15,821 173,081 107,298 2,851 110,149

Operating Cash Flow (Tables)

Operating Cash Flow (Tables)	12 Months Ended
	Jul. 31, 2021
Operating Cash Flow [Abstract]
Schedule of operating cash flow activity	For the year ended July 31, 2021 July 31,2020 $ $ Items not affecting cash Income tax recovery (397 ) (6,023 ) Depreciation of property, plant and equipment 6,097 6,072 Depreciation of property, plant and equipment in cost of sales 8,601 3,567 Amortization of intangible assets 2,050 3,939 Loss on convertible debentures 6,218 4,806 Unrealized gain on changes in fair value of biological assets (51,499 ) (29,356 ) Unrealized fair value adjustment on investments (1,994 ) 12,880 Amortization of deferred financing costs 793 56 Interest and other income 5,837 9,921 Loss on induced conversion of debenture - 54,283 Accretion of convertible debenture 4,075 - Non-cash finance and transaction fees 21,690 - Loss on investment - (24 ) License depreciation and prepaid royalty expenses 118 389 Write-off of inventory and biological assets 2,182 5,055 Write down of inventory to net realizable value 2,927 68,319 Realized fair value amounts on inventory sold 31,767 40,910 Loss from investment in associate and joint ventures 6,505 6,331 Share-based compensation 14,859 25,790 Revaluation of financial instruments (gain)/loss 2,283 (6,533 ) Impairment losses 20,230 299,484 Loss on onerous contract - 4,763 Loss on long lived assets and disposal of property, plant and equipment 1,358 3,855 Gain on exit of lease (789 ) - Foreign exchange gain (11,648 ) - Total items not affecting cash 71,263 508,484 Changes in non-cash operating working capital items Trade receivables (14,203 ) 267 Commodity taxes recoverable and other receivables 5,197 (784 ) Prepaid expenses (106 ) 5,717 Inventory (52,539 ) (100,492 ) Biological assets 53,678 28,493 Accounts payable and accrued liabilities 8,848 6,623 Excise taxes payable (444 ) 3,627 Total non-cash operating working capital 431 (56,549 )
Schedule of additional supplementary cash flow information	For the year ended July 31, 2021 July 31, 2020 $ $ Property, plant and equipment in accounts payable 1,152 19,751 Right-of-use asset additions 17,059 24,405 Capitalized borrowing costs 1,269 2,385 Interest paid 5,618 2,527

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2021
Income taxes paid (refund) [abstract]
Schedule of components of income tax expense	July 31, 2021 July 31, 2020 Current tax for the year $ 22 $ - Adjustments of previous years - - Total $ 22 $ -
Schedule of deferred income tax expense (recovery)	July 31, 2021 July 31, 2020 Origination and reversal of temporary differences $ (14,659 ) $ (98,141 ) Difference between statutory tax rate and deferred tax rate (249 ) 2,555 Change in temporary difference for which no deferred tax assets are recorded 14,489 89,563 Deferred income tax (recovery) $ (419 ) $ (6,023 )
Schedule of income tax rate reconciliation	July 31, 2021 July 31, 2020 Expected tax rate 26.50% 26.54% Earnings before income taxes $ (115,159 ) $ (552,512 ) Expected tax benefit resulting from loss (30,517 ) (146,637 ) Adjustments for the following items: Tax rate differences (652 ) 2,555 Permanent differences 8,696 48,965 Change in temporary differences for which no tax assets are recorded 22,148 89,094 True up and other (72 ) - $ (397 ) $ (6,023 )
Schedule of reconciliation of deferred tax assets and liabilities	Opening Recognize Business Recognized in Ending August 1, 2020 in income Combination equity July 31, 2021 $ $ $ $ $ Taxable temporary differences 10,415 (14,701 ) (310 ) (421 ) (5,017 ) Biological assets (1,330 ) 724 - - (606 ) Inventory (5,088 ) 1,514 (7,276 ) - (10,850 ) Loss carryforward - 14,028 14,665 - 28,693 Financing costs - (2,738 ) 2,738 - - Intangible assets (3,997 ) 1,592 (9,951 ) - (12,356 ) Net deferred tax asset (liability) - 419 (134 ) (421 ) (136 ) Opening Recognized in Recognized in Ending August 1, 2019 income equity July 31, 2020 $ $ $ $ Taxable temporary differences 6,858 3,557 - 10,415 Biological assets (1,514 ) 184 - (1,330 ) Inventory (2,920 ) (2,168 ) - (5,088 ) Loss carryforward 23,369 (23,369 ) - - Financing costs 721 (721 ) - - Intangible assets (32,537 ) 28,540 - (3,997 ) Net deferred tax asset (liability) (6,023 ) 6,023 - -
Schedule of deductible temporary differences and unused tax losses	July 31, 2021 July 31, 2020 $ Deductible temporary differences 11,556 8,328 Taxable temporary differences 26,444 8,412 Investments 17,030 14,890 Losses carried forward 278,115 255,635 Research and development expenditures 1,817 669 Fixed Assets, intangibles and other assets 114,384 52,852 Financing costs 40,401 22,599 489,747 363,385
Schedule of non-capital losses	$ 2022 219 2023 281 2024 164 2025 748 2026 632 2027 104 2028 2,092 2029 1,350 2030 75 2031 2,867 2032 3,018 2033 4,030 2034 1,772 2035 2,413 2036 12,889 2037 37,244 2038 64,821 2039 57,938 2040 157,595 2041 24,764 Indefinite 1,179 376,195

Going Concern (Narrative) (Deta

Going Concern (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)	Jul. 31, 2020CAD ($)	Oct. 22, 2021USD ($)	Jul. 31, 2021USD ($)
Disclosure Of Going Concern [Line Items]
Loss from operations	$ (85,495)	$ (476,551)
Cash used in operating activities	(43,068)	(94,554)
Accumulated deficit	$ (773,993)	$ (659,231)
Senior Secured Convertible Notes
Disclosure Of Going Concern [Line Items]
Threshold market price of equity condition				$ 5
Subsequent events | Senior Secured Convertible Notes
Disclosure Of Going Concern [Line Items]
Threshold market price of equity condition			$ 1.50

Basis of Preparation - Schedule

Basis of Preparation - Schedule of major subsidiaries (Details)	12 Months Ended
	Jul. 31, 2021
HEXO Operations Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
HEXO USA Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Zenabis Global Inc
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	60.00%
Keystone Isolation Technologies USA LLC. ("KIT USA'')
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%

Basis of Preparation - Schedu_2

Basis of Preparation - Schedule of major joint ventures (Details)	12 Months Ended
	Jul. 31, 2021
Belleville Complex Inc.
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture	25.00%

Basis of Preparation - Schedu_3

Basis of Preparation - Schedule of major associates (Details)	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Truss Limited Partnership ("Truss LP")
Disclosure of associates [line items]
Proportion of ownership interest in associate	42.50%	42.50%
Truss CBD USA LLC ("Truss CBD US")
Disclosure of associates [line items]
Proportion of ownership interest in associate	42.50%

Significant Accounting Polici_4

Significant Accounting Policies and Pronouncements (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Aug. 01, 2019	Jul. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Accounts payable repayment period	30 days
Trade and other payables repayment period	12 months
Lease liabilities	$ 43,885	$ 29,116	$ 21,360	$ 0
As reported under IFRS 16 August 1, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Short term leases with lease terms of less than twelve months			5,000
Lease liabilities			21,360
Right-of-use assets			$ 21,360
Minimum
Disclosure of detailed information about property, plant and equipment [line items]
Maturity term for short-term investments	3 months
Maximum
Disclosure of detailed information about property, plant and equipment [line items]
Maturity term for short-term investments	12 months

Significant Accounting Polici_5

Significant Accounting Policies and Pronouncements - Schedule of terms and method use to calculate amortization of tangible assets (Details)	12 Months Ended
	Jul. 31, 2021
Land
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Not depreciated
Amortization term	No term
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 40 years
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	lease term
Furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 20 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	3 years

Significant Accounting Polici_6

Significant Accounting Policies and Pronouncements - Schedule of terms and method use to calculate amortization of intangible assets (Details)	12 Months Ended
	Jul. 31, 2021
Domain names
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	10 years
Health Canada licenses
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years
Software
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	3-5 years
Patents
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years
Finite life, brands
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	3 years

Cash and Cash Equivalents - Sch

Cash and Cash Equivalents - Schedule of cash and cash equivalents (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Short Term Investments [Line Items]
Cash and cash equivalents	$ 67,462	$ 184,173	$ 113,568
Operating cash
Disclosure Of Short Term Investments [Line Items]
Interest rate	0.00%
Cash and cash equivalents	$ 31,702	70,318
High interest savings accounts
Disclosure Of Short Term Investments [Line Items]
Interest rate	0.60%
Cash and cash equivalents	$ 35,760	$ 113,855

Restricted Funds - Schedule of

Restricted Funds - Schedule of restricted funds (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Restricted Cash [Line Items]
Restricted funds	$ 132,246	$ 8,261
Debt service reserve account - term loan
Restricted Cash [Line Items]
Restricted funds	0	8,191
Letters of credit, collateral and guarantees for purchases
Restricted Cash [Line Items]
Restricted funds	2,552	70
Restricted cash under terms of the Senior Secured Convertible Note
Restricted Cash [Line Items]
Restricted funds	99,696	0
Cash restricted in captive insurance subsidiary
Restricted Cash [Line Items]
Restricted funds	$ 29,998	$ 0

Cash Held in Escrow (Narrative)

Cash Held in Escrow (Narrative) (Details) $ in Thousands, $ in Thousands	1 Months Ended
	May 27, 2021CAD ($)	May 27, 2021USD ($)	Jul. 31, 2021CAD ($)	May 27, 2021USD ($)	Jul. 31, 2020CAD ($)
Disclosure Of Cash Held In Escrow [Line Items]
Notional amount			$ 51,875
Cash held in escrow			$ 285,779		$ 0
Senior Secured Convertible Notes
Disclosure Of Cash Held In Escrow [Line Items]
Notional amount	$ 434,628			$ 360,000
Proceeds from issue of bonds, notes and debentures	$ 395,511	$ 327,600
Cash held in escrow				$ 229,320

Commodity Taxes Recoverable a_3

Commodity Taxes Recoverable and Other Receivables - Schedule of commodity taxes recoverable and other receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity taxes recoverable	$ 56	$ 12,821
Lease receivable - current	107	630
Receivable on conversion of Inner Spirit Holdings Shares	2,698	0
Loan receivable	5,000	0
Other receivables	5,688	3,282
Total	$ 13,549	$ 16,733

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Classes of current inventories [abstract]
Inventory expensed to cost of goods sold	$ 94,703	$ 127,205
Fair value adjustment on inventory sold	31,767	40,910
Reversal of inventory impairment	2,927	0
Reversal of fair value amounts on inventory sold	688	0
Stock based compensation expensed to costs of sales	1,505	6,105
Inventory capitalized depreciation costs	$ 15,677	$ 11,988

Inventory - Schedule of invento

Inventory - Schedule of inventories (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Classes Of Inventories [Line Items]
Dried cannabis	$ 106,041	$ 46,683
Purchased dried cannabis	1,754	1,956
Extracts	16,356	5,213
Purchased extracts	2,247	5,977
Hemp derived distillate		566
Packaging and supplies	8,929	4,538
Total inventory	135,327	64,933
Capitalized cost
Classes Of Inventories [Line Items]
Dried cannabis	81,784	29,702
Purchased dried cannabis	1,754	1,956
Extracts	11,945	4,828
Purchased extracts	2,247	5,977
Hemp derived distillate		566
Packaging and supplies	8,929	4,538
Total inventory	106,659	47,567
Biological asset fair value adjustment
Classes Of Inventories [Line Items]
Dried cannabis	24,257	16,981
Purchased dried cannabis	0	0
Extracts	4,411	385
Purchased extracts	0	0
Hemp derived distillate		0
Packaging and supplies	0	0
Total inventory	$ 28,668	$ 17,366

Biological Assets - Schedule of

Biological Assets - Schedule of changes in the carrying value of biological assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about biological assets [abstract]
Balance, beginning of year	$ 7,571	$ 7,371
Acquired on business combination	8,892	0
Production costs capitalized	36,156	38,638
Net increase in fair value due to biological transformation and estimates	51,499	29,356
Harvested cannabis transferred to inventory	(89,834)	(67,131)
Disposal of biological assets	0	(663)
Balance, end of year	$ 14,284	$ 7,571

Biological Assets - Schedule _2

Biological Assets - Schedule of detailed information about biological assets (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)CAD_per_DriedgramGram	Jul. 31, 2020CAD ($)CAD_per_DriedgramGram
Derived from actual retail prices on a per product
Weighted average selling price input values per dried gram | CAD_per_Driedgram	3.05	3.23
Sensitivity analysis, impact of variance on selling price to valuation	$ 746	$ 550
Obtained through historical harvest cycle results on a per strain basis
Sensitivity analysis, impact of variance on average yield per plant to valuation	460	376
Obtained through the estimates of post-harvest cost within the cultivation and production cycle
Sensitivity analysis impact of variance on wastage expectation result in change in valuation	$ 636	$ 219
Minimum
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	24	46
Obtained through the estimates of post-harvest cost within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	0.67%	0.26%
Maximum
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	116	135
Obtained through the estimates of post-harvest cost within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	0.84%	0.81%

Investments in Associates & J_3

Investments in Associates & Joint Ventures (Narrative) (Details) - Truss LP	Oct. 04, 2018shares
Disclosure of joint ventures [line items]
Number of shares held	42,500
Proportion of ownership interest in joint venture	42.50%
Molson Coors Canada (the "Partner")
Disclosure of joint ventures [line items]
Number of shares held	57,500
Proportion of ownership interest in joint venture	57.50%

Investments in Associates & J_4

Investments in Associates & Joint Ventures - Schedule of investment in associate and joint ventures (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	$ 76,306	$ 52,849
Cash consideration of investment	5,033	30,386
Capitalized transaction costs	0	109
Share of net loss for the year	(6,505)	(6,331)
Impairment	0	(707)
Foreign exchange loss through OCI	(155)	0
Ending Balance	74,679	76,306
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	74,966	51,786
Cash consideration of investment	4,250	29,155
Capitalized transaction costs	0	0
Share of net loss for the year	(6,343)	(5,975)
Impairment	0	0
Foreign exchange loss through OCI	0	0
Ending Balance	72,873	74,966
Other
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	1,340	1,063
Cash consideration of investment	783	1,231
Capitalized transaction costs	0	109
Share of net loss for the year	(162)	(356)
Impairment	0	(707)
Foreign exchange loss through OCI	(155)	0
Ending Balance	$ 1,806	$ 1,340

Investments in Associates & J_5

Investments in Associates & Joint Ventures - Schedule of investment in associate and joint ventures - Statement of financial position (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	$ 67,462	$ 184,173	$ 113,568
Current liabilities	503,638	82,487
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	6,757	19,561
Other current assets	14,182	7,867
Non-current assets	67,766	66,863
Current liabilities	11,184	11,112
Non-current liabilities	$ 8,667	$ 8,903

Investments in Associates & J_6

Investments in Associates & Joint Ventures - Schedule of investment in associate and joint ventures - Statement of comprehensive loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue	$ 123,769	$ 80,784
Operating expenses excluding depreciation and amortization	(134,293)	(418,576)
Loss from operations	(85,495)	(476,551)
Interest income	1,601	1,902
Other income	4,763	2,531
Interest expenses	32,124	10,043
Income tax expenses	(397)	(6,023)
Total comprehensive loss	(113,610)	(546,489)
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue	6,498	705
Operating expenses excluding depreciation and amortization	(14,261)	(12,647)
Depreciation and amortization	(4,884)	(617)
Other expenses	0	(7)
Loss from operations	(14,643)	(13,827)
Other income	130	1
Interest expenses	(412)	(233)
Income tax expenses	0	0
Total comprehensive loss	$ (14,925)	$ (14,059)

Investments in Associates & J_7

Investments in Associates & Joint Ventures - Schedule for reconciliation of investment in associate (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Line Items]
Total comprehensive loss	$ (113,610)	$ (546,489)
Total interest in associate value	74,679	76,306	$ 52,849
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Opening net assets	74,964	20,423
Acquisition of associate/capital calls	10,000	68,600
Total comprehensive loss	(14,925)	(14,059)
Closing net assets	$ 70,039	$ 74,964
Interest in associate	42.50%	42.50%
Interest in associate value	$ 29,767	$ 31,860
Fair value of warrant consideration	42,386	42,386
Capitalized transaction costs	720	720
Total interest in associate value	$ 72,873	$ 74,966	$ 51,786

Long-term Investments (Narrativ

Long-term Investments (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	Feb. 11, 2020	Jul. 21, 2021	Nov. 30, 2019	May 24, 2019	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Long Term Investment [Line Items]
Long-term investments					$ 2,492	$ 3,209
Receivable on conversion of Inner Spirit Holdings Shares					2,698	0
Fire & Flower Holdings Corp. common shares
Disclosure Of Long Term Investment [Line Items]
Conversion of debt, shares issued	319,377		1,000,000
Conversion of debt, converted amount			$ 800
Conversion rate of convertible debentures			$ 0.80
Conversion of debt, fair value of shares issued			$ 920
Fair value of convertible debentures settlement	$ 1,232
Shares held					1,319,377	$ 1,319,377
Long-term investments					$ 1,227
Share price					$ 0.93	$ 0.98
Inner Spirit common shares
Disclosure Of Long Term Investment [Line Items]
Shares held						$ 8,994,500
Long-term investments						$ 1,260
Number of common shares obtained				15,000,000
Fair value of investments				$ 2,850
Number of common shares disposed						6,005,500
Gain on disposal of common shares						$ 24
Share price						$ 0.14
Inner Spirit common shares | Minimum
Disclosure Of Long Term Investment [Line Items]
Share price						0.09
Inner Spirit common shares | Maximum
Disclosure Of Long Term Investment [Line Items]
Share price						$ 0.15
Sundial Growers Inc
Disclosure Of Long Term Investment [Line Items]
Consideration per common share in cash		$ 0.30
Consideration per common share paid in shares		$ 0.0835
Number of common shares obtained		751,041
Receivable on conversion of Inner Spirit Holdings Shares		$ 2,698
Share price		$ 0.87			$ 0.82

Long-term Investments - Schedul

Long-term Investments - Schedule of long-term investments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	$ 3,209
Long-term investments, ending balance	2,492	$ 3,209
Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	3,209	14,277
Investment/Transfer	0	1,749
Divestiture	(2,711)	(643)
Change in fair value	1,994	(12,174)
Long-term investments, ending balance	2,492	3,209
Fire & Flower Holdings Corp. common shares
Disclosure Of Long Term Investment [Line Items]
Long-term investments, ending balance	1,227
Fire & Flower Holdings Corp. common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	1,292	0
Investment/Transfer	0	1,232
Divestiture	0	0
Change in fair value	(65)	60
Long-term investments, ending balance	1,227	1,292
Sundial Growers Inc. common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0
Investment/Transfer	720
Divestiture	0
Change in fair value	(99)
Long-term investments, ending balance	621	0
Inner Spirit common shares
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	1,260
Long-term investments, ending balance		1,260
Inner Spirit common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	1,260	3,000
Investment/Transfer	(720)	0
Divestiture	(2,698)	(643)
Change in fair value	2,158	(1,097)
Long-term investments, ending balance	0	1,260
Inner Spirit common share purchase warrants | Level 2 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0	403
Investment/Transfer		0
Divestiture		0
Change in fair value		(403)
Long-term investments, ending balance		0
Other long-term investments | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	517	0
Investment/Transfer	0	517
Divestiture	(13)	0
Change in fair value	0	0
Long-term investments, ending balance	504	517
Greentank Technologies | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0	6,574
Investment/Transfer		0
Divestiture		0
Change in fair value		(6,574)
Long-term investments, ending balance		0
Neal Brothers Inc. | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0	4,000
Investment/Transfer		0
Divestiture		0
Change in fair value		(4,000)
Long-term investments, ending balance		0
Segra International Corp | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	140	300
Investment/Transfer	0	0
Divestiture	0	0
Change in fair value	0	(160)
Long-term investments, ending balance	$ 140	$ 140

Property, Plant and Equipment_2

Property, Plant and Equipment (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 17, 2020	Jan. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Inventory capitalized depreciation costs			$ 15,677	$ 11,988
Depreciation of property, plant and equipment			6,097	6,072
Impairments			20,230	79,418
Sale of property and related assets			93	10,966
Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			20,230	79,418
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Capitalized borrowing costs			$ 1,269	$ 2,385
Average annual interest rate			5.60%	7.22%
Buildings | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			$ 160	$ 19,006
Langley and Montreal facilities
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			17,820	1,178
Langley
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			17,059
Montreal
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			761
Construction in progress | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			0	48,990
Cultivation and production equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			2,104	9,937
Impairment and Sale of Niagara Facility
Disclosure of detailed information about property, plant and equipment [line items]
Impairment losses			$ 31,606
Sale of property and related assets	$ 12,250
Loss on disposal of property, plant and equipment	$ 2,219
Impairment of Certain Optimization Projects
Disclosure of detailed information about property, plant and equipment [line items]
Impairment losses				$ 43,585
Income based approach | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Increase in impairment loss		$ 24,283
Income based approach | DCF analysis, assumption one | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Short-term growth rate		10.00%
Terminal value growth rate		3.00%
Decrease in short-term growth rate		1.00%
Decrease in recoverable amount		$ 24,000
Income based approach | DCF analysis, assumption two | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Decrease in forecast revenues		3.00%
Decrease in recoverable amount		$ 34,000
Income based approach | DCF analysis, assumption three | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Terminal value growth rate		3.00%
Decrease in terminal value growth rate		1.00%
Decrease in recoverable amount		$ 38,000
Income based approach | DCF analysis, assumption four | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Post tax discount rate		14.10%
Increase in post tax discount rate		1.00%
Decrease in recoverable amount		$ 59,000

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of property, plant and equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 285,366	$ 258,793
Impairments	20,230	79,418
Ending balance	393,902	285,366
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	365,916	266,747
Business acquisitions	129,074
Additions	20,814	140,851
Disposals	(1,121)	(41,682)
Transfers	328	0
Ending balance	515,011	365,916
Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	80,550	7,954
Depreciation	21,774	18,060
Disposals	(964)	(24,882)
Transfers	(481)	0
Impairments	20,230	79,418
Ending balance	121,109	80,550
Land
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,349	5,339
Ending balance	2,449	1,349
Land | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,656	5,339
Business acquisitions	1,100
Additions	0	0
Disposals	0	(3,683)
Transfers	0	0
Ending balance	2,756	1,656
Land | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	307	0
Depreciation	0	0
Disposals	0	0
Transfers	0	0
Impairments	0	307
Ending balance	307	307
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	151,237	146,442
Ending balance	244,159	151,237
Buildings | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	164,949	150,834
Business acquisitions	95,788
Additions	1,213	24,432
Disposals	1	(18,260)
Transfers	3,951	7,943
Ending balance	265,902	164,949
Buildings | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	13,712	4,392
Depreciation	7,981	7,395
Disposals	0	(17,081)
Transfers	(110)	0
Impairments	160	19,006
Ending balance	21,743	13,712
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	23,430	497
Ending balance	38,900	23,430
Leasehold improvements | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	24,439	627
Business acquisitions	0
Additions	63	1,395
Disposals	0	0
Transfers	17,649	22,417
Ending balance	42,151	24,439
Leasehold improvements | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,009	130
Depreciation	2,173	879
Disposals	0	0
Transfers	(16)	0
Impairments	85	0
Ending balance	3,251	1,009
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	24,770	39,813
Ending balance	26,854	24,770
Cultivation and production equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	33,461	42,029
Business acquisitions	6,154
Additions	2,284	14,969
Disposals	(67)	(13,402)
Transfers	884	(10,135)
Ending balance	42,716	33,461
Cultivation and production equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	8,691	2,216
Depreciation	5,145	3,702
Disposals	0	(7,435)
Transfers	(78)	271
Impairments	2,104	9,937
Ending balance	15,862	8,691
Furniture, computers, vehicles and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	14,730	9,152
Ending balance	20,977	14,730
Furniture, computers, vehicles and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	18,871	10,368
Business acquisitions	8,578
Additions	294	9,404
Disposals	0	(909)
Transfers	1,388	8
Ending balance	29,131	18,871
Furniture, computers, vehicles and equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	4,141	1,216
Depreciation	4,229	3,562
Disposals	0	(366)
Transfers	(277)	(271)
Impairments	61	0
Ending balance	8,154	4,141
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	49,145	57,550
Ending balance	42,956	49,145
Construction in progress | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	98,135	57,550
Business acquisitions	395
Additions	16,960	66,246
Disposals	0	(5,428)
Transfers	(23,544)	(20,233)
Ending balance	91,946	98,135
Construction in progress | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	48,990	0
Depreciation	0	0
Disposals	0	0
Transfers	0	0
Impairments	0	48,990
Ending balance	48,990	48,990
Right-of-Use assets
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	20,705	0
Ending balance	17,607	20,705
Right-of-Use assets | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	24,405	0
Business acquisitions	17,059
Additions		24,405
Disposals	(1,055)	0
Transfers	0	0
Ending balance	40,409	24,405
Right-of-Use assets | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,700	0
Depreciation	2,246	2,522
Disposals	(964)	0
Transfers	0	0
Impairments	17,820	1,178
Ending balance	$ 22,802	$ 3,700

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about intangible assets [line items]
Research and development expense	$ 3,835	$ 4,639
Impairment loss	$ 0	108,189
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Impairment loss		108,189
Cultivating and processing license | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Impairment loss		106,189
Brands
Disclosure of detailed information about intangible assets [line items]
Impairment loss		2,000
Brands | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Impairment loss		$ 2,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of intangible assets and other longer-term assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 16,008	$ 127,282
Impairment	0	108,189
Ending balance	50,608	16,008
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	131,101	130,247
Additions	2,336	1,577
Business acquisitions	34,314
Disposals	(872)	(723)
Ending balance	166,879	131,101
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	115,093	2,965
Amortization	2,050	3,939
Impairment		108,189
Disposals	(872)
Ending balance	116,271	115,093
Cultivating and processing license
Disclosure of detailed information about intangible assets [line items]
Beginning balance	5,476	114,832
Ending balance	33,625	5,476
Cultivating and processing license | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	116,433	116,433
Additions	0	0
Business acquisitions	28,914
Disposals	0	0
Ending balance	145,347	116,433
Cultivating and processing license | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	110,957	1,601
Amortization	765	3,167
Impairment		106,189
Disposals	0
Ending balance	111,722	110,957
Brands
Disclosure of detailed information about intangible assets [line items]
Beginning balance	6,440	8,440
Impairment		2,000
Ending balance	11,670	6,440
Brands | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,440	8,440
Additions	0	0
Business acquisitions	5,400
Disposals	0	0
Ending balance	13,840	8,440
Brands | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,000	0
Amortization	170	0
Impairment		2,000
Disposals	0
Ending balance	2,170	2,000
Software
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,744	2,289
Ending balance	2,368	1,744
Software | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	3,710	3,558
Additions	1,546	702
Business acquisitions	0
Disposals	(872)	(550)
Ending balance	4,384	3,710
Software | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,966	1,269
Amortization	922	697
Impairment		0
Disposals	(872)
Ending balance	2,016	1,966
Domain names
Disclosure of detailed information about intangible assets [line items]
Beginning balance	460	519
Ending balance	401	460
Domain names | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	585	585
Additions	0	0
Business acquisitions	0
Disposals	0	0
Ending balance	585	585
Domain names | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	125	66
Amortization	59	59
Impairment		0
Disposals	0
Ending balance	184	125
Patents
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,888	1,202
Ending balance	2,544	1,888
Patents | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,933	1,231
Additions	790	875
Business acquisitions	0
Disposals	0	(173)
Ending balance	2,723	1,933
Patents | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	45	29
Amortization	134	16
Impairment		0
Disposals	0
Ending balance	$ 179	$ 45

Business Acquisition (Narrative

Business Acquisition (Narrative) (Details) $ / shares in Units, $ in Thousands	Jun. 01, 2021CAD ($)Share	Jun. 01, 2021CAD ($)ShareYear$ / shares	Jul. 31, 2021CAD ($)ShareYear$ / shares	Jul. 31, 2020CAD ($)Year$ / shares
Disclosure of detailed information about business combination [line items]
Risk free interest rate of options			1.24%	1.79%
Expected life of options (years) | Year			5	5
Expected volatility, share options granted			85.00%	75.00%
Exercise price of options granted | $ / shares			$ 17.03	$ 26.04
Lending of convertible debenture receivable			$ 19,500	$ 0
Net revenue			123,769	80,784
Net loss			(114,814)	$ (546,489)
Zenabis Global Inc
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired	100.00%	100.00%
Exchange ratio	0.01772	0.01772
Lending of convertible debenture receivable		$ 19,500
Convertible debentures interest rate		8.00%
Net revenue			6,800
Net loss			1,513
Increase in net revenue based on management estimates if acquisition had occurred earlier			54,746
Increase in net loss based on management estimates if acquisition had occurred earlier			9,078
Total expensed commission and transaction costs			9,634
Share-based compensation			$ 3,614
Number of shares issued | Share	17,579,336	17,579,336	448,639
Settlement of pre-existing debt	$ 20,760	$ 20,760
Cultivation and processing license	28,914	$ 28,914
Percentage of decrease in valuation cultivation and processing license		10.00%
Decrease in valuation of cultivation and processing license	6,336
Reduce valuation of cultivation and production ramp up	$ 18,665
Zenabis Global Inc | Warrant reserves
Disclosure of detailed information about business combination [line items]
Volatility rate of warrants		96.00%
Stock price of warrants | $ / shares		$ 8.61
Zenabis Global Inc | Warrant reserves | Minimum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants		0.31%
Expected life of warrants		3 months 25 days
Exercise price of warrants | $ / shares		$ 3.96
Zenabis Global Inc | Warrant reserves | Maximum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants		0.74%
Expected life of warrants		4 years 4 months 6 days
Exercise price of warrants | $ / shares		$ 151.24
Zenabis Global Inc | Replacement Options
Disclosure of detailed information about business combination [line items]
Expected volatility, share options granted		96.00%
Stock price of options | $ / shares		$ 8.61
Zenabis Global Inc | Replacement Options | Minimum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of options		0.31%
Expected life of options (years) | Year		0.25
Exercise price of options granted | $ / shares		$ 2.54
Zenabis Global Inc | Replacement Options | Maximum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of options		0.74%
Expected life of options (years) | Year		4.49
Exercise price of options granted | $ / shares		$ 234.7

Business Acquisition - Schedule

Business Acquisition - Schedule of business acquisition (Details) $ / shares in Units, $ in Thousands	Jul. 31, 2021CAD ($)Share	Jun. 01, 2021CAD ($)Share$ / sharesshares	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)
Non-current assets
Goodwill	$ 88,189		$ 0	$ 111,877
Non-current liabilities
Non-controlling interest	$ (1,340)		0
Zenabis Global Inc
Disclosure of detailed information about business combination [line items]
Number of shares issued | Share	448,639	17,579,336
Par value of shares issued | $ / shares		$ 8.61
Value of shares issued		$ 151,358
Number of Replacement warrants outstanding | shares		5,196,164
Value of Replacement warrants outstanding		$ 32,354
Number of Replacement options issued | shares		905,902
Value of Replacement options issued		$ 5,727
Number of Replacement RSU's and DSU's issued | shares		223,497
Value of Replacement RSU's and DSU's issued		$ 1,554
Settlement of pre-existing debt		20,760
Total fair value of consideration		211,753
Current assets
Cash and cash equivalents		2,804
Accounts receivable		3,822
Other receivables		198
Excise taxes receivable		86
Inventory		40,636
Biological assets		8,892
Non-current assets
Property, plant and equipment		129,074
Prepaid expenses		5,670
Cultivation and processing license		28,914
Brands		5,400
Goodwill	$ 88,189	88,189	$ 0	$ 0
Total assets		313,685
Current liabilities
Accounts payable and accrued liabilities		(22,161)
Loan		(52,194)
Convertible debentures		(11,724)
Non-current liabilities
Lease Liability		(17,059)
Deferred tax liabilities		(134)
Total liabilities		(103,272)
Non-controlling interest		1,340
Total net assets acquired		$ 211,753

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill impairment loss	$ (111,877)	$ 0	$ (111,877)
Zenabis Global Ltd
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill impairment loss			0
Zenabis Global Ltd | Market-based approach
Disclosure of reconciliation of changes in goodwill [line items]
Adjusted control premium		5.00%
Share price declined		5.00%
Increase in impairment loss		$ 45,087
Share price increase		5.00%
Decrease in impairment loss		$ 42,941
Newstrike
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill impairment loss			$ (111,877)
Newstrike | Market-based approach
Disclosure of reconciliation of changes in goodwill [line items]
Adjusted control premium	10.00%
Share price declined	5.00%
Increase in impairment loss	$ 26,647
Newstrike | Income based approach
Disclosure of reconciliation of changes in goodwill [line items]
Adjusted control premium		5.00%
Increase in impairment loss	24,283
Newstrike | Income based approach | DCF analysis, assumption five
Disclosure of reconciliation of changes in goodwill [line items]
Increase in impairment loss	$ 12,598
Short-term growth rate	10.00%
Terminal value growth rate	3.00%
Decrease in short-term growth rate	1.00%
Newstrike | Income based approach | DCF analysis, assumption six
Disclosure of reconciliation of changes in goodwill [line items]
Increase in impairment loss	$ 27,000
Terminal value growth rate	3.00%
Decrease in short-term growth rate	1.00%
Newstrike | Income based approach | DCF analysis, assumption seven
Disclosure of reconciliation of changes in goodwill [line items]
Increase in impairment loss	$ 53,933
Post tax discount rate	15.90%
Increase in post tax discount rate	1.00%

Goodwill - Schedule of reconcil

Goodwill - Schedule of reconciliation of changes in goodwill (Details) - CAD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Disclosure of reconciliation of changes in goodwill [line items]
Balance		$ 0	$ 111,877
Acquisition		88,189
Impairment	$ (111,877)	0	(111,877)
Balance		88,189	0
Newstrike Brand Ltd
Disclosure of reconciliation of changes in goodwill [line items]
Balance		0	111,877
Acquisition		0
Impairment			(111,877)
Balance		0	0
Zenabis Global Ltd
Disclosure of reconciliation of changes in goodwill [line items]
Balance		0	0
Acquisition		88,189
Impairment			0
Balance		$ 88,189	$ 0

Warrant Liabilities (Narrative)

Warrant Liabilities (Narrative) (Details) $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended			12 Months Ended
	Dec. 18, 2020$ / sharesshares	Jan. 21, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Jul. 31, 2021shares	Jul. 31, 2020CAD ($)shares	Jul. 31, 2020USD ($)$ / sharesshares	Jan. 20, 2020shares	Jul. 31, 2019shares
Warrant Liabilities [Line Items]
Number of warrants issued				0	30,976,394	30,976,394
Number of outstanding warrants				36,666,958	33,379,408	33,379,408		7,396,354
Number of warrants exercised				2,146,931	1,103,469	1,103,469
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Proceeds from direct offering | $		$ 20,000
Number of warrants issued		5,988,024
Exercise price of warrants issued | $ / shares	$ 9.80	$ 2.45
Number of outstanding warrants	1,497,007			1,497,007	1,497,007	1,497,007	1,497,007
US$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Proceeds from direct offering | $			$ 25,000
Number of warrants issued			7,485,032
Exercise price of warrants issued | $ / shares	$ 9.80		$ 2.45
Number of outstanding warrants	1,871,259		1,871,259	1,871,259	1,871,259	1,871,259
2017 Unsecured Convertible Debentures Warrants
Warrant Liabilities [Line Items]
Number of warrants exercised					17,856	17,856
Proceeds from warrants exercised					$ 72	$ 54
Exercise price of warrants exercised | $ / shares						$ 3.04

Warrant Liabilities - Schedule

Warrant Liabilities - Schedule of warrant liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Warrant Liabilities [Line Items]
Opening balance	$ 3,450	$ 493
Issued		9,596
Exercised		(106)
(Gain) Loss in revaluation of financial instruments	2,283	(6,533)
Ending balance	5,733	3,450
2017 Unsecured Convertible Debentures Warrants
Warrant Liabilities [Line Items]
Opening balance	0	493
Issued		0
Exercised		(106)
(Gain) Loss in revaluation of financial instruments	0	(387)
Ending balance	0	0
US$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Opening balance	1,917	0
Issued		5,629
Exercised		0
(Gain) Loss in revaluation of financial instruments	1,269	(3,712)
Ending balance	3,186	1,917
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Opening balance	1,533	0
Issued		3,967
Exercised		0
(Gain) Loss in revaluation of financial instruments	1,014	(2,434)
Ending balance	$ 2,547	$ 1,533

Warrant Liabilities - Schedul_2

Warrant Liabilities - Schedule of fair value assumptions for warrants (Details)	5 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)$ / $$ / sharesshares	Jan. 20, 2020USD ($)$ / $$ / sharesshares	Jul. 31, 2021USD ($)$ / $$ / sharesshares	Jul. 31, 2020USD ($)$ / $$ / sharesshares	Dec. 18, 2020shares	Jul. 31, 2019shares
Warrant Liabilities [Line Items]
Number of warrants			36,666,958	33,379,408		7,396,354
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Number of warrants		1,497,007	1,497,007	1,497,007	1,497,007
Share price | $ / shares		$ 5.80	$ 3.97	$ 2.72
Expected life (years)		2 years 6 months	2 years 6 months	2 years 6 months
Dividend | $		$ 0	$ 0	$ 0
Volatility		80.00%	95.00%	97.00%
Risk free rate		1.57%	0.38%	0.22%
Exchange rate (USD/CAD) | $ / $		1.3116	1.2462	1.3404
US$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Number of warrants	1,871,259		1,871,259	1,871,259	1,871,259
Share price | $ / shares	$ 6.36		$ 3.97	$ 2.72
Expected life (years)	2 years 6 months		2 years 6 months	2 years 6 months
Dividend | $	$ 0		$ 0	$ 0
Volatility	79.00%		95.00%	97.00%
Risk free rate	1.71%		0.38%	0.22%
Exchange rate (USD/CAD) | $ / $	1.2988		1.2462	1.3404

Convertible Debentures (Narrati

Convertible Debentures (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	Jun. 01, 2021	Jun. 10, 2020	Dec. 05, 2019	Jun. 30, 2020	May 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Unsecured convertible debenture- March 2019
Disclosure of detailed information about borrowings [line items]
Acquired on business combination						$ 3,722
Interest rate	6.00%
Conversion price	$ 147.29
Interest expense						56
Unsecured convertible debenture- March 2019 | Subsequent Events [Member]
Disclosure of detailed information about borrowings [line items]
Repayment of debt						3,461
Unsecured convertible debenture- December 2019
Disclosure of detailed information about borrowings [line items]
Principal amount of debentures			$ 70,000			40,140	$ 40,140
Interest rate			8.00%
Conversion price			$ 12.64
Interest expense						7,331	6,854
Minimum daily volume weighted average trading price of common shares specified for conversion of debentures			$ 30
Number of consecutive trading days			15 days
Discounted early conversion price of conversion units					$ 0.80
Description of conversion units					Each Conversion Unit provided the holder one common share and one half common share purchase warrant (with an exercise price of $1.00 and term of three years).
Exercise price of conversion units					$ 1
Conversion unit, term					three years
Conversion of convertible debenture amount							20,602
Loss from reduction of the conversion price to induce early conversion							54,283
Accrued and unpaid interest						483	$ 202
Unsecured convertible debenture- December 2019 | First phase
Disclosure of detailed information about borrowings [line items]
Conversion of convertible debenture amount		$ 23,595
Stock issued for conversion of convertible securities		29,493,750
Warrants issued for conversion of convertible securities		14,746,875
Unsecured convertible debenture- December 2019 | Second phase
Disclosure of detailed information about borrowings [line items]
Conversion of convertible debenture amount				$ 6,265
Stock issued for conversion of convertible securities				7,831,250
Warrants issued for conversion of convertible securities				3,915,625
Unsecured convertible notes
Disclosure of detailed information about borrowings [line items]
Acquired on business combination						7,790
Interest rate	6.00%
Conversion price	$ 147.86
Repayment of debt						$ 7,790

Convertible Debentures - Schedu

Convertible Debentures - Schedule of unsecured convertible debenture (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about borrowings [line items]
Total convertible loans and debentures	$ 36,495	$ 28,969
Current	3,406	0
Non-Current	33,089	28,969
Unsecured convertible debenture- March 2019
Disclosure of detailed information about borrowings [line items]
Total convertible loans and debentures	3,406	0
Unsecured convertible debenture- December 2019
Disclosure of detailed information about borrowings [line items]
Total convertible loans and debentures	33,089	28,969	$ 0
Unsecured convertible notes
Disclosure of detailed information about borrowings [line items]
Total convertible loans and debentures	$ 0	$ 0

Convertible Debentures - Sche_2

Convertible Debentures - Schedule of convertible debentures (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about borrowings [line items]
Beginning balance	$ 28,969
Interest paid	(3,583)	$ (3,205)
Ending balance	36,495	28,969
Unsecured convertible debenture- March 2019
Disclosure of detailed information about borrowings [line items]
Beginning balance	0
Acquired on business combination	3,722
Interest payments	(372)
Interest expense	56
Ending balance	3,406	0
Unsecured convertible debenture- December 2019
Disclosure of detailed information about borrowings [line items]
Beginning balance	28,969	0
Issued at amortized cost, net issuance costs		45,922
Conversion		(20,602)
Interest expense	7,331	6,854
Interest paid	(3,211)	(3,205)
Ending balance	33,089	28,969
Unsecured convertible notes
Disclosure of detailed information about borrowings [line items]
Beginning balance	0
Acquired on business combination	7,790
Debt repayment	(7,790)
Ending balance	$ 0	$ 0

Senior Secured Convertible No_3

Senior Secured Convertible Note (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	May 27, 2021CAD ($)$ / sharesshares	May 27, 2021USD ($)shares	Jul. 31, 2021CAD ($)$ / sharesshares	Jul. 31, 2021USD ($)shares	Jul. 31, 2020CAD ($)	Oct. 31, 2021USD ($)	Oct. 22, 2021USD ($)	Jul. 31, 2021USD ($)	Jul. 23, 2021USD ($)	May 27, 2021USD ($)	Jul. 31, 2020USD ($)
Disclosure of detailed information about borrowings [line items]
Notional amount			$ 51,875
Redemption amount			458,710	$ 368,087,000
Deferred financing costs			86,974		$ 0			$ 72,214,000			$ 0
Transaction costs			18,100	$ 14,524,000
Shortfall cash payments			3,893
Loss on fair value due to changes in credit spread			$ 1,169		0
Senior Secured Convertible Notes
Disclosure of detailed information about borrowings [line items]
Notional amount	$ 434,628									$ 360,000,000
Proceeds from issue of bonds, notes and debentures	$ 395,511	$ 327,600,000
Percentage of principal amount of notes sold	91.00%	91.00%
Description of conversion terms for debt instrument			The Note can be converted in full or in part by the Holder into freely tradeable common shares of the Company at any time before the second last trading day before the maturity date at a conversion rate of 142.6533 common shares per US$1 ("conversion rate"). The Note includes different conversion and redemption options (summarized below) available to the Holder and the Company, subject to certain terms and limitations. At any given point, the beneficial ownership of the Holder in the Company is restricted to 9.99% (the "maximum ownership threshold"). Any conversion or redemption option exercised in common shares which would result in the Holder exceeding the maximum ownership threshold is null and void. Any outstanding payments due on maturity date will be settled in cash.	The Note can be converted in full or in part by the Holder into freely tradeable common shares of the Company at any time before the second last trading day before the maturity date at a conversion rate of 142.6533 common shares per US$1 ("conversion rate"). The Note includes different conversion and redemption options (summarized below) available to the Holder and the Company, subject to certain terms and limitations. At any given point, the beneficial ownership of the Holder in the Company is restricted to 9.99% (the "maximum ownership threshold"). Any conversion or redemption option exercised in common shares which would result in the Holder exceeding the maximum ownership threshold is null and void. Any outstanding payments due on maturity date will be settled in cash.
Number of shares issued per $1,000 principal amount of notes | shares			142.6533	142.6533
Early conversion option	$ 60,365									50,000,000
Redemption amount	478,091	$ 396,000,000
Optional redemption option						$ 20,000,000				15,000,000
Optional redemption options, maximum amount from previous months										50,000,000
Threshold market price of equity condition								$ 5
Fair value of senior secured convertible note	$ 491,714		$ 454,673
Share price | $ / shares	$ 6.53		$ 3.98
Volatility	85.00%	85.00%	85.00%	85.00%
Risk-free rate	0.227%	0.227%	0.327%	0.327%
Credit spread	16.06%	16.06%	15.44%	15.44%
Dividend payment	$ 0		$ 0
Number of diluted common shares | shares	284,600,000	284,600,000
Description of monthly redemptions			the Company must	the Company must
Description of forced conversion			The Company has an option, subject to certain conditions, to force the holder to redeem the outstanding principal at a forced conversion price if the Daily VWAP is greater than 150% of the conversion price on each of 20 consecutive trading days after the issue date. The Company may elect to redeem all or a portion of the Principal Amount into common shares or cash. An additional amount of 5% of the Principal Amount at the time of the forced conversion will also be payable in cash by the Company to the Holder unless the Daily VWAP exceeds 175% of the conversion price for five days for each of the 20 previous trading days.	The Company has an option, subject to certain conditions, to force the holder to redeem the outstanding principal at a forced conversion price if the Daily VWAP is greater than 150% of the conversion price on each of 20 consecutive trading days after the issue date. The Company may elect to redeem all or a portion of the Principal Amount into common shares or cash. An additional amount of 5% of the Principal Amount at the time of the forced conversion will also be payable in cash by the Company to the Holder unless the Daily VWAP exceeds 175% of the conversion price for five days for each of the 20 previous trading days.
Deposit with a collateral agent									$ 80,000,000	$ 95,000,000
Transaction costs			$ 18,078	$ 14,975,000
Unrecognized day 1 loss			96,200	$ 79,700,000
Loss on fair value due to changes in credit spread			(1,590)		$ 0
Foreign exchange gain (loss) adjustment due to one percent increase (decrease) in foreign exchange rate			4,547
Change in fair value by increase/decrease of credit spread by 0.5%			2,614
Change in fair value by increase/decrease of share price by 10%			$ 7,443
Senior Secured Convertible Notes | Subsequent events
Disclosure of detailed information about borrowings [line items]
Threshold market price of equity condition							$ 1.50

Senior Secured Convertible No_4

Senior Secured Convertible Note - Schedule of senior secured convertible note (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)	Jul. 31, 2021USD ($)	Jul. 31, 2021USD ($)	Jul. 31, 2020CAD ($)
Senior Secured Convertible Note [Abstract]
Opening balance, beginning of the year	$ 0	$ 0
Issued at fair value	491,714	407,284
Early conversions	(497)	(413)
Redemptions	(33,525)	(27,500)
Gain on fair value adjustment	(18,100)	(14,524)
Foreign exchange loss	15,081	0
Ending balance, end of the year	454,673	364,847
Deferred financing costs
Opening balance, beginning of the year	0	0
Unrecognized loss at issuance	(96,203)	(79,684)
Recognized loss	9,229	7,470
Ending balance, end of the year	(86,974)	$ (72,214)
Total balance, end of year, net	367,699		$ 292,633
Current portion	367,699		292,633	$ 0
Non-current	$ 0		$ 0

Senior Secured Convertible No_5

Senior Secured Convertible Note - Schedule of senior secured convertible note conversions (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)shares	Jul. 31, 2021USD ($)shares	Jul. 31, 2020CAD ($)
Disclosure of detailed information about borrowings [line items]
Shares Issued | shares	0	0
Redemption amount	$ 458,710	$ 368,087
Initial issuance
Disclosure of detailed information about borrowings [line items]
Redemption amount | $			$ 478,091
Early Conversion
Disclosure of detailed information about borrowings [line items]
Shares Issued | shares	53,495	53,495
Redemption amount | $			(497)
Optional Redemptions
Disclosure of detailed information about borrowings [line items]
Shares Issued | shares	4,548,746	4,548,746
Redemption amount | $			(33,525)
Foreign exchange loss
Disclosure of detailed information about borrowings [line items]
Shares Issued | shares	0	0
Redemption amount | $			$ 14,641

Senior Secured Convertible No_6

Senior Secured Convertible Note - Schedule of senior secured convertible note monthly redemption option up to the instrument's maturity date (Details) - 12 months ended Jul. 31, 2021 $ in Thousands, $ in Thousands	CAD ($)	USD ($)
Disclosure of detailed information about borrowings [line items]
Redemption amount	$ 458,710	$ 368,087
Fiscal Year 2022
Disclosure of detailed information about borrowings [line items]
Redemption amount	315,289	253,000
Fiscal Year 2023
Disclosure of detailed information about borrowings [line items]
Redemption amount	$ 143,421	$ 115,087

Lease Liabilities (Narrative) (

Lease Liabilities (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of quantitative information about leases for lessee [abstract]
Gain from exiting real estate leases	$ 181
Impairment losses	17,820
Expensed variable lease payments	$ 3,885	$ 3,769

Lease Liabilities - Schedule of

Lease Liabilities - Schedule of lease liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Aug. 01, 2019	Jul. 31, 2019
Operating Lease [Line Items]
Total lease liabilities	$ 43,885	$ 29,116	$ 21,360	$ 0
Lease additions		9,030
Lease liabilities acquired on business combination	17,059
Lease disposals	(789)
Lease payments	(4,835)	(4,341)
Interest expense on lease liabilities	3,334	3,067
Current	1,730	4,772
Non-current	$ 42,155	$ 24,344
Adjustment on adoption of IFRS 16
Operating Lease [Line Items]
Total lease liabilities			$ 21,360

Lease Liabilities - Schedule _2

Lease Liabilities - Schedule of lease obligations over next five fiscal years (Details) $ in Thousands	Jul. 31, 2021CAD ($)
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	$ 78,370
2022
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	6,155
2023 - 2024
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	11,858
2025 - 2026
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	10,835
Thereafter
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	$ 49,522

Loans and Borrowings (Narrative

Loans and Borrowings (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 14, 2019	Jul. 31, 2021	Jul. 31, 2020	Jun. 01, 2021
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 50,159	$ 29,930
Term loan
Disclosure of detailed information about borrowings [line items]
Proceeds from term loan	$ 35,000
Financing costs incurred	1,347
Borrowings		0	29,930
Total interest expense		990	723
Interest costs capitalised		419	896
Senior Notes Payable
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 50,159	$ 0	$ 51,875
Borrowings, interest rate		14.00%
Canadian Imperial Bank of Commerce and Bank of Montreal
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing	$ 65,000
Expected averate rate of interest	mid-to-high 5% per annum range
Minimum repayment of outstanding balance in percentage	minimum 2.5% of the initial amount drawn each quarter
Canadian Imperial Bank of Commerce and Bank of Montreal | Term loan
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing	$ 50,000
Canadian Imperial Bank of Commerce and Bank of Montreal | Revolving credit facility
Disclosure of detailed information about borrowings [line items]
Remaining undrawn facility	$ 15,000

Loans and Borrowings - Schedule

Loans and Borrowings - Schedule of components of loans and borrowings (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jun. 01, 2021	Jul. 31, 2020
Disclosure of detailed information about borrowings [line items]
Total Loans and Borrowings	$ 50,159		$ 29,930
Current	50,159		29,930
Non-current	0		0
Term loan
Disclosure of detailed information about borrowings [line items]
Total Loans and Borrowings	0		29,930
Current	0		29,930
Non-current	0		0
Senior Notes Payable
Disclosure of detailed information about borrowings [line items]
Total Loans and Borrowings	50,159	$ 51,875	0
Current	50,159		0
Non-current	0		0
RDC Loan
Disclosure of detailed information about borrowings [line items]
Total Loans and Borrowings	$ 0		$ 0

Loans and Borrowings - Schedu_2

Loans and Borrowings - Schedule of term loan (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)	Jul. 31, 2021USD ($)	Jul. 31, 2020CAD ($)
Deferred financing costs
Opening balance, beginning of the year	$ 0	$ 0
Ending balance	86,974	$ 72,214	$ 0
Total Loans and Borrowings	50,159		29,930
Current portion	50,159		29,930
Long-term portion	0		0
Term loan
Term Loan
Opening balance	30,625		34,125
Repayments	(30,625)		(3,500)
Ending balance	0		30,625
Deferred financing costs
Opening balance, beginning of the year	(695)		(751)
Additions	(98)		(445)
Amortization of deferred finance costs	793		501
Ending balance	0		(695)
Total Loans and Borrowings	0		29,930
Current portion	0		29,930
Long-term portion	$ 0		$ 0

Loans and Borrowings - Schedu_3

Loans and Borrowings - Schedule of senior notes payable (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of detailed information about borrowings [line items]
Opening balance	$ 29,930
Closing balance	50,159	$ 29,930
Current portion	50,159	29,930
Long-term portion	0	0
Senior Notes Payable
Disclosure of detailed information about borrowings [line items]
Opening balance	0
Assumed on business combination	50,138	0
Interest paid	(1,210)	0
Interest expense	1,231	0
Closing balance	50,159	0
Current portion	50,159	0
Long-term portion	$ 0	$ 0

Loans and Borrowings - Loans an

Loans and Borrowings - Loans and borrowings repayment schedule (Details) $ in Thousands	Jul. 31, 2021CAD ($)
Disclosure of detailed information about borrowings [line items]
Loans and borrowings	$ 51,875
July 31, 2022
Disclosure of detailed information about borrowings [line items]
Loans and borrowings	51,875
Thereafter
Disclosure of detailed information about borrowings [line items]
Loans and borrowings	$ 0

Loans and Borrowings - Schedu_4

Loans and Borrowings - Schedule of RDC Loan (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)
Disclosure of detailed information about borrowings [line items]
Opening balance	$ 29,930
Closing balance	50,159
RDC Loan
Disclosure of detailed information about borrowings [line items]
Opening balance	0
Acquired on business acquisition	2,056
Debt repayment	(2,056)
Closing balance	$ 0

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands

May 11, 2021CAD ($)

Dec. 11, 2020

Apr. 13, 2020CAD ($)$ / shares

Dec. 31, 2020CAD ($)

Dec. 31, 2020USD ($)$ / shares

Jun. 16, 2020CAD ($)

May 21, 2020CAD ($)$ / shares

Jan. 22, 2020CAD ($)

Jan. 22, 2020USD ($)$ / shares

Jul. 31, 2021CAD ($)shares

Jul. 31, 2020CAD ($)shares

Aug. 05, 2020shares

Jul. 31, 2019shares

Disclosure of classes of share capital [line items]

Post-consolidation common share ratio

4:1

Number of shares | shares

152,645,946

120,616,441

64,245,441

Share issue related cost

$ 3,612

May 2021 At-the-market ("ATM") Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

6,373,926

Proceeds from issuing shares

$ 46,987

Share issue related cost

$ 1,730

May 2021 At-the-market ("ATM") Offering | Maximum

Disclosure of classes of share capital [line items]

Proceeds from issuing shares

$ 150,000

June 2020 At-the-market ("ATM") Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

244,875

8,235,620

244,875

Proceeds from issuing shares

$ 34,551

Receivable remained for irrevocable sales

$ 883

June 2020 At-the-market ("ATM") Offering | Maximum

Disclosure of classes of share capital [line items]

Proceeds from issuing shares

$ 34,500

May 2020 Underwritten Public Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

15,985,000

Proceeds from issuing shares

$ 57,545

Units issued in period, price per unit | $ / shares

$ 3.60

Warrants, grants in period, exercise price | $ / shares

$ 4.20

Net contribution to share capital, after warrant reserve adjustment

$ 46,547

Share issue related cost

$ 3,052

April 2020 Underwritten Public Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

14,950,000

Proceeds from issuing shares

$ 46,046

Units issued in period, price per unit | $ / shares

$ 3.08

Warrants, grants in period, exercise price | $ / shares

$ 3.84

Net contribution to share capital, after warrant reserve adjustment

$ 25,863

Share issue related cost

$ 2,936

January 2020 Registered Direct Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

2,994,012

Proceeds from issuing shares

$ 26,290

$ 20,000

Units issued in period, price per unit | $ / shares

$ 6.68

Warrants, grants in period, exercise price | $ / shares

$ 9.80

Net contribution to share capital, after warrant reserve adjustment

22,323

Share issue related cost

$ 1,250

December 2019 Registered Direct Offering

Disclosure of classes of share capital [line items]

Number of shares | shares

3,742,516

Proceeds from issuing shares

$ 32,411

$ 25,000

Units issued in period, price per unit | $ / shares

$ 6.68

Warrants, grants in period, exercise price | $ / shares

$ 9.80

Share Capital (Schedule of issu

Share Capital (Schedule of issued and outstanding common shares) (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Aug. 05, 2020	Jul. 31, 2020	Jul. 31, 2019
Disclosure of classes of share capital [line items]
Number of shares	152,645,946		120,616,441	64,245,441
Share capital	$ 1,267,967		$ 1,023,788	$ 799,706
May 2021 at the market offering, net
Disclosure of classes of share capital [line items]
Number of shares	6,373,926
Share capital	$ 45,257
June 2020 at the market offering
Disclosure of classes of share capital [line items]
Number of shares	244,875	244,875	8,235,620
Share capital	$ 0		$ 33,263
May 2020 underwritten public offering
Disclosure of classes of share capital [line items]
Number of shares			15,985,000
Share capital			$ 43,495
April 2020 underwritten public offering
Disclosure of classes of share capital [line items]
Number of shares			14,950,000
Share capital			$ 22,928
January 2020 registered offering
Disclosure of classes of share capital [line items]
Number of shares			2,994,012
Share capital			$ 21,073
December 2019 registered offering
Disclosure of classes of share capital [line items]
Number of shares			3,742,516
Share capital			$ 25,229
December 2019 private placement
Disclosure of classes of share capital [line items]
Number of shares			9,331,250
Share capital			$ 72,005
Senior secured convertible, net
Disclosure of classes of share capital [line items]
Number of shares	4,602,241
Share capital	$ 29,540
Acquisition shares - Zenabis
Disclosure of classes of share capital [line items]
Number of shares	17,579,336
Share capital	$ 151,358
Transaction costs
Disclosure of classes of share capital [line items]
Number of shares	448,639
Share capital	$ 3,612
Exercise of warrants
Disclosure of classes of share capital [line items]
Number of shares	2,146,931		1,103,469
Share capital	$ 9,932		$ 5,866
Exercise of stock options
Disclosure of classes of share capital [line items]
Number of shares	410,051		29,133
Share capital	$ 3,213		$ 223
Exercise of equity settled RSUs
Disclosure of classes of share capital [line items]
Number of shares	223,506
Share capital	$ 1,267

Common Share Purchase Warrant_2

Common Share Purchase Warrants (Narrative) (Details) - shares	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of warrants expired	535,889	3,889,871
Cashless exercises
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of warrants expired	509,089

Common Share Purchase Warrant_3

Common Share Purchase Warrants - Schedule of warrant activity (Details) - $ / shares	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure Of Common Share Purchase Warrants [Abstract]
Number of warrants Outstanding, beginning of year	33,379,408	7,396,354
Weighted average exercise price, Outstanding, beginning of year	$ 7.60	$ 39.80
Number of warrants Expired and cancelled during period	(535,889)	(3,889,871)
Weighted average exercise price, Expired and cancelled during period	$ 4.09	$ 49
Number of warrants Issued on acquisition	5,970,370	0
Weighted average exercise price, Issued on acquisition	$ 14.59	$ 0
Number of warrants Issued	0	30,976,394
Weighted average exercise price, Warrants issued during period	$ 0	$ 4.96
Number of warrants Exercised during period	(2,146,931)	(1,103,469)
Weighted average exercise price, Exercised during period	$ 4.10	$ 3.88
Number of warrants Outstanding, end of year	36,666,958	33,379,408
Weighted average exercise price, Outstanding, end of year	$ 8.85	$ 7.60

Common Share Purchase Warrant_4

Common Share Purchase Warrants - Schedule of warrants issued (Details)	12 Months Ended
	Jul. 31, 2021$ / sharesshares	Jul. 31, 2020$ / sharesshares	Jul. 31, 2020$ / shares
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants assumed and issued through acquisition	5,970,370	30,976,394
Number of warrants issued	0	30,976,394
Issuance on December 31, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares			$ 9.80
Number of warrants issued		1,871,259
Expiry period		5 years
Issuance on January 22, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares			$ 9.80
Number of warrants issued		1,497,007
Expiry period		5 years
Issuance on April 13, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 3.84
Number of warrants issued		14,950,000
Expiry period		5 years
Issuance on May 21, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 4.20
Number of warrants issued		7,992,500
Expiry period		5 years
Issuance on June 10, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 4
Number of warrants issued		3,686,721
Expiry period		3 years
Issuance on June 30, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 4
Number of warrants issued		978,907
Expiry period		3 years
Issuance on June 01, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants assumed and issued through acquisition	5,970,370
Issuance on June 01, 2021 | Minimum
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares	$ 3.96
Expiry period	2 months 1 day
Issuance on June 01, 2021 | Maximum
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares	$ 155.19
Expiry period	4 years

Common Share Purchase Warrant_5

Common Share Purchase Warrants - Schedule of warrants outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)$ / sharesshares	Jul. 31, 2021$ / shares	Jul. 31, 2020CAD ($)shares	Jul. 31, 2019shares
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	36,666,958		33,379,408	7,396,354
Net book value | $	$ 129,845		$ 99,067
Classified as Equity
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	33,298,692		30,011,142
Net book value | $	$ 124,112		$ 95,617
Classified as Equity | June 2019 financing warrants Exercise price of $63.16 expiring June 19, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	546,135		546,135
Net book value | $	$ 10,022		$ 10,022
Warrants exercise price | $ / shares	$ 63.16
Warrants expiration date	Jun. 19, 2023
Classified as Equity | April 2020 underwritten public offering warrants Exercise price of $3.84 expiring April 13, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	11,830,075		14,004,375
Net book value | $	$ 15,971		$ 18,906
Warrants exercise price | $ / shares	$ 3.84
Warrants expiration date	Apr. 13, 2025
Classified as Equity | May 2020 underwritten public offering warrants Exercise price of $4.20 expiring May 21, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	7,591,876		7,852,513
Net book value | $	$ 10,446		$ 10,805
Warrants exercise price | $ / shares	$ 4.20
Warrants expiration date	May 21, 2025
Classified as Equity | Conversion Unit warrants Exercise price of $4.00 expiring June 10, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	3,686,721		3,686,721
Net book value | $	$ 11,427		$ 11,426
Warrants exercise price | $ / shares	$ 4
Warrants expiration date	Jun. 10, 2023
Classified as Equity | Conversion Unit warrants Exercise price of $4.00 expiring June 30, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	978,907		978,907
Net book value | $	$ 1,928		$ 1,928
Warrants exercise price | $ / shares	$ 4
Warrants expiration date	Jun. 30, 2023
Classified as Equity | Broker/Consultant warrants Exercise price of $3.00 expiring November 3, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	18,905		43,905
Net book value | $	$ 34		$ 78
Warrants exercise price | $ / shares	$ 3
Warrants expiration date	Nov. 3, 2021
Classified as Equity | Broker/consultant warrants Exercise price of $3.00 expiring March 14, 2022
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	23,571		23,571
Net book value | $	$ 66		$ 66
Warrants exercise price | $ / shares	$ 3
Warrants expiration date	Mar. 14, 2022
Classified as Equity | Broker/consultant warrants Exercise price of $63.16 expiring June 19, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	15		15
Net book value | $	$ 0		$ 0
Warrants exercise price | $ / shares	$ 63.16
Warrants expiration date	Jun. 19, 2023
Classified as Equity | Molson warrants Exercise price of $24.00 expiring October 4, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	2,875,000		2,875,000
Net book value | $	$ 42,386		$ 42,386
Warrants exercise price | $ / shares	$ 24
Warrants expiration date	Oct. 4, 2021
Classified as Equity | Issued in connection with business acquisition Exercise price of $3.96 expiring April 23, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	631,322		0
Net book value | $	$ 4,232		$ 0
Warrants exercise price | $ / shares	$ 3.96
Warrants expiration date	Apr. 23, 2025
Classified as Equity | Issued in connection with business acquisition Exercise price of $5.64 expiring September 23, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	1,228,873		0
Net book value | $	$ 7,902		$ 0
Warrants exercise price | $ / shares	$ 5.64
Warrants expiration date	Sep. 23, 2025
Classified as Equity | Issued in connection with business acquisition Exercise price of $8.47 expiring October 30, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	43,856		0
Net book value | $	$ 261		$ 0
Warrants exercise price | $ / shares	$ 8.47
Warrants expiration date	Oct. 30, 2025
Classified as Equity | Issued in connection with business acquisition Exercise price of $9.03 expiring June 25, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	3,205,378		0
Net book value | $	$ 18,236		$ 0
Warrants exercise price | $ / shares	$ 9.03
Warrants expiration date	Jun. 25, 2025
Classified as Equity | Issued in connection with business acquisition Exercise price of $11.29 expiring January 27, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	356,689		0
Net book value | $	$ 1,195		$ 0
Warrants exercise price | $ / shares	$ 11.29
Warrants expiration date	Jan. 27, 2023
Classified as Equity | Issued in connection with business acquisition Exercise price of $78.16 expiring August 21, 2022
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	15,992		0
Net book value | $	$ 3		$ 0
Warrants exercise price | $ / shares	$ 78.16
Warrants expiration date	Aug. 21, 2022
Classified as Equity | Issued in connection with business acquisition Exercise price of $102.71 expiring August 21, 2022
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	24,338		0
Net book value | $	$ 2		$ 0
Warrants exercise price | $ / shares	$ 102.71
Warrants expiration date	Aug. 21, 2022
Classified as Equity | Issued in connection with business acquisition Exercise price of $151.24 expiring September 27, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	14,617		0
Net book value | $	$ 0		$ 0
Warrants exercise price | $ / shares	$ 151.24
Warrants expiration date	Sep. 27, 2021
Classified as Equity | Issued in connection with business acquisition Exercise price of $155.19 expiring April 17, 2022
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	226,422		0
Net book value | $	$ 1		$ 0
Warrants exercise price | $ / shares	$ 155.19
Warrants expiration date	Apr. 17, 2022
Classified as Liability
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	3,368,266		3,368,266
Net book value | $	$ 5,733		$ 3,450
Classified as Liability | USD$25m Registered Direct Offering Warrants Exercise price of USD$9.80 expiring December 31, 2024
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	1,871,259		1,871,259
Net book value | $	$ 3,185		$ 1,917
Warrants exercise price | $ / shares		$ 9.80
Warrants expiration date	Dec. 31, 2024
Classified as Liability | USD$20m Registered Direct Offering Warrants Exercise price of USD$9.80 expiring January 22, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	1,497,007		1,497,007
Net book value | $	$ 2,548		$ 1,533
Warrants exercise price | $ / shares		$ 9.80
Warrants expiration date	Jan. 22, 2025

Share-based Compensation (Narra

Share-based Compensation (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)Shareshares	Jul. 31, 2020CAD ($)Shareshares	Jul. 31, 2019Share
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	12,018,143	7,503,691	6,072,245
Amount of stock based compensation allocated to inventory | $	$ 1,506	$ 6,105
Omnibus Plan
Stock Options And Restricted Share Units [Line Items]
Description of maximum term of options granted for share-based payment arrangement	Expiry dates are up to 10 years from issuance, as determined by the Board of Directors at the time of issuance.
Expiry period of RSUs	10 years
Maximum percentage of common shares reserved for issuance for options	10.00%
Maximum number of common shares reserved for issuance for options | shares	15,264,595	12,061,644
Number of share options issued and outstanding	10,624,759
Maximum percentage of RSU authorized to issue for common shares inclusive of outstanding stock options	10.00%
Former Plan
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	780,429
Assumed plan from business combinations
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	612,955

Share-based Compensation - Sche

Share-based Compensation - Schedule of stock option activity (Details)	12 Months Ended
	Jul. 31, 2021Share$ / shares	Jul. 31, 2020Share$ / shares
Share Capital [Abstract]
Number of options, Opening balance | Share	7,503,691	6,072,245
Weighted average exercise price, Opening balance | $ / shares	$ 16.30	$ 23.48
Options Granted | Share	5,273,906	2,986,507
Weighted average exercise price, Granted | $ / shares	$ 5.21	$ 6.48
Replacement options issued | Share	905,902	0
Weighted average exercise price, replacement options issued | $ / shares	$ 3.81	$ 0
Options Forfeited | Share	(630,473)	(1,145,610)
Weighted average exercise price, Forfeited | $ / shares	$ 12.80	$ 22.20
Options Expired | Share	(624,832)	(380,318)
Weighted average exercise price, Expired | $ / shares	$ 25.95	$ 36.64
Options Exercised | Share	(410,051)	(29,133)
Weighted average exercise price, Exercised | $ / shares	$ 3	$ 4.60
Number of options, Closing balance | Share	12,018,143	7,503,691
Weighted average exercise price, Closing balance | $ / shares	$ 10.63	$ 16.30

Share-based Compensation - Sc_2

Share-based Compensation - Schedule of stock options granted (Details)	12 Months Ended
	Jul. 31, 2021Share$ / shares	Jul. 31, 2020Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price, share options granted | $ / shares	$ 17.03	$ 26.04
Options granted	5,273,906	2,986,507
Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	1,385,489	1,196,015
Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	3,888,417	1,790,492
Stock option grant date October 29, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		October 29, 2019
Exercise price, share options granted | $ / shares		$ 13.20
Options granted		890,327
Expiry period		10 years
Stock option grant date October 29, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		207,259
Stock option grant date October 29, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		683,068
Stock option grant date January 29, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		January 29, 2020
Exercise price, share options granted | $ / shares		$ 7.20
Options granted		73,255
Expiry period		10 years
Stock option grant date January 29, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date January 29, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		73,255
Stock Option Grant Date April 28, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		April 28, 2020
Exercise price, share options granted | $ / shares		$ 2.76
Options granted		866,331
Expiry period		10 years
Stock Option Grant Date April 28, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		225,000
Stock Option Grant Date April 28, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		641,331
Stock option grant date June 26, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		June 26, 2020
Exercise price, share options granted | $ / shares		$ 4.08
Options granted		946,859
Expiry period		10 years
Stock option grant date June 26, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		763,756
Stock option grant date June 26, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		183,103
Stock option grant date July 28, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		July 28, 2020
Exercise price, share options granted | $ / shares		$ 3.84
Options granted		209,735
Expiry period		10 years
Stock option grant date July 28, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date July 28, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		209,735
Stock option grant date October 30, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	October 30, 2020
Exercise price, share options granted | $ / shares	$ 3.88
Options granted	665,010
Expiry period	10 years
Stock option grant date October 30, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	349,652
Stock option grant date October 30, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	315,358
Stock option grant date December 22, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	December 22, 2020
Exercise price, share options granted | $ / shares	$ 5.44
Options granted	1,340,773
Expiry period	10 years
Stock option grant date December 22, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	380,673
Stock option grant date December 22, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	960,100
Stock option grant date April 28, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	April 28, 2021
Exercise price, share options granted | $ / shares	$ 7.54
Options granted	85,389
Expiry period	10 years
Stock option grant date April 28, 2021 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date April 28, 2021 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	85,389
Stock option grant date June 17, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	June 17, 2021
Exercise price, share options granted | $ / shares	$ 7.43
Options granted	120,613
Expiry period	10 years
Stock option grant date June 17, 2021 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	75,000
Stock option grant date June 17, 2021 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	45,613
Stock option grant date July 29, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	July 29, 2021
Exercise price, share options granted | $ / shares	$ 5.24
Options granted	3,062,121
Expiry period	10 years
Stock option grant date July 29, 2021 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	580,164
Stock option grant date July 29, 2021 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	2,481,957

Share-based Compensation - Sc_3

Share-based Compensation - Schedule of stock options outstanding (Details) - Share	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	12,018,143	7,503,691	6,072,245
Number exercisable	4,114,387
Exercise Price $2.32-$10.76
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	8,292,550
Weighted average remaining contractual life (years)	8 years 9 months 25 days
Number exercisable	1,853,536
Weighted average remaining contractual life (years)	6 years 3 months 18 days
Exercise Price $15.56-$26.16
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	1,576,409
Weighted average remaining contractual life (years)	7 years 9 months 14 days
Number exercisable	1,779,478
Weighted average remaining contractual life (years)	7 years 3 months 29 days
Exercise Price $28.52-$34.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	2,141,186
Weighted average remaining contractual life (years)	7 years 4 months 24 days
Number exercisable	474,040
Weighted average remaining contractual life (years)	7 years 6 months
Exercise Price $47.36-$234.76
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	7,998
Weighted average remaining contractual life (years)	4 months 6 days
Number exercisable	7,333
Weighted average remaining contractual life (years)	3 months 25 days

Share-based Compensation - Sc_4

Share-based Compensation - Schedule of restricted share units activity (Details)	12 Months Ended
	Jul. 31, 2021Share$ / shares	Jul. 31, 2020Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Opening balance | Share	587,108	0
Opening balance, value of units	$ 8.41	$ 0
Granted | Share	24,008	609,636
Granted, value of units		$ 8.52
Replacement units issued | Share	223,506	0
Replacement units issued, value of units	$ 8.61	$ 0
Exercised - equity settled | Share	(223,506)	0
Exercised - equity settled, value of units	$ 8.61	$ 0
Exercised - cash settled | Share	(25,483)	0
Exercised - cash settled, value of units		$ 0
Forfeited | Share	(34,801)	(22,528)
Forfeited, value of units	$ 11.76	$ 11.76
Closing balance | Share	550,832	587,108
Closing balance, Value of units	$ 7.91	$ 8.41
Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted, value of units	3.17
Exercised - cash settled, value of units	5.62
Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted, value of units	7.17
Exercised - cash settled, value of units	$ 8.60

Share-based Compensation - Sc_5

Share-based Compensation - Schedule of restricted share units granted (Details)	12 Months Ended
	Jul. 31, 2021Share$ / shares	Jul. 31, 2020Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	24,008	609,636
Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	24,008	609,636
October 29, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares		$ 11.76
Expiry period of RSUs		10 years
October 29, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted		357,111
October 29, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0
June 26, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares		$ 3.96
Expiry period of RSUs		10 years
June 26, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted		252,525
June 26, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0
October 30, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 3.16
Expiry period of RSUs	10 years
October 30, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	7,161
October 30, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0
June 17, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 7.17
Expiry period of RSUs	10 years
June 17, 2021 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	9,413
June 17, 2021 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0
July 29, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 5.38
Expiry period of RSUs	10 years
July 29, 2021 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	7,434
July 29, 2021 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0

Share-based Compensation - Sc_6

Share-based Compensation - Schedule of fair value of stock options and Restricted stock units granted (Details)	12 Months Ended
	Jul. 31, 2021Year$ / shares	Jul. 31, 2020Year$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (weighted average)	$ 17.03	$ 26.04
Share price (weighted average)	$ 17.19	$ 26.44
Risk-free interest rate (weighted average)	1.24%	1.79%
Expected life (years) of options (weighted average) | Year	5	5
Expected annualized volatility (weighted average)	85.00%	75.00%

Share-based Compensation - Sc_7

Share-based Compensation - Schedule of equity-settled and cash-settled share-based payments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	$ 13,150	$ 31,503
Total cash-settled share-based compensation	127	393
Stock option share-based compensation
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	12,863	31,503
RSU share-based compensation
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	287	0
Total cash-settled share-based compensation	$ 127	$ 393

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of anti-dilutive securities excluded from computation of diluted earnings per share (Details) - shares	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	49,235,933	41,470,206
Stock options
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	12,018,143	7,503,690
RSUs
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	550,832	587,108
Acquired and reissued warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	5,747,487	0
2019 June financing warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	546,135	546,135
USD$25m registered direct offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	1,871,259	1,871,259
USD$20m registered direct offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	1,497,007	1,497,007
2020 April underwritten public offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	11,830,075	14,004,375
2020 May underwritten public offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	7,591,876	7,852,513
Warrants issued under conversion of debentures
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	4,665,628	4,665,628
Joint venture issued warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	2,875,000	2,875,000
Convertible debenture broker/finder warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	42,491	67,491

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)	Jul. 31, 2020CAD ($)	Jul. 31, 2021USD ($)	Jul. 31, 2020USD ($)	Jul. 31, 2019CAD ($)
Disclosure of risk management strategy related to hedge accounting [line items]
Notes payable	$ 50,159	$ 29,930
Restricted funds	132,246	8,261
Cash and cash equivalents	67,462	184,173			$ 113,568
Current liabilities	503,638	82,487
Contractual commitments	47,267
Unrealized gain or loss on foreign exchange	9,108	1,392
Price Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Conversion of debt, converted amount		$ 29,860
Percentage of unsecured convertible debentures		8.00%
Amount of increase or decrease in comprehensive loss due to 10% of increase or decrease in the fair value of these financial assets	37,100
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents and short-term investments held in credit union without publicly available credit rating	111
Restricted funds	29,999
Expected credit loss	66	$ 35
Maximum exposure to credit risk	$ 522,908	$ 211,860
Economic Dependence Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Percentage of sales recorded from Société québécoise du cannabis	42.00%
Percentage of sales recorded from the Ontario Cannabis Store	20.00%
Percentage of sales recorded from the Alberta Gaming, Liquor and Cannabis agency	14.00%
Percentage of sales recorded from one crown corporation		70.00%
Percentage of trade receivable from crown corporations Societe quebecoise du cannabis	13.00%	47.00%
Percentage of trade receivable from the Ontario Cannabis Store	29.00%	25.00%
Percentage of trade receivables from the Alberta Gaming, Liquor and Cannabis agency	13.00%
Liquidity Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents	$ 67,462	$ 184,173
Trade receivables	37,421	19,426
Current liabilities	503,638
Contractual commitments	18,244
Foreign Currency Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents	$ 434,838	$ 42,981	$ 348,931	$ 57,652
Immaterial change in foreign exchange rates	1.00%
Unrealized gain or loss on foreign exchange	$ 4,348

Financial Instruments - Schedul

Financial Instruments - Schedule of price risk exposure (Details) - Price Risk - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Disclosure of risk management strategy related to hedge accounting [line items]
Financial assets	$ 2,492	$ 2,692
Financial liabilities	(373,432)	(3,450)
Total exposure	$ (370,940)	$ (758)

Financial Instruments - Sched_2

Financial Instruments - Schedule of aging of trade receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 37,421	$ 19,426
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	37,421	19,426
Credit Risk | 0-30 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	22,971	15,253
Credit Risk | 31-60 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	12,390	2,972
Credit Risk | 61-90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	1,435	412
Credit Risk | Over 90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 625	$ 789

Financial Instruments - Sched_3

Financial Instruments - Schedule of analysis of contractual maturities for financial liabilities (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	$ 63,557
Excise taxes payable	6,591	$ 7,121
Loans and borrowings	60,297
Convertible debentures	47,989
Undiscounted future lease payments	78,370
Financial liabilities before senior secured convertible note	256,804
Senior secured convertible note	458,710
Total	715,514
2022
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	63,557
Excise taxes payable	6,591
Loans and borrowings	60,297
Convertible debentures	6,716
Undiscounted future lease payments	6,155
Financial liabilities before senior secured convertible note	143,316
Senior secured convertible note	315,289
Total	458,605
2023
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	0
Excise taxes payable	0
Loans and borrowings	0
Convertible debentures	41,273
Undiscounted future lease payments	5,785
Financial liabilities before senior secured convertible note	47,058
Senior secured convertible note	143,421
Total	190,479
2024
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	0
Excise taxes payable	0
Loans and borrowings	0
Convertible debentures	0
Undiscounted future lease payments	6,073
Financial liabilities before senior secured convertible note	6,073
Senior secured convertible note	0
Total	6,073
2025
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	0
Excise taxes payable	0
Loans and borrowings	0
Convertible debentures	0
Undiscounted future lease payments	5,561
Financial liabilities before senior secured convertible note	5,561
Senior secured convertible note	0
Total	5,561
Thereafter
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Accounts payable and accrued liabilities	0
Excise taxes payable	0
Loans and borrowings	0
Convertible debentures	0
Undiscounted future lease payments	54,796
Financial liabilities before senior secured convertible note	54,796
Senior secured convertible note	0
Total	$ 54,796

Operating Expenses by Nature -

Operating Expenses by Nature - Schedule of operating expenses by nature (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Expenses by nature [abstract]
Salaries and benefits	$ 21,116	$ 12,202
Professional fees	11,962	9,811
Facilities	6,550	6,895
Selling, general and administrative	13,915	14,409
Consulting	4,379	7,425
Travel	265	2,051
Total selling, general and administrative expense	$ 58,187	$ 52,793

Operating Expenses by Nature _2

Operating Expenses by Nature - Schedule of operating expenses by nature - stock based compensation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Expenses by nature [abstract]
General and administrative related share-based compensation	$ 10,945	$ 24,650
Marketing and promotion related wages and benefits	786	1,140
Total operating expense related share-based compensation	11,731	25,790
Share based compensation capitalized to inventory	1,505	6,105
Total share-based compensation	$ 13,236	$ 31,895

Operating Expenses by Nature _3

Operating Expenses by Nature - Schedule of operating expenses by nature - payroll related wages and benefits (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Expenses by nature [abstract]
General and administrative related wages and benefits	$ 21,116	$ 12,202
Marketing and promotion related share-based compensation	5,543	5,625
Research and development related wages and benefits	2,706	2,717
Total operating expense related wages and benefits	29,365	20,544
Wages and benefits capitalized to inventory	14,993	21,128
Total wages and benefits	$ 44,358	$ 41,672

Other Income and Losses - Sched

Other Income and Losses - Schedule of other income and losses (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Other Income And Losses [Abstract]
Interest and financing expenses	$ (32,124)	$ (10,043)
Interest income	1,601	1,902
Interest income (expense), net	(30,523)	(8,141)
Revaluation of warrant liabilities	(2,283)	6,533
Share of loss from investment in associates and joint ventures	(6,505)	(6,331)
Loss on Unsecured Convertible Debentures - December 2019	0	(54,283)
Fair value gain/(loss) on convertible debenture	1,260	(4,806)
Fair value loss on senior secured convertible note	(7,478)	0
Unrealized gain/(loss) on investments	1,994	(12,880)
Realized gain on investments	0	24
Foreign exchange gain/(loss)	9,108	1,392
Other income	4,763	2,531
Non-operating income (expense), net	$ 859	$ (67,820)

Related Party Disclosure (Narra

Related Party Disclosure (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Belleville Complex Inc.
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in related party	25.00%
Percentage of ownership interest owned by directors	75.00%
Cash advances and loans made to related parties			$ 20,279
Description of lease transaction	The Company will be the anchor tenant for a 15-year lease, with an option to renew for 15 years and additional space to rent. The Company has also subleased a portion of the space to Truss Limited Partnership (Note 11).
Consideration for interest on joint venture
Carrying value for interest on joint venture	798	$ 0
Lease and operating expenses	$ 5,369	$ 7,511
Truss Limited Partnership ("Truss LP")
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in associate	42.50%	42.50%
Payables due to associates	$ 6,928	$ 1,247
Raw materials purchased	7,624	2,159
Revenue from rendering of services, related party transactions	$ 1,844	$ 2,531

Related Party Disclosure - Sche

Related Party Disclosure - Schedule of compensation provided to key management (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Disclosure of transactions between related parties [abstract]
Salary and/or consulting fees	$ 2,321	$ 3,069
Termination benefits	1,008	1,043
Bonus compensation	800	42
Stock-based compensation	6,800	15,702
Total	$ 10,929	$ 19,856

Capital Management (Narrative)

Capital Management (Narrative) (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Capital Management [Abstract]
Shareholders' equity	$ 732,265	$ 556,676	$ 788,712

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jan. 01, 2021	Aug. 01, 2020
Commitments And Contingencies [Line Items]
Discharges of debenture and related security	$ 72,000
Amount to discharge debenture	$ 53,000
Onerous contract provision		$ 4,763
Letter of Credit
Commitments And Contingencies [Line Items]
Period of letter of credit	5 years
Maximum limit under agreement	$ 250			$ 2,581
Letter of credit annual amortization expense	50
Remaining balance of letter of credit	$ 200
Letter of credit reduced by amendment			$ 2,352

Commitments and Contingencies -

Commitments and Contingencies - Schedule of future minimum payments under contractual financial obligations (Details) $ in Thousands	Jul. 31, 2021CAD ($)
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 47,267
July 31, 2022
Commitments And Contingencies [Line Items]
Annual minimum payments payable	18,244
July 31, 2023
Commitments And Contingencies [Line Items]
Annual minimum payments payable	3,846
July 31, 2024
Commitments And Contingencies [Line Items]
Annual minimum payments payable	3,474
July 31, 2025
Commitments And Contingencies [Line Items]
Annual minimum payments payable	2,429
July 31, 2026
Commitments And Contingencies [Line Items]
Annual minimum payments payable	5,802
Thereafter
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 13,472

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of carrying value of financial instruments (Details) $ in Thousands, $ in Thousands	Jul. 31, 2021CAD ($)	Jul. 31, 2021USD ($)	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)
Assets
Cash and cash equivalents	$ 67,462		$ 184,173	$ 113,568
Restricted funds	132,246		8,261
Trade receivables	37,421		19,426
Commodity taxes recoverable and other receivables	13,549		16,773
Lease receivable - long term	4,453		3,865
Long - term investments	2,492		3,209
Liabilities
Accounts payable and accrued liabilities	63,557		32,451
Warrant liability	5,733		3,450
Convertible debt- current	3,406		0
Convertible debt	33,089		28,969
Convertible Debentures	36,495		28,969
Senior secured convertible note - current	367,699	$ 292,633	0
Loans and borrowings - current	50,159		29,930
Term loan - current			29,930
Other long-term liabilities	520		393
Amortized cost of financial assets
Assets
Cash and cash equivalents	67,462		184,173
Restricted funds	132,246		8,261
Trade receivables	37,421		19,426
Commodity taxes recoverable and other receivables	13,549		16,773
Lease receivable - long term	4,453		3,865
Long - term investments	0		0
Amortized cost of financial assets as FVTPL
Assets
Cash and cash equivalents	0		0
Restricted funds	0		0
Trade receivables	0		0
Commodity taxes recoverable and other receivables	0		0
Lease receivable - long term	0		0
Long - term investments	2,492		3,209
Amortized cost of financial liabilities
Liabilities
Accounts payable and accrued liabilities	63,557		32,451
Warrant liability	0		0
Convertible debt- current	3,406
Convertible debt	33,089
Convertible Debentures			28,969
Senior secured convertible note - current	0
Loans and borrowings - current	50,159
Term loan - current			29,930
Other long-term liabilities	0		0
Amortized cost of financial liability as FVTPL
Liabilities
Accounts payable and accrued liabilities	0		0
Warrant liability	5,733		3,450
Convertible debt- current	0
Convertible Debentures			0
Senior secured convertible note - current	367,699
Term loan - current			0
Other long-term liabilities	$ 520		$ 393

Non-Controlling Interest (Narra

Non-Controlling Interest (Narrative) (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2021CAD ($)	Jul. 31, 2020	Jul. 31, 2021USD ($)
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Percentage of ownership interest	60.00%
Proportion of ownership interests held by non-controlling interests	40.00%	40.00%
Contributed cash	$ 4,699		$ 3,100
Contributions in kind responsible from Partner	371
Capital production equipment to be received from Partner	$ 325
ZenPharm Limited
Disclosure of subsidiaries [line items]
Percentage of ownership interest	60.00%
Proportion of ownership interests held by non-controlling interests	40.00%

Non-Controlling Interest - Sche

Non-Controlling Interest - Schedule of change in non-controlling interests (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Non Controlling Interest [Abstract]
Balance, Beginning of year	$ 3,379	$ 0
Non-controlling interest acquired on business combination	(1,340)	0
Partnership contributions	81	3,379
Share of comprehensive loss for the period	(133)	0
Balance, End of year	$ 1,987	$ 3,379

Non-Controlling Interest - Sc_2

Non-Controlling Interest - Schedule of non-controlling interest (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2019
Disclosure of subsidiaries [line items]
Current assets	$ 693,558	$ 305,703
Current liabilities	503,638	82,487
Accumulated deficit	(773,993)	(659,231)
Non-controlling interests	1,987	3,379	$ 0
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Current assets	0	0
Non-current assets	8,651	7,455
Current liabilities	0	0
Non-current liabilities	$ 0	$ 0
Non-controlling interest (%)	40.00%	40.00%
Non-controlling interests	$ 3,460	$ 3,379
ZenPharm Limited
Disclosure of subsidiaries [line items]
Current assets	313
Non-current assets	141
Current liabilities	(3,233)
Non-current liabilities	0
Accumulated deficit	$ (133)
Non-controlling interest (%)	40.00%
Non-controlling interests	$ (1,475)

Revenue from Sale of Goods (Nar

Revenue from Sale of Goods (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Revenue [abstract]
Sales returns and recoveries	$ 3,736	$ 6,942

Revenue from Sale of Goods - Sc

Revenue from Sale of Goods - Schedule of gross revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	$ 173,081	$ 110,149
Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	157,260	107,298
Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	15,821	2,851
Retail
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	158,919	104,564
Retail | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	143,098	101,713
Retail | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	15,821	2,851
Medical
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	1,769	3,299
Medical | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	1,769	3,299
Medical | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	0	0
Wholesale
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	2,458	995
Wholesale | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	2,458	995
Wholesale | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	0	0
International
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	9,935	1,291
International | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	9,935	1,291
International | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	$ 0	$ 0

Segmented Information (Narrativ

Segmented Information (Narrative) (Details)	12 Months Ended
	Jul. 31, 2021Segment
Disclosure of operating segments [abstract]
Number of operating segment	1

Operating Cash Flow - Schedule

Operating Cash Flow - Schedule of restructuring provision (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Items not affecting cash
Income tax recovery	$ (397)	$ (6,023)
Depreciation of property, plant and equipment	6,097	6,072
Depreciation of property, plant and equipment in cost of sales	8,601	3,567
Amortization of intangible assets	2,050	3,939
Loss on convertible debentures	6,218	4,806
Unrealized gain on changes in fair value of biological assets	(51,499)	(29,356)
Unrealized fair value adjustment on investments	(1,994)	12,880
Amortization of deferred financing costs	793	56
Interest and other income	5,837	9,921
Loss on induced conversion of debenture	0	54,283
Accretion of convertible debenture	4,075	0
Non-cash finance and transaction fees	21,690	0
Loss on investment	0	(24)
License depreciation and prepaid royalty expenses	118	389
Write-off of inventory and biological assets	2,182	5,055
Write (up)/down of inventory to net realizable value	2,927	68,319
Realized fair value amounts on inventory sold	31,767	40,910
Loss from investment in associate and joint ventures	6,505	6,331
Share-based compensation	14,859	25,790
Revaluation of financial instruments (gain)/loss	2,283	(6,533)
Impairment losses	20,230	299,484
Loss on onerous contract	0	4,763
Loss on long lived assets and disposal of property, plant and equipment	1,358	3,855
Gain on exit of lease	(789)	0
Foreign exchange gain	(11,648)	0
Total items not affecting cash	71,263	508,484
Changes in non-cash operating working capital items
Trade receivables	(14,203)	267
Commodity taxes recoverable and other receivables	5,197	(784)
Prepaid expenses	(106)	5,717
Inventory	(52,539)	(100,492)
Biological assets	53,678	28,493
Accounts payable and accrued liabilities	8,848	6,623
Excise taxes payable	(444)	3,627
Total non-cash operating working capital	$ 431	$ (56,549)

Operating Cash Flow - Schedul_2

Operating Cash Flow - Schedule of additional supplementary cash flow information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Operating Cash Flow [Abstract]
Property, plant and equipment in accounts payable	$ 1,152	$ 19,751
Right-of-use asset additions	17,059	24,405
Capitalized borrowing costs	1,269	2,385
Interest paid	$ 5,618	$ 2,527

Income Taxes - Schedule of comp

Income Taxes - Schedule of components of income tax expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income taxes paid (refund) [abstract]
Current tax for the year	$ 22	$ 0
Adjustments of previous years	0	0
Total	$ 22	$ 0

Income Taxes - Schedule of defe

Income Taxes - Schedule of deferred income tax expense (recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income taxes paid (refund) [abstract]
Origination and reversal of temporary differences	$ (14,659)	$ (98,141)
Difference between statutory tax rate and deferred tax rate	(249)	2,555
Change in temporary difference for which no deferred tax assets are recorded	14,489	89,563
Deferred income tax recovery	$ (419)	$ (6,023)

Income Taxes - Schedule of inco

Income Taxes - Schedule of income tax rate reconciliation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income taxes paid (refund) [abstract]
Expected tax rate	26.50%	26.54%
Earnings before income taxes	$ (115,159)	$ (552,512)
Expected tax benefit resulting from loss	(30,517)	(146,637)
Adjustments for the following items:
Tax rate differences	(652)	2,555
Permanent differences	8,696	48,965
Change in temporary differences for which no tax assets are recorded	22,148	89,094
True up and other	(72)	0
Income tax expenses	$ (397)	$ (6,023)

Income Taxes - Schedule of reco

Income Taxes - Schedule of reconciliation of deferred tax assets and liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	$ 0	$ (6,023)
Recognized in income	419	6,023
Business Combination	(134)
Recognized in Equity/OCI	(421)	0
Ending balance	(136)	0
Taxable temporary differences
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	10,415	6,858
Recognized in income	(14,701)	3,557
Business Combination	(310)
Recognized in Equity/OCI	(421)	0
Ending balance	(5,017)	10,415
Biological assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(1,330)	(1,514)
Recognized in income	724	184
Business Combination	0
Recognized in Equity/OCI	0	0
Ending balance	(606)	(1,330)
Inventory
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(5,088)	(2,920)
Recognized in income	1,514	(2,168)
Business Combination	(7,276)
Recognized in Equity/OCI	0	0
Ending balance	(10,850)	(5,088)
Loss carryforward
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	0	23,369
Recognized in income	14,028	(23,369)
Business Combination	14,665
Recognized in Equity/OCI	0	0
Ending balance	28,693	0
Financing costs
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	0	721
Recognized in income	(2,738)	(721)
Business Combination	2,738
Recognized in Equity/OCI	0	0
Ending balance	0	0
Intangible assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(3,997)	(32,537)
Recognized in income	1,592	28,540
Business Combination	(9,951)
Recognized in Equity/OCI	0
Ending balance	$ (12,356)	$ (3,997)

Income Taxes - Schedule of dedu

Income Taxes - Schedule of deductible temporary differences and unused tax losses (Details) - CAD ($) $ in Thousands	Jul. 31, 2021	Jul. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 489,747	$ 363,385
Deductible temporary differences
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	11,556	8,328
Taxable temporary differences
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	26,444	8,412
Investments
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	17,030	14,890
Losses carried forward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	278,115	255,635
Research and development expenditures
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	1,817	669
Fixed Assets, intangibles and other assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	114,384	52,852
Financing costs
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 40,401	$ 22,599

Income Taxes - Schedule of non-

Income Taxes - Schedule of non-capital losses (Details) $ in Thousands	Jul. 31, 2021CAD ($)
Income taxes paid (refund) [abstract]
2022	$ 219
2023	281
2024	164
2025	748
2026	632
2027	104
2028	2,092
2029	1,350
2030	75
2031	2,867
2032	3,018
2033	4,030
2034	1,772
2035	2,413
2036	12,889
2037	37,244
2038	64,821
2039	57,938
2040	157,595
2041	24,764
Indefinite	1,179
Total	$ 376,195

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 24, 2021USD ($)$ / sharesshares	Jul. 31, 2021CAD ($)	Jul. 31, 2020CAD ($)	Sep. 01, 2021CAD ($)Share$ / $	Aug. 30, 2021CAD ($)Share
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from underwritten public offering		$ 46,140	$ 186,673
Closing of Underwritten Public Offering
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from underwritten public offering	$ 144,786
Number of units issued in underwritten public offering | shares	49,080,024
Units issued, price per unit | $ / shares	$ 2.95
Exercise price of warrants | $ / shares	$ 3.45
Acquisition of Private Cannabis Licensed Producer Redecan
Disclosure of non-adjusting events after reporting period [line items]
Cash transferred					$ 400,000
Number of shares issued | Share					69,721,116
Equity interests of acquirer					$ 214,043
Acquisition of 48North Cannabis Corp.
Disclosure of non-adjusting events after reporting period [line items]
Conversion rate of acquired shares to issued shares | $ / $				0.02366
Number of shares issued | Share				5,352,005
Equity interests of acquirer				$ 16,951